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CHAPTER 1 
 
Introduction 
The prenatal environment is influenced by a number of factors; the most important of 
which being the maternal environment. There is a growing body of evidence suggesting that the 
maternal and intrauterine milieu, through the action of inflammatory mediators, hormones, and 
nutrient availability may permanently change the health of the fetus (Barker, 1995, 2004). This 
work will focus on two possible environmental stressors, both of which have the potential to 
influence fetal development and programming; gestational diabetes mellitus (GDM) and 
maternal immune activation (MIA). 
 Gestational diabetes mellitus is the most common metabolic disorder during pregnancy 
and causes considerable morbidity, mortality, and long-term complications for both mother and 
child ("Gestational diabetes mellitus," 2004; Monteiro, Norman, Rice, & Illanes, 2016). A major 
barrier to reducing the incidence and burden of GDM is a lack of clarity regarding the underlying 
pathophysiological mechanisms and environmental factors that contribute to these complications. 
Aberrant systemic inflammation is associated with a multitude of metabolic disorders, including 
GDM and maternal obesity (Gregor & Hotamisligil, 2011). Maternal immune activation (MIA), 
another prenatal insult, occurs as the result of an infection during pregnancy and activates that 
maternal immune system (Howerton & Bale, 2012). Several epidemiological as well as clinical 
studies have shown associations between infection and excessive inflammation during pregnancy 
and an increased risk for developing neurocognitive disorders such as autism and schizophrenia 
in offspring (Buka et al., 2001; M. Cannon, P. B. Jones, & R. M. Murray, 2002; Gardener, 
Spiegelman, & Buka, 2009). The aberrant inflammation caused by GDM and maternal obesity is 
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also gaining evidence as a possible cause for the same neurocognitive disorders (M. Cannon et 
al., 2002; Xiang et al., 2015). In order for progress to be made in the prevention and treatment of 
these disorders it is important to identify both the biological and environmental factors 
underlying disorder pathogenesis.  
The research put forth in this document will focus primarily on the interactions of 
metabolic stress and immune activation. More specifically the impact of GDM on placental 
structure, inflammation-associated risk factors during pregnancy, pathological alterations within 
the fetal brain and placenta as a result of inflammation, and how maternal inflammation 
influences placental cellular structure. The role of sexual dimorphism will also be addressed as it 
relates to the placental response to metabolic stress and maternal immune activation. 
 
The Placenta: Anatomy, function, and importance 
          The placenta is a transient, but complex organ, acting as the link between the mother and 
the developing fetus. This maternal-fetal structure acts as the interface between the uterine 
mucosa and the extraembryonic tissues of the developing fetus. It plays important roles 
throughout pregnancy, maintaining intrauterine homeostasis, mediating the selective exchange of 
nutrients, waste, gases, and other modulatory factors across the maternal/fetal interface (Lo & 
Frias, 2017). The placenta also orchestrates and maintains maternal/fetal immune tolerance and 
acts in an endocrine fashion by producing key modulatory hormones while separating the fetus 
from a possibly adverse or harmful maternal environment (Lo & Frias, 2017).  
The placenta is composed of both maternally and fetally-derived cells (Huppertz, 2008). 
The uterus and maternally-derived decidua contain large numbers of maternal leukocytes such as 
uterine natural killer cells, compromising roughly 30-40% of the total cells in the first trimester 
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decidua, macrophages, remaining stable at 10% to 15% of the total cells within the decidua 
throughout pregnancy, and dendritic cells all of which display a unique uterine and placental 
phenotype (Hunt, Petroff, & Burnett, 2000; Schumacher & Sharkey, 2018). The presence of 
these cells and their proper contextual phenotype is essential for successful implantation and a 
subsequent successful and healthy pregnancy. Maternal blood supplied from the spiral arteries 
and fetal blood coming in from the umbilical arteries exchange waste and nutrients within an 
area known as the labyrinth zone in mice or the chorionic villous in human.  Separating the 
maternal and fetal endothelial cells is a layer of trophoblast cells that function to control 
maternal-fetal exchange, to prevent the direct mixing of maternal and fetal blood circulations, 
and to coordinate maternal-fetal tolerance (Hsiao & Patterson, 2012). In order for proper 
placentation to occur increased vascular expansion is crucial. This is made possible through the 
invasion of fetal trophoblasts into the decidua and the expansion of maternal spiral arteries into 
the villous core. This vascular remodeling is orchestrated with the help of maternal leukocytes in 
order to ensure sufficient blood supply for the growing fetus. (Harris et al., 2010; Hazan et al., 
2010; Moffett & Loke, 2006).   
Although mouse and human pregnancies are similar in their hemochorial mode of 
placentation and the accumulation of uterine natural killer cells within the decidua during 
placentation, they differ in many ways. The obvious is that mouse pregnancies last 
approximately 20 days where as human gestation takes 9 months. Another significant difference 
is the architecture of the labyrinth zone and villous core of the placenta where fetal-maternal 
exchange occurs. Within the mouse placenta, the placental trophoblasts do not invade into the 
decidual arterioles as deeply and invasively as they do in the human placenta. In humans 
however, placental trophoblasts are much more intrusive and actually temporarily replace 
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maternal endothelial cells stretching all the way to the smooth muscle of the uterus creating a 
much more vascular environment (Erlebacher, 2013). These differences account for some of the 
differential conclusions when comparing mouse models of maternal-fetal outcomes to human 
outcomes. Despite these differences, the relationship between mouse and human studies can 
reveal promising insights in to pathophysiological mechanisms driving an array of human 
pregnancy complications.    
Maternal-fetal tolerance is essential to a successful pregnancy. Thus, a delicate balance of 
fetal immune tolerance, without overt maternal immunosuppression, is required for the survival 
of the developing fetus (T. Jansson & Powell, 2007). The maternal-fetal interface utilizes 
multiple unique mechanisms to ensure maternal tolerance to the developing fetus. The maternal 
decidua plays a seminal role in orchestrating systemic immunological tolerance of the 
developing embryo (Arck & Hecher, 2013). Some of the multiple mechanisms of tolerance 
include fetal trophoblast cell microchimerism, trophoblast shedding in order to desensitize 
maternal circulating cells to paternal alloantigens, limited MHC expression on trophoblasts, and 
dendritic cell entrapment which limits their migration from the decidua to the uterine lymph 
nodes (Aluvihare, Kallikourdis, & Betz, 2004; Erlebacher, 2013; Makhseed et al., 2001). Any 
significant disruption in fetal immune tolerance can cause fetal rejection and/or impaired 
placental function, which has devastating effects on pregnancy success. 
The placenta, although transient in nature, is a dynamic organ paramount to the 
interrelationship between mother and fetus. The studies presented in this work are important in 
order to expand our understanding of how environmental stressors such as maternal 
inflammation caused by infectious agents and GDM and metabolic stress affect placental health 
 5 
therefore increasing our understanding of how these processes can be modified to improve fetal 
outcome.     
 
Placental macrophages 
Macrophages function as a first line of antimicrobial defense. As an abundant leukocyte 
population within the placenta, totaling ~20% of the total leukocytes within the decidua, 
macrophages play an important role at the maternal-fetal interface as initiators and targets of 
immune modulation (Erlebacher, 2013). Placental macrophages (PMs) consist of both fetally-
derived macrophages, known as Hofbauer cells (HBC), which are found in the villous core, and 
maternally-derived decidual macrophages, which reside in the maternal decidua.  HBCs have 
been characterized, in healthy pregnancies, as having an anti-inflammatory profile, characterized 
by high cell surface expression of the receptors CD163, CD209, and CD206 and increased 
secretion of IL-10 and transforming growth factor (TGF)-β (Gustafsson et al., 2008; Svensson et 
al., 2011; Z. Tang et al., 2011). Furthermore, the DNA methylation pattern of HBCs is consistent 
with an anti-inflammatory phenotype (S. Y. Kim et al., 2012). Placental macrophages are known 
to perform various functions including matrix remodeling during placental development, 
maintaining fetal tolerance, host defense, and the initiation of parturition (Erlebacher, 2013). The 
documented anti-inflammatory phenotype and importance of placental macrophages in 
maintaining immune tolerance suggest that these cells not only protect against infection, but also 
play a regulatory role within the placenta.  
Macrophages within the placenta and decidua play various pivotal roles during 
pregnancy; from conception, to implantation, to parturition. The importance of the macrophage 
begins at insemination. The introduction of seminal fluid into the uterus induces the production 
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of various cytokines and chemokines into the stromal compartment recruiting innate immune 
cells including macrophages, dendritic cells, and granulocytes (Schjenken, Glynn, Sharkey, & 
Robertson, 2015). The newly recruited macrophages allow for successful implantation by 
clearing away debris, infectious agents, and excess sperm that may have been introduced during 
insemination (De, Choudhuri, & Wood, 1991). It was recently shown that the ablation of 
CD11b+ macrophages in mice resulted in implantation failure stressing their importance in the 
successful origination of pregnancy (Care et al., 2013). Human decidual macrophages have been 
shown to localize in close proximity to invading trophoblasts early in pregnancy suggesting their 
potentially important role in successful invasion and placentation (Helige et al., 2014).  As 
pregnancy progresses, the macrophage takes on other roles such as  the secretion of 
immunosuppressive molecules and the presentation of reproductive antigens to T-cells 
contributing to maternal-fetal tolerance (Schumacher & Sharkey, 2018). Lastly, the initiation of 
parturition is partially induced by a macrophage phenotype switch from that of an anti-
inflammatory phenotype, which sustains pregnancy, to a pro-inflammatory phenotype 
characterized by the release of pro-inflammatory cytokines and mediators such as prostaglandin 
E2 (Nagamatsu & Schust, 2010). Numerous studies have concluded that macrophages play an 
important role throughout pregnancy from insemination through parturition.  
The varied, yet critical, functions that the macrophage displays within the context of the 
placenta make its understanding a difficult and overwhelming endeavor in the context of both 
healthy and diseased states. Yet, given the pleiotropic nature of macrophages in essentially all 
organ systems, they are a natural candidate to study for their importance in maintaining a healthy 
pregnancy and regulating the maternal-fetal interface. These studies highlight how 
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environmental stressors have the ability to influence basic macrophage function and phenotype 
in an already established pregnancy. 
 
Macrophages and their role in iron homeostasis 
Iron is critical for the function of many systems, including the immune system. 
Macrophages are involved in iron homeostasis and couple this iron cycling to activation status. 
Tissue resident macrophages are responsible for roughly 80% of the iron (Fe) availability within 
the body on a daily basis making them critical to iron homeostasis and availability (Andrews, 
2008). The role of the macrophage in Fe homeostasis is essential as mammals do not have the 
ability to secrete excess Fe in a regulated fashion. As a way to reduce high extracellular Fe levels 
macrophages sequester excess Fe. The sequestration of high levels of extracellular Fe can lead to 
phenotypic changes within the macrophage leading to the release of pro-inflammatory mediators 
(Cairo, Recalcati, Mantovani, & Locati, 2011). Macrophage polarization and inflammatory status 
are associated with differential expression patterns of genes related to Fe storage, uptake, and 
release. Pro-inflammatory macrophages increase expression of proteins associated with Fe 
storage while decreasing the expression of heme importers and Fe exporters. In contrast, anti-
inflammatory macrophages increase the expression of heme importers and Fe exporters in order 
to decrease the intracellular storage of Fe (Cairo et al., 2011).  
Iron-cycling in macrophages involves multiple proteins. Fe can enter the macrophage 
through multiple different mechanisms. Fe bound to transferrin is taken up into cells through the 
transferrin receptor (TfrC). Extracellular heme complexes with hemopexin in the plasma and is 
taken in through CD91. Hemoglobin bound to its plasma carrier haptoglobin is internalized 
through CD163. Within the endosome, heme-bound Fe is released through the action of heme-
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oxygenase 1 (Hmox1) then transported out of the endosome through Nramp1 and DMT1. Iron 
can be stored within the macrophage in the form of ferritin (Fth1 and Ftl) or can be exported 
through the iron exported ferroportin (Fpn).     
CD163 is a hemoglobin scavenger receptor exclusively expressed on macrophages. 
CD163 is a signal-inducing receptor that scavenges hemoglobin through the endocytosis of 
hemoglobin-haptoglobin (Hb:Hp) complexes (Kristiansen et al., 2001). The pro-inflammatory 
mediators IFN-γ, TNF-α, and Lipopolysaccharide (LPS), a gram negative bacterial cell wall 
component, suppress the expression of CD163 while IL-6 and IL-10 increase its expression 
(Buechler et al., 2000). The binding of the Hb:Hp complex to CD163 initiates a heme-
oxygenase-dependent anti-inflammatory signaling pathway eliciting IL-10 secretion initiating a 
positive feedback loop ultimately resulting in increased expression of CD163 and heme-
oxygenase-1 (Landis, Philippidis, Domin, Boyle, & Haskard, 2013; Philippidis et al., 2004). 
CD163 also exists in a soluble form (sCD163) (Etzerodt, Maniecki, Moller, Moller, & Moestrup, 
2010; Moller, Nielsen, Maniecki, Madsen, & Moestrup, 2010). sCD163 is a biomarker for a 
number of inflammation related diseases. Recent evidence has correlated elevated levels of 
sCD163 to such conditions as GDM (Bari et al., 2014). The role of macrophages in iron-cycling 
and homeostasis has been described within the liver, spleen, and adipose tissue; however, no 
such mechanism has been investigated in the placenta. The significance of how iron and iron 
storage within the placenta change in response to maternal stressors will be investigated in this 
work. 
Iron is transferred to the infant from maternal circulation by way of the placenta. It has 
been reported that the presence of maternal stressors, such as psychological stress, can influence 
the exchange of micronutrients across the placenta. It was reported that infants born to mothers 
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who suffered stress during pregnancy developed iron deficiency anemia soon after birth (Lubach 
& Coe, 2006). In rodent models, low levels of iron in neonates is associated with decreased 
numbers of macrophages, decreased natural killer cell activity, and an impairment in antibody 
formation all leading to increased susceptibility to neonatal infection (Hallquist, McNeil, 
Lockwood, & Sherman, 1992; Kochanowski & Sherman, 1985). Due to the importance of 
macrophages in iron cycling, storage, and availability and the evidence that this micronutrient is 
known to play a role in fetal outcomes, we investigated how maternal stress influences iron in 
the placenta. 
 
Developmental origins of health and disease 
The developmental origins of health and disease (DOHaD) framework posits that the 
gravid in utero environment influences the risk for non-communicable diseases (NCDs) for 
offspring throughout life (Eriksson, 2016). The fundamental belief of DOHaD is that hormonal, 
metabolic, inflammatory, as well as nutritional factors during specific and sensitive stages impact 
fetal health and development (Lucas AA 1994, Barker DJ 2004, Warner MJ 2010). In utero 
development sets the stage for the lifelong health of offspring. But sometimes stressors can 
adversely impact fetal development in such a way that the health of the offspring is put at risk. It 
is possible that this programming may be advantageous from an evolutionary stand point, but 
may also have long-term detrimental outcomes for society as a whole. By no means does the 
DOHaD framework rule out the role of genetics in the development of NCDs, but rather 
incorporates the idea that prenatal stressors can modify genetic susceptibility further enhancing 
or decreasing already programmed genetic predisposition. Many studies exploring the DOHaD 
framework have centered on neurocognitive outcomes in offspring, probably because brain 
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development seems to be very sensitive to the in utero environment. These two outcomes will be 
further introduced in the following sections.   
Strong associations have been identified between various stressors during pregnancy and 
the occurrence of NCDs, including cardiovascular disease, metabolic disorders (e.g., obesity and 
diabetes mellitus), and neurocognitive problems (Eriksson, 2016). In a study conducted in 
Scotland, maternal obesity during pregnancy was associated with the increased risk of premature 
death of the offspring in adulthood (Reynolds RM, 2013). An analysis of the Helsinki birth 
cohort study revealed compelling evidence that a high maternal body mass index (BMI) is 
associated with an increased risk of cancer, cardiovascular disease, and type-2 diabetes (T2D). 
Interestingly, the association with T2D was stronger in female offspring than male (Eriksson JG, 
2014). Evidence suggests that many commonly occurring diseases that have a substantial impact 
on society and long-term health appear to have some basis in the prenatal environment to which 
they were exposed.    
Studies are increasing in number and specificity to identify links between maternal 
morbidity during pregnancy and the risk for developing disease later in life. The studies 
presented in this work were developed under the DOHaD framework under the hypotheses that 
maternal inflammatory stressors during pregnancy influence fetal development.    
 
Maternal inflammation modifies the fetal environment and adverse outcome risk 
There are obvious sources of inflammation such as prenatal infection and autoimmune 
disease, and there are the more complex sterile forms of inflammatory states such as obesity and 
gestational diabetes (Berk et al., 2013). Many low- or middle-income countries are 
disproportionately affected by highly endemic infections such as tuberculosis, malaria, and HIV, 
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but are also challenged by GDM and obesity as societies transition from poor access to nutrition 
to a Western food culture (Popkin, Adair, & Ng, 2012). This is noteworthy because metabolic 
stressors such as these are associated, like some infections, with pro-inflammatory alterations 
within the placenta. The placenta functions in a protective manner as well, protecting the 
developing fetus from a possibly adverse maternal environment. For example, in cases of 
nutritional-deprivation, the placenta maintains fetal growth and development by sacrificing itself 
through autophagy in an attempt to save the fetus (Alwasel, 2010; Broad and Keverne, 2011). 
Placental adaptations to an adverse maternal environment are to increase the likelihood of 
offspring survival in the short-term, however, these adaptations can lead to adverse long-term 
effects. One possible long-term effect of these placental adaptations is the development of 
psychiatric disorders and developmental delays in the offspring.   
Psychiatric disorders affect a large portion of the world’s population (Kessler et al., 
2009). Psychiatric disorders are highly heritable. Schizophrenia has an estimated heritability of 
between 30 – 70% (Light et al., 2014; Sullivan, Kendler, & Neale, 2003; Wray & Gottesman, 
2012) and in the case of autism spectrum disorder (ASD), heritability estimates are around 50% 
(Sandin et al., 2014), thus making genetics a factor in disease incidence. Genetic factors, 
however, are insufficient in entirely explaining the incidence of psychiatric disorders. 
Excess inflammation leads to pathologic alterations contributing to psychiatric disorder 
development and progression later in life (Muller, 2014; Saetre et al., 2007). Both genetic and 
environmental risk factors contribute to an altered inflammatory state, working in tandem to 
influence the pathological basis for such psychiatric disorders (Horvath & Mirnics, 2014). 
Environment-associated risk factors modify genetic risk by altering brain development and 
function (Jaffee & Price, 2007; Klengel & Binder, 2015). Important neurodevelopmental stages, 
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such as in utero, are especially sensitive to environmental perturbations (M. H. Johnson, Jones, 
& Gliga, 2015; Meredith, 2015; Roth & Sweatt, 2011). Both schizophrenia and autism have been 
associated with numerous in utero disruptions, including prenatal infection (Atladóttir et al., 
2010; Buka et al., 2001), and gestational diabetes (M. Cannon et al., 2002; Gardener et al., 2009; 
Xiang et al., 2015). This latter fact raises an important question concerning the convergence of 
such metabolic and infectious stressors on neurocognitive development and long term outcomes 
in offspring.  
 
Fetal and placental sex modifies disease risk and pregnancy outcomes 
Because the predominant tissue-specific cell of the placenta, the trophoblast, is derived 
from the blastocyst and is genetically fetal, placental sex is biologically congruent with that of 
the fetus and may influence developmental origins of disease (Di Renzo, Picchiassi, Coata, 
Clerici, & Brillo, 2015; Rosenfeld, 2015; Sedlmeier et al., 2014). In fact, recent studies suggest 
that the placental transcriptome is largely driven by the fetal genome and that placental gene 
networks inﬂuence postnatal risk of multiple human diseases (Peng et al., 2017). Thus sexual 
dimorphism in DOHaD might reflect an influence of placental sex on fetal development. 
While the majority of investigations linking antenatal stress to adverse outcomes in 
offspring have focused on a single type of stress (such as metabolic stress or infection) (J. A. 
Goldstein, S. A. Norris, & D. M. Aronoff, 2017), real world experience demonstrates that human 
populations are routinely subjected to more than one fetal stressor at a time. For example, 
diabetes is often accompanied by obesity, collectively referred to as diabesity (Sims et al., 1973), 
a condition that has received significant attention for its impact on fetal development and 
developmental outcomes (Desoye & van Poppel, 2015; Tomar et al., 2015). In contrast, the co-
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occurrence of infectious diseases and metabolic stress has received little formal attention (J. A. 
Goldstein et al., 2017).  
 
Gestational diabetes  
One in ten pregnancies are complicated by glucose intolerance (DeSisto, Kim, & Sharma, 
2014; Perkins, Dunn, & Jagasia, 2007). GDM is the most common metabolic disorder during 
pregnancy with a mean prevalence in North America and the Caribbean of 7 %. It is defined as 
glucose intolerance newly diagnosed in the second or third trimester of pregnancy ("2. 
Classification and Diagnosis of Diabetes," 2017). GDM occurs as a result of a breakdown in 
normal glucose utilization during pregnancy. The placenta produces human chorionic 
somatomammotropin that inhibits peripheral uptake of glucose by the mother while stimulating 
the secretion of insulin by the fetus. In healthy pregnancies, some level of insulin resistance is 
required to preferentially transfer nutrients to the fetus, however, in cases of GDM, a lack of β-
cell hyperplasia leads to an exacerbated state of insulin resistance (Perkins et al., 2007). GDM 
not only affects levels of circulating glucose and insulin within the mother, but also circulating 
systemic inflammatory mediators. For example, circulating TNF-α levels are increased in 
patients with GDM when compared to healthy controls (Radaelli, Varastehpour, Catalano, & 
Hauguel-de Mouzon, 2003). Both placental and subcutaneous adipose tissue explants exhibited 
higher levels of TNF-α release when incubated in the presence of glucose (Coughlan, Oliva, 
Georgiou, Permezel, & Rice, 2001), suggesting that both the placenta and adipose tissue are 
responsible for increased secretion of TNF-α under high glucose conditions. 
Type 2 diabetes and GDM are often found in conjunction with maternal obesity (K. E. 
Martin, Grivell, Yelland, & Dodd, 2015; Whiteman et al., 2015). Both GDM and T2D are known 
 14 
to increase the risk of complications such as macrosomia, hypoglycemia, hypocalcemia, and 
hyperinsulinemia from islet cell hyperplasia at birth (Frias, Frias, Frias, & Martinez-Frias, 2007; 
Perkins et al., 2007). Fetal hypoxia, fetal brain-iron deficiency, and respiratory distress syndrome 
can also occur as a result of diabetes during pregnancy due to the fact that the placenta shows 
signs of increased hypoxia and is unable to provide the increased oxygen delivery required for 
the increased metabolic functioning (Georgieff, 2006). GDM, T2D, and obesity are often 
accompanied by an increase in circulating levels of free-fatty acids (FFA) and characterized by 
low-grade inflammation endotoxemia (Catalano, 2002; Lappas, 2011; Winzer, 2004; Wolf, 
2004). Multiple studies have demonstrated that these FFA byproducts of diabesity constitute 
metabolic danger signals and have the ability to alter the activation status of the NLRP3 
inflammasome leading to changes in the inflammatory environment (L'Homme et al., 2013; 
Vandanmagsar et al., 2011; Wen et al., 2011; Y. Yan et al., 2013).In addition to the metabolic 
related consequences of GDM, this condition is also associated with the dysregulation of 
multiple inflammatory pathways (Abell, De Courten, Boyle, & Teede, 2015). Gestational 
diabetes has also been associated with increased leptin, IL-6, and TNF-α as well as decreased 
adiponectin (insulin-sensitizing adipokine) levels midgestation (Gao, Yang, & Zhao, 2008; 
Kautzky-Willer et al., 2001; Kinalski, Telejko, Kuzmicki, Kretowski, & Kinalska, 2005; Nergiz 
et al., 2014; Ortega-Senovilla et al., 2011; Park et al., 2013; Vitoratos et al., 2001). Similar to and 
sometimes in conjunction with maternal obesity, gestational diabetes leads to an increased 
production of reactive oxygen species by hyperglycemia-induced increased electron transport in 
mitochondria (Nishikawa et al., 2000). In addition, placenta from gestationally diabetic mothers 
exhibit gene expression patterns and DNA methylation consistent with a pro-inflammatory 
phenotype, highlighting the potential role for placental inflammation in negative fetal outcomes 
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(Enquobahrie, Williams, Qiu, Meller, & Sorensen, 2009; Rong et al., 2015). Taken together, 
gestational diabetes induces maternal and placental changes consistent with a shift to a pro-
inflammatory state and an increase in hypoxic conditions within the placenta. 
 
Gestational diabetes induces changes in placental characteristics 
In cases of GDM, evidence suggests that within the placenta the number of macrophages, 
CD68+CD14+ cells, increases compared to control groups (Yu et al., 2013). Diabetes during 
pregnancy has been shown to induce a pro-inflammatory phenotype in placental macrophages, as 
characterized by an increase in the expression of IL-1β and CCR7 and a decrease in the anti-
inflammatory markers CD163, CD209, and IL-10 (Sisino et al., 2013). Another recent study, 
however, concluded that HBCs maintain their anti-inflammatory phenotype even in the presence 
of GDM (Schliefsteiner et al., 2017). T-cell directed immunoregulation is skewed in patients 
with GDM, as evidenced by reduced development and suppressive capacity of regulatory CD4+ 
T cell (Treg) populations (Pendeloski et al., 2015). Thus, there is ample evidence suggesting that 
the presence of GDM influences phenotypic properties of the placenta, although some 
controversy regarding the impact of GDM on the inflammatory potential of placental 
macrophages and the overall inflammatory state of the placenta exists.  
Gestational diabetes is associated with increased levels of maternal serum ferritin. Serum 
ferritin is an iron containing protein that functions as an intracellular iron storage compound 
(Charlton, Jacobs, Torrance, & Bothwell, 1963). In cases of iron-overload, ferritin can be 
excreted from macrophages in an apo-form into serum (Cohen et al., 2010). Multiple studies 
have demonstrated that GDM is accompanied by an increase in serum ferritin levels (Afkhami-
Ardekani & Rashidi, 2009; Amiri et al., 2013; Chen, Scholl, & Stein, 2006). These findings 
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suggest that GDM may be accompanied by, or influenced by, an increase in intracellular iron 
levels within macrophages. 
Literature regarding iron supplementation during pregnancy and risk of GDM is unclear. 
Prospective cohort studies have been performed to determine if iron intake during pregnancy 
correlates with an increased incidence of GDM. The reports thus far have been conflicting and 
correlative at best. One study reported a 2-fold higher incidence of GDM, hypertension, and 
metabolic syndrome in iron-supplemented women compared to controls while a different study 
concluded that high iron intake increased the risk of GDM for only a small subset of individuals 
(Bo et al., 2009; Helin et al., 2012). Neither of the studies looked at iron supplementation 
throughout the course of pregnancy and results were mostly based upon patient surveys.  
Interestingly, one identifying characteristic of placental macrophages is the high 
expression of the anti-inflammatory marker CD163, which is a scavenger receptor known to be 
involved in the clearance of hemoglobin-haptoglobin complexes and iron uptake (Svensson et 
al., 2011). The role of CD163 in iron recycling and handling is especially of interest in GDM as 
iron-containing proteins, iron availability, and levels of CD163 differ between women with 
GDM and non-diabetic pregnancies (Afkhami-Ardekani & Rashidi, 2009; Amiri et al., 2013; Bo 
et al., 2009; Chen et al., 2006; Helin et al., 2012; Rawal et al., 2017). Women with GDM exhibit 
signs of elevated iron stores, as estimated by an increase in maternal serum, hepcidin, and ferritin 
levels (Amiri et al., 2013; Chen et al., 2006; Rawal et al., 2017); all of which have been shown to 
play a possible role in the development of GDM. Two independent studies have shown that 
antenatal iron supplementation, leading to increased levels of maternal iron, increased the risk of 
GDM and was also associated with glucose impairment and hypertension throughout gestation 
suggesting a link between imbalanced iron homeostasis and GDM (Bo et al., 2009; Helin et al., 
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2012). Although a relationship has been established between GDM and maternal iron levels, the 
causal nature of this interaction and the extent to which it influences placental health and fetal 
outcome has yet to be well established. 
 
Maternal obesity and GDM: their impact on placental biology and fetal development 
Maternal obesity, excessive gestational weight gain, and other maternal metabolic 
disorders have been shown to have a significant impact on the physiology of the offspring 
(Maftei et al., 2015; Olson, Strawderman, & Dennison, 2009; Stice, Yokum, Burger, Epstein, & 
Small, 2011). Obesity is characterized by a low-grade inflammatory state (Friis et al., 2013) and 
leads to adipocyte hyperplasia and an increased secretion of pro-inflammatory adipokines and 
cytokines. Consequently, macrophage and T lymphocyte populations in adipose tissue increase, 
gut permeability decreases, and the gut microbiome is altered (Castanon, Luheshi, & Laye, 
2015). Of these obesity related biological factors, many are known to mediate risk to the 
developing fetus including excessive nutrient availability (e.g. glucose), circulating hormones 
(e.g. insulin, leptin), and inflammatory cytokines (Rivera, Christiansen, & Sullivan, 2015). The 
placenta is not immune to the effects of maternal obesity and as a result shows significant 
reduction in vascular function (N. Jansson et al., 2013; Stewart et al., 2007). An increase in 
maternal BMI is also associated with placental phosphorylation of NFκB and increases IL-1β 
levels, suggesting changes in placental inflammatory potential (Aye et al., 2014; Martino et al., 
2016).  
Uncontrolled diabetes in conjunction with obesity leads to increased adiposity and 
hyperglycemia increasing signs of oxidative stress and systemic inflammation (Guest, Gao, 
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O'Connor, & Freund, 2007). When obese women become pregnant, the inflammatory burden 
further increases as made evident by increases in maternal C reactive protein, IL-6, IL-1β, and 
MCP-1 midgestation compared to non-obese pregnant women (Christian & Porter, 2014; Friis et 
al., 2013). In the context of predisposing factors, such as maternal obesity and an unhealthy diet, 
gestational diabetes often inevitably develops (K. E. Martin et al., 2015; Whiteman et al., 2015). 
Pregnancy itself induces an insulin resistant maternal state allowing for increased glucose 
availability for the fetus (Salzer, Tenenbaum-Gavish, & Hod, 2015). Increased maternal glucose 
and free fatty acid production to accommodate the developing fetus combined with heightened 
inflammation exacerbate an already heightened state of insulin resistance as a consequence of 
pregnancy (Shoelson, Lee, & Goldfine, 2006). Most pregnant females are able to compensate for 
this increase in insulin resistance with pancreatic beta cell hyperplasia, hypertrophy and 
increased insulin production, leading to a hyperinsulinemic, normoglycemic state (Pasek & 
Gannon, 2013). However, when the factors propagating insulin resistance cannot be overcome 
by maternal compensation, gestational diabetes often develops (Georgieff, 2006). For the 
developing fetus, this translates into increases in both inflammatory (e.g. cytokines) and 
metabolic (e.g. insulin, leptin, glucose, free fatty acids) factors that either act at the placenta or 
freely cross the placenta to disrupt normal development (Silverman, Rizzo, Cho, & Metzger, 
1998).  
 
Models of gestational diabetes 
There are numerous rodent models of gestational diabetes. Many utilize a drug-induced 
streptozotocin (STZ) model of diabetes both during gestation and in the absence of pregnancy. 
STZ destroys pancreatic beta cells therefore producing a type 1 diabetic-like phenotype (López-
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Soldado & Herrera, 2003). Although genetic models inhibiting maternal beta cell proliferation 
exist and are shown to produce a gestational diabetic phenotype, these mutations are rarely if 
ever found in gestationally diabetic women and were therefore not chosen to be utilized in our 
studies (Pasek & Gannon, 2013). Even though other animal models are often used and known to 
induce a state of maternal hyperglycemia, the high fat diet induction of gestational diabetes is the 
most clinically relevant model of gestational diabetes for our studies. 
It is well established that a high fat diet produces obesity in rodents. Most researchers 
utilize a 32% to 60% fat by calorie diet producing a steady increase in weight over time without 
overt nutritional deficiencies (Pasek & Gannon, 2013). As a result of this high fat diet, adult 
female offspring from high fat fed dams exhibit increases in inflammation characterized by 
increases in IL-1β and TNFα levels (Kang, Kurti, Fair, & Fryer, 2014). Adult offspring of 
gestationally diabetic mothers, females in particular, present with various phenotypes including 
increased weight, hyperinsulinemia, hyperglycemia, hypertension, and higher serum levels of 
triglycerides and C reactive protein (Elahi et al., 2009; Liang, Oest, & Prater, 2009; Plagemann 
et al., 1998). Increases in the expression and/or activity of cytokines and proteins related to 
hypoxic response and oxidative stress have also been reported (Chandna et al., 2015; Lian, 
Dheen, Liao, & Tay, 2004; Melo et al., 2014; X. Tang, Qin, Xie, & He, 2015; Wu et al., 2015). 
As a result of a maternal high fat diet, the placenta exhibited signs of hypoxia and inflammation 
(Jones et al., 2009; Li, Chen, & Li, 2013; Liang, DeCourcy, & Prater, 2010). 
Maternal obesity, even in the absence of diagnosed diabetes, is a state of metabolic 
dysfunction and exhibits signs of excessive inflammation, which contribute to insulin resistance, 
an increased risk for the development of diabetes, and further excessive inflammation (Abell et 
al., 2015). The ongoing presence of inflammation in association with the presence of metabolic 
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dysfunction induces a positive feedback in which the two conditions promote the presence and 
intensity of one another. Rodent models of obesity exhibit signs of hyperglycemia and 
hyperinsulinemia both of which are known to increase the risk of developing gestational diabetes 
(Gallou-Kabani et al., 2007; Rivera et al., 2015). This knowledge not only makes the use of a 
high-fat induced model of gestational diabetes an effective one, but a physiologically relevant 
one as well for studying its effects on placental and fetal development. 
 
Gestational diabetes influences fetal neurodevelopment 
 Although the link between gestational diabetes and neurocognitive disorders is not as 
well documented as with maternal immune activation, there is growing evidence indicating that 
diabetes and obesity during gestation negatively affect neurodevelopment. With regards to 
autism and maternal diabetes, a meta-analysis performed by Xu and colleagues found significant 
pooled odds ratios of 1.48 (95% CI: 1.25 – 1.75) and 1.72 (95% CI: 1.24-2.41) for 3 cohort and 9 
case-control studies, respectively (Xu, Jing, Bowers, Liu, & Bao, 2014). Furthermore, 
schizophrenia risk has been documented as increased with diabetes during gestation, with a 
meta-analysis by Mary Cannon finding a significant odds ratio of 7.76 (95% CI: 1.37 – 43.9) 
(Mary Cannon, Peter B. Jones, & Robin M. Murray, 2002; Van Lieshout & Voruganti, 2008). 
Similarly, a study of 1051 offspring from 315 Finnish families found a 1.66-fold increase risk for 
developing schizophrenia with gestational diabetes exposure (Wegelius et al., 2011). Although 
limited, a possible link between gestational diabetes and neurocognitive disorders has been 
established. In order to further evaluate the causative nature of this association and possible 
mechanisms involved further studies are necessary.  
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Maternal immune activation 
Inflammation when appropriate is protective, but aberrant inflammation is not. 
Inflammation during critical developmental time windows can produce long-lasting changes in 
both immune and brain function (Coe & Lubach, 2003; U. Meyer, Yee, & Feldon, 2007). Many 
different environmental stressors, including infections, gestational diabetes, obesity, and altered 
nutrition have the potential to influence critical stages of development (Berk et al., 2013; 
Fagundes, Glaser, & Kiecolt-Glaser, 2013). Perturbations within the intrauterine environment 
have the potential to induce long lasting and significant consequences on immune function. 
Infections traditionally pose a persistent threat to human reproductive health through direct fetal 
tissue damage (e.g., congenital Zika virus, cytomegalovirus or syphilis infections) or, indirectly 
via immune-mediated interference with normal fetal programming and/or other mechanisms such 
as epigenetics (Bobetsis et al., 2007). The later indirect cause can be referred to as maternal 
immune activation (MIA). MIA as might be provoked by viral infections that do not cross the 
placenta, such as influenza or medically-treated HIV, appears to impact the risk for NCDs in 
exposed offspring (Adams Waldorf & McAdams, 2013; Zager et al., 2015). Perhaps one of the 
most dramatic impacts maternal immune activation can have on pregnancy and fetal 
development is preterm birth and early pregnancy loss. Preterm birth can lead to a multitude of 
complications for the offspring including an increase in the occurrence of allergies and asthma 
(Fergusson, Crane, Beasley, & Horwood, 1997; Kent et al., 2016; Pekkanen, Xu, & Jarvelin, 
2001) 
MIA can be modeled in rodents through multiple different scenarios. The two most 
common include the use of polyinosinic:polycytidylic acid (poly(I:C)) and the administration of 
LPS during midgestation inducing immune activation between gestational day (GD) 6 and 14 in 
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rodents. Both LPS and poly(I:C) are associated with a pro-inflammatory phenotype in the 
offspring (Garay, Hsiao, Patterson, & McAllister, 2013; Mandal et al., 2013; Onore, Schwartzer, 
Careaga, Berman, & Ashwood, 2014). Poly(I:C) is a synthetic double stranded RNA (dsRNA) 
that activates an acute antiviral immune response. dsRNA is recognized by TLR3, leading to an 
innate immune response that includes NFκB activation and pro-inflammatory cytokine 
expression (Urs Meyer, 2014; U. Meyer & Feldon, 2012). As with viral infection, poly(I:C) 
induces acute fever, sickness behavior, and weight loss usually resolving within 1 to 2 days 
(Patterson, 2009). The administration of poly(I:C) produces an effective antiviral response 
stimulating maternal immune activation in the absence of live pathogens mimicking an in utero 
viral infection (U. Meyer, Feldon, Schedlowski, & Yee, 2006; U. Meyer et al., 2007) (U. Meyer 
& Feldon, 2012). The ability of poly(I:C) to produce a consistent viral-like maternal response 
makes it a valuable tool in maternal immune activation research.   
 
Viral infections and maternal immune activation are linked to psychiatric disorders 
Since many psychiatric disorders are thought to have developmental origins, much 
research has focused on the importance of prenatal and early postnatal inflammation-associated 
events. It has long been known that in utero infections can alter the fetal brain, ranging from 
mild anomalies to severe deficits. Multiple studies have demonstrated that active maternal 
infections such as herpes simplex virus, cytomegalovirus, rubella, and toxoplasmosis can lead to 
childhood intellectual disabilities and learning difficulties (Hagberg & Kyllerman, 1983; H. M. 
Meyer, Jr., 1969). Recent events make this association all the more important since the 
emergence of Zika virus as the newest viral threat to the developing fetus. The most frequently 
studied association between maternal infections and neurocognitive disorders is influenza 
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(O'Callaghan, Sham, Takei, Glover, & Murray, 1991; Simanek & Meier, 2015; Zerbo et al., 
2015). The earliest studies of in utero infection and psychiatric risk observed increases in 
schizophrenia diagnosis after influenza epidemics. Groups in Wales, England, and Finland 
reported increases in schizophrenia risk in those born a few months after the 1957 A2 influenza 
pandemic (Mednick, Machon, Huttunen, & Bonett, 1988; O'Callaghan et al., 1991). Study results 
investigating other influenza outbreaks and schizophrenia risk associations, however, show 
inconsistent results. Some studies find a relationship between second trimester infections and 
increased schizophrenia diagnosis (J. Adams et al., 1993; Barr, Mednick, & Munk-Jorgensen, 
1990; Kendell & Kemp, 1989; Kunugi et al., 1995; Limosin, Rouillon, Payan, Cohen, & Strub, 
2003; Sham et al., 1992; Takei, O'Callaghan, Sham, Glover, & Murray, 1993; Takei et al., 1994) 
while other groups find no association (Grech, Takei, & Murray, 1997; Kendell & Kemp, 1989; 
Mino, Oshima, Tsuda, & Okagami, 2000; Morgan et al., 1997; Susser, Lin, Brown, Lumey, & 
Erlenmeyer-Kimling, 1994; Takei, Murray, Sham, & O'Callaghan, 1995). Conflicting results 
have also been found for other infections during pregnancy such as diphtheria, pneumonia, 
measles, varicella, mumps, and poliovirus (Cahill, Chant, Welham, & McGrath, 2002; 
O'Callaghan et al., 1994; Suvisaari, Haukka, Tanskanen, Hovi, & Lonnqvist, 1999; Torrey, 1988; 
Watson, Kucala, Tilleskjor, & Jacobs, 1984).  
Comparable to schizophrenia, autism has been associated with maternal infections during 
pregnancy. Rubella and other viral pathogens such as cytomegalovirus as well as some bacterial 
infections in the second trimester have been associated with a diagnosis of autism in the 
offspring (Atladóttir et al., 2010; Chess, 1977; Libbey, Sweeten, McMahon, & Fujinami, 2005; 
Sweeten, Posey, & McDougle, 2004; Yamashita, Fujimoto, Nakajima, Isagai, & Matsuishi, 
2003; Zerbo et al., 2015). 
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Similar to viral infections, prenatal poly(I:C) has demonstrated molecular, structural, and 
behavioral abnormalities reminiscent of psychiatric disorder pathology in the offspring in rodent 
models (Winter et al., 2009). Prenatal poly(I:C) treatment also has effects on immune 
development which may play a role in the progression of neurodevelopmental disorders. After 
treatment, high levels of many inflammatory markers are increased in the fetal brain, including 
IL-1β, IL-13, and MCP-1 (Arrode-Bruses & Bruses, 2012). In addition to changes in the brain, 
offspring usually present with a generalized, systemic pro-inflammatory phenotype. MIA via 
poly(I:C) in a mouse induces immune changes that last long after the initial insult. These long-
lasting immune perturbations could potentially contribute to the dysfunction observed throughout 
the postnatal period in MIA offspring. 
 
Metabolic stress, inflammation, and inflammasomes 
A strong foundation of evidence exists linking metabolic disorders and inflammation. 
With recent discoveries suggesting that chronic inflammation plays an essential role in the 
pathogenesis of many metabolic driven diseases. Highly conserved across species both the 
immune and metabolic responses to a variety of stimuli are essential for survival. In order to 
maintain a physiologically homeostatic environment proper communication between these two 
essential pathways is vital. A hallmark of chronic inflammation is increased levels of circulating 
inflammatory markers such as cytokines and chemokines which have been implicated in 
promoting the progression of chronic inflammation in metabolic disease. As the incidence of 
gestational diabetes rises, it is important that we seek to understand the immunological and 
metabolic processes responsible for its progression and how these processes affect one another 
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within the context of disease. Understanding the cellular responses to such perturbations could 
lead to the development of new or repurposed therapeutic and preventative treatments. 
 
The NLRP3 Inflammasome 
Pattern recognition receptors (PRRs) were first characterized for their ability to recognize 
microbial signals and mediate host immune responses to microbial insults. It is becoming ever 
more apparent that the PRRs have the ability to not only recognize and respond to microbial 
insults, but to respond to various endogenous danger signals such as those that may arise as a 
consequence of metabolic disease. Several different families of PRRs have since been discovered 
including the primarily membrane-bound toll-like receptors (TLRs) and c-type lectin receptors 
(Takeuchi & Akira, 2010). Another important family of PRRs is the nucleotide-oligomerization 
domain-like receptors (NLRs). The NLRs encompass a large family of intracellular proteins that 
respond to microbial patterns as well as changes in cellular homeostasis. NLR family is 
evolutionarily conserved in both plants and animals, although unlike the TLRs which are found 
in Drosophila, NLRs are unique to higher eukaryotes (Ting & Davis, 2005).   
The NLR family of PRRs contains 22 members with broad ranging and often times 
divergent functions. The most extensively studied of the NLR sub-families are those proteins 
known to be involved in the formation of large multimeric complexes known as inflammasomes 
(Martinon, Burns, & Tschopp, 2002). The best characterized of these inflammasomes is that 
which is formed around NLRP3. Activation of the NLRP3 inflammasome induces 
oligomerization of NLRP3 leading to the recruitment of ASC (apoptosis-associated speck-like 
protein containing CARD), which in turn, forms large structures leading to the recruitment of 
pro-caspase-1. Autocatalytic cleavage of pro-caspase-1 into the p10 and p20 caspase-1 subunits 
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allows for the formation of active caspase-1 as the two subunits form hetero-tetramers which are 
then able to convert pro-IL-1β and pro-IL-18 into their bioactive secreted forms (C. A. Dinarello, 
2009; Wilson et al., 1994). The importance of IL-1β and its possible role in metabolic stress 
during pregnancy will be discussed further in the following sections.  
NLRP3 activation occurs in two steps. The strict regulation of inflammasome activation 
is important to restrict aberrant activation which may lead to possible damage of surrounding 
tissues through an unnecessary and excessive inflammatory response. Signal 1 is a priming step 
and is required for complete activation. This initial priming can be mediated through various 
pathways such as PRRs, cytokine receptors, or other factors known to activate NF-κB. This 
priming step is critical as it produces a pool of pro-IL-1β and increases NLRP3 to functional 
levels (Bauernfeind et al., 2009; Franchi, Eigenbrod, & Nunez, 2009). The second signal is the 
activating signal and can vary in nature from microbial signals, toxins, crystalline substances, 
and ATP released from dead or dying cells (Stutz, Golenbock, & Latz, 2009).  
The NLRP3 inflammasome is important in the context of metabolic disease as it has the 
ability to be activated by a number of different byproducts of metabolic disease resulting in a 
state of sterile inflammation (Agostini et al., 2004; Mariathasan et al., 2004; Meylan, Tschopp, & 
Karin, 2006; Miao et al., 2006). This is in contrast to other NLR inflammasomes such as 
NLRC4/NAIP and NLRP1 which have a more restricted repertoire of agonists (L. C. Hsu et al., 
2008; Newman et al., 2010). Due to this fact, the NLRP3 inflammasome is recognized as a 
sensor of metabolic dysregulation. For example, ER stress, as seen in patients with T2D, 
activates the NLRP3 inflammasome resulting in the release of IL-1β (Menu et al., 2012). In 
mice, studies inducing obesity through the administration of a high fat diet (HFD) have shown 
that expression of inflammasome components ASC, Caspase-1, and NLRP3 are elevated in 
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adipose tissue macrophages and isolated adipocytes, which can also produce IL-1β, further 
promoting obesity (Koenen et al., 2011; Stienstra, Tack, Kanneganti, Joosten, & Netea, 2012; 
Stienstra et al., 2011). Further evidence outlining the importance and possible role for the 
NLRP3 inflammasome in the context of metabolic stress will be outlined in later chapters.     
 
The importance of IL-1β 
The IL-1 family of cytokines are important regulators of inflammation. It has multiple 
functions including acting as a co-stimulatory molecule of T lymphocytes, inducing a humoral 
Th2 immune response, and promoting Th17 cell differentiation (Charles A. Dinarello, 2009; V. 
J. Johnson, Yucesoy, & Luster, 2005; Sutton, Brereton, Keogh, Mills, & Lavelle, 2006). IL-1 can 
also increase adhesion molecule expression on mesenchymal and endothelial cells, promote 
angiogenesis and tumor metastasis, and stimulate myeloid differentiation (Dinarello, 2007; 
Charles A. Dinarello, 2009; Voronov et al., 2003). The IL-1 family of cytokines includes the IL-
1α and IL-1β isoforms, IL-1 receptors 1 and 2, IL-1 receptor accessory protein, and IL-1 receptor 
antagonist. IL-1α is expressed constitutively in most cell types whereas IL-1β is mostly produced 
by immune cells (Berda-Haddad et al., 2011). Biological activity is controlled at both the 
transcriptional and post-translational levels of processing. IL-1β is produced in an inert pro-
peptide form that must be cleaved by enzymes such as caspase-1 or neutrophil serine proteases 
(Guma et al., 2009; Joosten et al., 2009). Upon binding of biologically active IL-1, the IL-1 
receptor heterodimerizes, interacts with IL-1 receptor accessory protein, and promotes pro-
inflammatory signaling through a myeloid differentiation factor 88 (MyD88)-dependent pathway 
to activate NF-κB and multiple stress-activated kinases such as JNK and ERK (Palomo, Dietrich, 
Martin, Palmer, & Gabay, 2015). The IL-1 receptor antagonist is usually released by the same 
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immune cells that release IL-1, dampening excess IL-1 signaling via competitive antagonism 
(Dripps, Brandhuber, Thompson, & Eisenberg, 1991; Schreuder et al., 1997). IL-1 receptor 2 is 
expressed on immune cells and other cytokine targets decreasing IL-1 signaling by acting as 
decoy receptor (Gabellec, Griffais, Fillion, & Haour, 1996; McMahan et al., 1991). IL-1 receptor 
2 expression is induced by anti-inflammatory factors whereas pro-inflammatory cytokines induce 
IL-1 receptor 1 expression (Colotta et al., 1993; P. Martin et al., 2013; Orlando et al., 1997).  
Interleukin-1β is a pro-inflammatory cytokine that is produced by activated monocytes 
and macrophages in response to stimuli acting as an important regulator of systemic 
inflammation. It is the primary cause of both chronic and acute inflammation in response to 
injury, infection, and other immunological challenges (Dinarello, 1998). As mentioned 
previously, IL-1β is produced in its inactive precursory form, pro-IL-1β p35, which requires 
cleavage into its active p17 form by IL-1β-converting enzyme, also known as caspase-1 (Cerretti 
et al., 1992; Thornberry et al., 1992).   
As an important regulator of inflammation, it is not surprising that IL-1β has been shown 
to play a role in metabolic disorders such as T2D and obesity. Both IL-1β and IL-18 have been 
shown to be risk factors for T2D (Spranger et al., 2003; Thorand et al., 2005). IL-1β has been 
linked to the possible development and progression of T2D through multiple mechanisms. 
Through increasing the expression of other inflammatory mediators, via IL-1R signaling, IL-1β 
can initiate the expression of IL-18 and IL-33 families of cytokines initiating a self-amplifying 
cytokine system (Arend, Palmer, & Gabay, 2008). IL-1β also induces cell stress pathways which 
have been linked to the progression of T2D (Cardozo et al., 2005; Verma & Datta, 2010). High 
glucose and high free fatty acid levels, as seen in T2D and often times obesity, have been shown 
to directly increase inflammatory responses and IL-1β production (Boni-Schnetzler et al., 2009). 
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Multiple studies have focused on the identification of endogenous and exogenous ligands 
responsible for activating the inflammasome in murine models of T2D.  Multiple danger 
associated molecular patters (DAMPs) including islet amyloid polypeptide and glucose itself 
have been associated with increased NLRP3 inflammasome activation in T2D to name just a few 
(Maedler et al., 2002; Masters et al., 2010).  
 
The role of Toll-like receptors in metabolic disease 
One of the most studied and best characterized of the PRR families is the TLR family. 
TLRs are responsible for sensing invading pathogens as well as endogenous DAMPs both 
extracellularly and within endosomes and lysosomes intracellularly (Akira, 2006). Ten different 
TLRs have been identified in humans while 12 have been identified in mice and are 
characterized by N-terminal leucine-rich repeats, a transmembrane region, and a cytoplasmic 
Toll/IL-1R homology (TIR) domain (Kawai & Akira, 2007). TLRs differ not only in their 
localization within the cell, but also in their ability to recognize specific molecular patterns 
whether exogenous in nature such as microbial components or endogenous in nature. Some of 
the relevant TLRs will be introduced in brief. TLR2, has the widest specificity, and senses 
various gram-positive as well as gram-negative bacterial and fungal components when in 
complex with other TLRs, TLR1/TLR2 or TLR6/TLR2, the heterodimer recognizes triacyl and 
dicyl lipoproteins (Aliprantis et al., 1999; Iwaki et al., 2002; Krutzik et al., 2003; Lien et al., 
1999; Opitz et al., 2001; Takeuchi et al., 2001; Yoshimura et al., 1999). When stimulated, TLR2 
induces pro-inflammatory cytokine production. TLR5 is highly expressed in the small intestine 
and recognizes flagellated bacteria. In response, dendritic cells induce differentiation of naïve T 
cells in to Th17 and Th1 cells (Uematsu et al., 2008). TLR3, TLR7, TLR8, and TLR9 all 
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recognize bacterial and viral nucleic acids as well as endogenous nucleic acids (Akira, 2006). 
The nature of the nucleic acid and the downstream effects vary depending on the TLR. TLR4, 
was the first human TLR to be identified, in complex with MD2, recognizes lipopolysaccharide 
(LPS) (Medzhitov, 2001; Poltorak et al., 1998) and is also involved in the recognition of viruses 
(Imai, 2008).  
TLR signaling can be divided into two main groups dependent upon the TIR domain-
containing adaptor molecules recruited to the TLR upon activation. The most common signaling 
pathway is through the adaptor protein MyD88 (Takeuchi et al., 2001). Upon pathogen 
associated molecular pattern (PAMP) recognition MyD88 is recruited to the TIR domain of the 
TLR initiating the subsequent kinase cascade that triggers the downstream activation of NF-κB 
and MAPK pathways resulting in an inflammatory response (Akira, 2003). TLR3 and TLR4, 
however, can signal in a MyD88 independent fashion through another adaptor protein, TRIF. 
TRIF, although also responsible for NF-κB activation, also phosphorylates IRF-3 resulting in an 
anti-viral response (Akira, 2003; Yamamoto et al., 2002). 
The ability to sense a bacterial or viral infection at the maternal fetal interface is essential 
to a successful and healthy pregnancy. In vivo models of bacterial infections during pregnancy in 
multiple animal models have shown that live or heat-killed bacterial products can trigger preterm 
birth (Elovitz, Wang, Chien, Rychlik, & Phillippe, 2003). PRRs, more specifically TLRs, have 
been implicated in the pathogenesis of infection-associated preterm birth (Ilievski, Lu, & Hirsch, 
2007; Wang & Hirsch, 2003). These PRRs are expressed throughout the immune system as well 
as on non-immune cells, especially within the pregnant uterus, thus increasing their capacity to 
initiate an inflammatory response. For example, amniotic epithelial cells possess TLR2 and 
TLR4 that recognize and respond to bacterial threats (K. M. Adams, Lucas, Kapur, & Stevens, 
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2007; Y. M. Kim et al., 2004). In cases of chorioamnionitis, infection of the fetal membranes, 
TLR4 expression is upregulated (Y. M. Kim et al., 2004). Within the decidua, term decidual 
immune cells express TLR2 and TLR4 (Y. M. Kim et al., 2004). Decidual stromal cells also 
express TLRs. Term decidua express all 10 at the transcript level (Krikun et al., 2007) while 
expression at the protein level is gestation dependent with TLR2 and TLR4 being exressed 
during the first trimester and all 10 show expression at term (Canavan & Simhan, 2007; Krikun 
et al., 2007). The TLRs with the decidua are active and mount an inflammatory response upon 
activation with their known ligands (Canavan & Simhan, 2007; Krikun et al., 2007; Simhan, 
Chiao, Mattison, & Caritis, 2008). The majority of research regarding pattern recognition in at 
the maternal fetal interface has focused on the placenta. Normal term placentae express all 10 
TLRs (Chuang & Ulevitch, 2000; Zarember & Godowski, 2002). Like within the decidua, the 
expression of these changes throughout gestation in a time dependent fashion. In first trimester 
placental tissues, villous cytotrophoblasts and extravillous trophoblasts express high levels of 
TLR2 and TLR4, however, the outermost syncytiotrophoblasts do not express any TLRs 
(Abrahams et al., 2004). These outer most fetal cells are in direct contact with maternal blood 
and the lack of TLR expression is more than likely a method of immune tolerance. This 
expression pattern continues into the second trimester (Rindsjo, Holmlund, Sverremark-Ekstrom, 
Papadogiannakis, & Scheynius, 2007).  By the time the pregnancy has reached the third 
trimester, TLR2 and TLR4 expression can be found in the villous cytotrophoblasts, extravillous 
trophoblasts, and the syncytiotrophoblasts (Holmlund et al., 2002; Kumazaki, Nakayama, 
Yanagihara, Suehara, & Wada, 2004; Rindsjo et al., 2007). This altered PRRs expression pattern 
may reflect the changes in placental function as gestation proceeds. TLR expression may be just 
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another way that the placenta orchestrates the delicate balance between tolerance of the fetal 
allograft and maintaining defense against pathogens.  
As is many aspects of the immune system, TLR expression and function is altered in 
response to systemic inflammation and metabolic stress. Although a link between TLR4 and 
metabolic stress has been established, little work specifically looking at gestational diabetes has 
been completed. A case-control study looking at 30 females with GDM and 32 healthy pregnant 
females reported that both TLR4 expression levels in peripheral blood monocytes and serum 
TNF-α levels were increased in females with GDM compared to controls (Xie, Jin, & Zhu, 
2014). Additionally they found a positive correlation between serum TNF-α levels and blood 
monocyte TLR4 expression in all females. This indicates that TLR4 expression may be involved 
in the pathogenesis of gestational diabetes although the causal relationship cannot be 
interrogated. In a model of diet-induced obesity in mice, similar results were found. Mice lacking 
TLR4 and wild-type mice were fed either a normal chow diet or a HFD for 8 weeks at which 
point their thoracic aorta was removed. Samples from wild-type mice on a HFD showed 
increased markers of vascular inflammation, NF-κB expression, and impaired insulin sensitivity 
compared to normal chow mice. The TLR4-/- mice, however, showed no signs of vascular 
inflammation or impaired insulin responsiveness as a result of HFD despite comparable body fat 
mass implicating a role for TLR4 in diet-induced vascular inflammation and insulin resistance 
(F. Kim et al., 2007). Using a diet-induced model of T2D, Lu, et al. reported that mice who 
received Rhodobacter sphaeroides lipopolysaccharide (rs-LPS), a TLR4 antagonist, had an 
attenuated presence of atherosclerotic lesions compared to non-rs-LPS treated mice. 
Furthermore, rs-LPS treated mice displayed a reduction in the number of infiltrating monocytes 
and macrophages into atherosclerotic lesions when present (Lu, Zhang, Li, Lopes-Virella, & 
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Huang, 2015). Together, these studies establish the basis for the possible role of TLR4 in the 
onset and progression of inflammation associated complications and progression as a result of 
metabolic stress in the form of obesity and diabetes.                        
 
Hypotheses 
This thesis provides an overview of how maternal inflammatory stress, in the form of 
metabolic stress induced by GDM and MIA, affects placental health and fetal outcomes thus 
possibly influencing the developmental origin of health and disease. Our central hypothesis is 
that maternal inflammation alters placental physiology thus increasing the risk of adverse fetal 
outcomes. We apply this hypothesis to both human and mouse studies and in multiple scenarios 
looking at both metabolic stresses alone and in combination with the additional stress of maternal 
immune activation to assess the combined effect on placental and fetal health. The combination 
of these two common and often co-occurring stressors has never been interrogated.  
Chapter 1 is an overview of the background information necessary for the understanding 
of where the field of maternal health is now regarding gestational diabetes and maternal immune 
activation. The now widely accepted viewpoint that the maternal environment during pregnancy 
can influence the health of the offspring, in both a negative and positive way, is also introduced. 
The work proposed and conducted in this thesis was developed under the framework of DOHaD 
to better understand how maternal immune stress during pregnancy affects not only maternal and 
placental health, but the long-term health of the offspring as well.     
Chapter 2 tested the hypothesis that women with gestational diabetes exhibited altered 
placental physiology and placental macrophage phenotypes. We utilized a newly developed 
research tool at Vanderbilt University known as Pathlink which allowed us to search deidentified 
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patient medical records linked to archived formalin-fixed paraffin embedded (FFPE) placental 
tissue blocks obtained from the same patients. Comparison of placentae from women with GDM 
and healthy controls uncovered that GDM is associated with altered placental histology and 
altered placental macrophage phenotypes as evidenced by the higher level of expression of 
CD163 on macrophage-like cells of the chorion and decidua suggesting an increase in anti-
inflammatory like macrophages. Increases in meconium-laden macrophages and greater iron 
stores within the placentae of women with GDM were noted and are consistent with reports that 
iron excess is associated with an increased risk for GDM. Overall, our results add to the growing 
amount of evidence that GDM has direct effects on placental structure. 
In Chapter 3, we developed and characterized a rodent model of diet-induced gestational 
diabetes. This model was then utilized to test the combined effect of GDM and MIA via 
poly(I:C), both of which are inflammation-inducing psychiatric disorder risk factors, on markers 
of maternal inflammation and fetal brain gene expression patterns. Work presented in chapter 4 
utilizes the same experimental premise as chapter 3 and assesses the placental gene expression 
patterns in the same mice after exposure to GDM, MIA, and the combination of the two 
stressors. For these studies, however, we were interested not only in how gene expression 
patterns change as a result of different sources of maternal inflammatory stress, but also the role 
of sexual dimorphism in influencing placental gene expression patterns.  
Chapter 5 takes a more mechanistic approach investigating how metabolic stress alters 
placental macrophage IL-1β production. Dyslipidemia is often a hallmark of metabolic stress. 
Excess circulating FFAs can act as extracellular danger signals leading to the activation of the 
inflammasome culminating in the characteristic increased production of IL-1β seen in many 
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metabolic disorders including gestational diabetes. A summary of these findings as well as future 
directions for the field will be included in chapter 6. 
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CHAPTER 2 
 
GESTATIONAL DIABETES MELLITUS IS ASSOCIATED WITH INCREASED CD163 
EXPRESSION AND IRON STORAGE IN THE PLACENTA 
 
Theresa L. Barke, Jeffery A. Goldstein, Alexandra C. Sundermann, Arun P. Reddy, Jodell E. 
Linder, Hernan Correa, Digna R. Velez-Edwards, David M. Aronoff 
 
Introduction 
GDM significantly increases the risk of pregnancy complications, including fetal 
macrosomia, neonatal hypoglycemia and hypocalcemia, preeclampsia, premature labor, and 
Cesarean delivery ("2. Classification and Diagnosis of Diabetes," 2017). It also increases the risk 
of postpartum complications in mother and child including late onset diabetes and cardiovascular 
disease ("2. Classification and Diagnosis of Diabetes," 2017). A major barrier to reducing the 
complications of GDM is a lack of clarity regarding how this disease changes placental 
physiology, morphology, and overall the pathophysiological mechanisms contributing to the 
impact of the disease.   
Maternal hyperglycemia, as observed in GDM, alters placental morphometric 
characteristics, changes the structural integrity of syncytiotrophoblasts, and provokes major 
changes in placental gene expression related to chronic stress and inflammation (al-Okail & al-
Attas, 1994; Calderon et al., 2007; Radaelli et al., 2003). Some evidence also suggests that 
within the placenta of women with GDM, the number of CD68+CD14+ cells, macrophages, 
increases compared to control groups (Yu et al., 2013). Elevated biomarkers of systemic 
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maternal inflammation have been described in women with GDM, including an increase in 
circulating levels of interleukin (IL)-6, IL-8, IL-18 and C-reactive protein (CRP) in conjunction 
with decreased levels of IL-10 (Kuzmicki et al., 2008). Multiple studies have shown that in 
conjunction with an increase in maternal circulating inflammatory mediators, GDM is also 
associated with pro-inflammatory changes within the placenta (Hara Cde et al., 2016; Kuzmicki 
et al., 2008; Li et al., 2013; Radaelli et al., 2003). In particular, macrophages, the primary 
phagocyte in the healthy placenta, appear to be impacted by this endocrine disorder (Mrizak et 
al., 2014; Sisino et al., 2013; Yu et al., 2013).  
An identifying characteristic of placental macrophages is a high level of the anti-
inflammatory marker CD163, which is involved in the clearance of hemoglobin-haptoglobin 
complexes and iron uptake (Svensson et al., 2011). The role of CD163 in iron recycling and 
handling is especially of interest in GDM as iron-containing proteins, iron availability, and levels 
of CD163 differ between women with GDM and non-diabetic pregnancies (Afkhami-Ardekani 
& Rashidi, 2009; Amiri et al., 2013; Bo et al., 2009; Chen et al., 2006; Helin et al., 2012; Rawal 
et al., 2017). Circulating levels of hemoglobin and iron are higher in GDM patients compared to 
controls (Afkhami-Ardekani & Rashidi, 2009). Elevated iron stores, as estimated by increased 
maternal serum hepcidin and ferritin levels, may be involved with the development of GDM 
(Amiri et al., 2013; Chen et al., 2006; Rawal et al., 2017). Two independent studies have shown 
that antenatal iron supplementation, leading to increased levels of maternal iron, increased the 
risk of GDM and was associated with glucose impairment and hypertension throughout gestation 
suggesting a link between imbalanced iron homeostasis and GDM (Bo et al., 2009; Helin et al., 
2012).  
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Given the relationships among GDM, placental macrophage activation and iron 
homeostasis, we sought to conduct a retrospective, case-control, study of archived human 
placental tissue from women with or without GDM to better define placental pathology, 
placental iron stores, and both macrophage density and CD163 expression in situ.  
 
Materials and Methods 
Study Design 
           This study was reviewed and approved by the Vanderbilt University Institutional Review 
Board (protocol #150498). This study was a retrospective conceptualized and completed in 
collaboration with the Vanderbilt Institute for Clinical and Translational Research (VICTR) at 
Vanderbilt University Medical Center. Placental tissue specimens were identified through the 
Synthetic Derivative (SD), a queryable, real-time, deidentified electronic medical record 
(EMR)(Roden et al., 2008). The SD allowed us to identify patient medical records that were 
linked to archived formalin-fixed paraffin embedded (FFPE) placental tissue blocks obtained 
from the same patients. Placentae had been sent for histopathological review at the discretion of 
the attending obstetrician. The SD was queried to identify possible cases of women with GDM as 
well as healthy controls who also had placental FFPE blocks available. The databases were 
searched for key words including GDM, abnormal glucose, and International Statistical 
Classification of Diseases and Related Health Problems (ICD) 9 codes suggesting GDM 
including, Personal History of Gestational Diabetes (V12.21), Diabetes Mellitus Complicating 
Pregnancy Childbirth or the Puerperium (648.0), Gestational Diabetes, Antepartum (648.83). To 
identify unaffected controls, we required the absence of these key words and codes.  
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Participants  
      Our initial query identified 1,292 possible GDM cases and 554 possible control cases 
(Figure 1). The number of participants in this study was limited to 25 patients with GDM and 25 
matched controls. The study design and sample distribution are outlined in Figure 1. From 
possible cases, we selected 25 cases, in which were able to confirm a diagnosis of GDM 
according to prespecified inclusion and exclusion criteria. Inclusion criteria included an 
abnormal oral glucose tolerance test (OGTT, defined below) and having access to a full FFPE 
placental cross-section, record of gestational age at birth, maternal age, and delivery method 
(Supplemental Table 1).The presence of GDM was established if the woman had at least 2 
values of the 100 g 3-hour OGTT above normal. Normal 100 g OGTT levels was defined as 95 
mg/dl at fasting, 180 mg/dl at 1 hour, 155 mg/dl at 2 hours, and 140 mg/dl at 3 hours. Women 
were excluded from the study if they were diagnosed with preeclampsia, had previously 
diagnosed diabetes, or had tested positive for illicit drug use. We also excluded women who had 
active signs of infection during pregnancy or at the time of delivery based on placental pathology 
notes and noted fetal abnormalities during pregnancy or at delivery. Controls were then matched 
to cases on the basis of gestational age at delivery, maternal age, and method of delivery.       
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Figure 1 Study design and sample distribution Workflow diagram depicting study design and 
distribution of investigated population including the numbers of patients included and excluded 
from the study. Our goal for this pilot study was to include 25 cases and controls. Once we 
confirmed the first 25 cases, we excluded the remaining 830 possible cases from review. 
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Data Collection 
Patient demographic information, vital statistics, and laboratory results including age, 
race/ethnicity, indication for delivery, body mass index (BMI), placental weight and volume, 
fasting glucose and 3-hr OGTT results, and maternal hematocrit were obtained through the SD. 
Not all patient records provided data on BMI or maternal hematocrit levels. We were able to 
collect data for calculating BMI for 27.2% of participants and maternal hematocrit for 86.3% of 
participants at time of delivery. Due to the nature of our study design, we could not recover all 
missing data points for these variables and have listed the missing number of data points where 
appropriate (Table 1).  
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Table 1 Characteristics of study participants by case status Cases and controls were matched 
by maternal age, gestational age, and indication for delivery. Maternal hematocrit (Hct) levels 
are from the day of delivery and were significantly higher in the case population compared to 
control with a p value of 0.02.  
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Immunohistochemistry and Pathological Analysis 
A total of 50 FFPE blocks were requested from Pathlink, the Vanderbilt Tissue Biobank 
which accrues patient samples and is linked to a de‐identified version of data extracted from an 
EMR system, in which all personal identifiers have been removed for analysis (Pulley, Clayton, 
Bernard, Roden, & Masys, 2010). FFPE blocks containing cross-sectional human placenta were 
sectioned and stained for analysis by the Translational Pathology Shared Resource (TPSR) at 
Vanderbilt University Medical Center. In some instances, full-thickness cross-sections 
containing the decidua, placental disc, and chorion, were unavailable. For these patients, pairs of 
blocks jointly forming a full-thickness cross section were obtained for analysis. Serial sections 
were prepared from the FFPE blocks and were stained with hematoxylin and eosin (H&E), 
Prussian blue, CD163 and CD68 at TPSR using standard protocols. Some requested samples 
were unavailable or in poor quality and thus were excluded from the study. While other samples, 
once cut from the FFPE blocks and stained, were missing sections of the decidua, chorion, or 
both. When this occurred, we excluded the corresponding tissue section in the matched sample. 
In total, 22 FFPE blocks from cases and 22 FFPE blocks from controls were available for 
analysis (Figure 1). 
All H&E-stained slides were reviewed by a pathologist blinded to GDM status and prior 
diagnostic findings using a custom data entry form. Amnion, villous disc, and decidual surface 
were systematically evaluated for multiple abnormalities including meconium laden 
macrophages, acute inflammation, infarcts, hydrops, villous maturity, and decidual and fetal 
vessel maturation. This allowed for uniformity and comparability in description. Histological 
findings were determined using standard clinical criteria. Representative images were captured 
under bright-field illumination with automated exposure. 
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Slide Imaging and Digital Quantification 
Slides were digitally scanned at 20X magnification using a Leica SCN400 Slide Scanner 
by the Digital Histology Shared Resource (DHSR) at Vanderbilt University. Digital analysis and 
quantification was performed using Leica Biosystems Digital analysis software. For 
quantification of CD68, CD163, and iron within placental tissue, digital annotations were made 
segregating the chorion and decidua from the remainder of the placental disc (villous core). 
Cellular staining and iron staining were quantified for the entire placental tissue and individually 
for the chorionic and decidual annotated sections. The whole specimen encompasses all tissue on 
the slide including chorion and decidua if present as well as the villous core. CD68 and CD163 
were quantified as the percentage of positively staining cells per total cells. Iron staining was 
quantified as the percentage of positively staining area of total tissue within the given region. 
When either the decidua or chorion was absent from a patient sample, the corresponding region 
was excluded from analysis for its matched control or case.  
 
Statistical Analysis 
Pearson’s X2 and two-sample t-tests were used to assess variation in categorical and 
continuous study participant characteristics, respectively. We used beta regression to predict the 
marginal effects of gestational diabetes for histological features that were measured as the 
proportion of cells with a given characteristic (proportion of cells to stain for CD68, CD163, and 
iron moderately, strongly, and overall). Beta regression accounts for a continuous outcome 
variable being bounded [0, 1], unlike linear regression. We used logistic regression to calculate 
the odds ratio (OR) of placental tissue from cases having abnormalities that were either present 
or absent as compared to controls. For histological characteristics with more than two levels, we 
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used polytomous regression to calculate ORs of the placental tissue from cases having the feature 
as compared to controls. We provide crude estimates and estimates adjusted for maternal 
hematocrit. In our supplemental analysis, we used linear regression to estimate the expected 
change in absorbance and intensity for CD68 and CD163 staining in cases compared to controls. 
 
Results 
Study Participant Characteristics 
Study participant characteristics and data gathered from the SD are summarized in Table 
1.  The average maternal age for controls was 27.0 while cases had an average maternal age of 
29.3 (S.D. for controls and cases were 5.5 and 5.8 respectively). Average gestational age at time 
of delivery for controls was 37.5 weeks and 37.2 for cases (S.D. for controls and cases were 2.1 
and 1.8 respectively). The retrospective nature of this study limited our ability to collect BMI 
information on all subjects. The pre-pregnancy BMI and 1st trimester BMI information collected 
did not reveal significant difference between controls and cases. Placental weight and placental 
volume did not differ between cases and matched controls. The 50g OGTT was elevated in cases 
compared to controls, as expected. All control subjects had a normal 50g OGTT, therefore 3-
hour OGTT was neither clinically indicated nor performed. Maternal hematocrit levels at 
delivery were significantly elevated in GDM women compared to controls at 35.3% versus 33% 
for controls (p=0.02). In light of hematocrit differences between cases and controls, and given 
the relationship between iron and hemoglobin, we adjusted analyses for differences in maternal 
hematocrit levels. 
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Table 2 Differences in histological characteristics by gestational diabetes status Histological 
characteristics were identified on H & E stained slides by a clinical pathologist blinded to 
gestational diabetes status.  
 47 
GDM placentae exhibit an increase in abnormal histology 
Meconium-laden macrophage levels within the amnion of GDM placentae were 
significantly higher at 36.4% compared to 4.6% of controls. Correspondingly, a greater 
percentage of GDM placentae showed amnion epithelial reactive changes suggestive of 
meconium exposure - 68.2% of GDM placentae versus 36.4% of controls (Table 2, Figure 
2).These differences remained statistically significant after adjustment for maternal hematocrit. 
GDM placentae exhibited abnormal villous size compared to controls with the GDM 
placentae showing signs of accelerated maturation for gestational age. When adjusted for 
maternal hematocrit levels however, the difference was no longer significant. The presence of 
calcifications was significantly increased in GDM placentae in the crude, but not adjusted 
analysis (Table 2).  
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Figure 2 Histological characteristics of placenta from women with GDM and healthy 
controls. Histological characteristics were identified on H & E stained slides by a clinical 
pathologist  blinded to gestational diabetes status. A) Image of normal amnion tissue from a 
control placenta (40x) B) Amnion displaying example of reactive changes suggestive of 
meconium in a placenta from a mother with GDM (40x) C) Black arrow indicating meconium-
laden macrophage and stripped arrow indicates reactive macrophage from GDM placenta (100x) 
D) Prussian blue staining black arrows indicate hemosideran-laden macrophages in GDM 
placenta (100x) E -H) Representative H & E images showing differing levels of villous 
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maturation in placental villi (40x). Normal villi from control, large villi from GDM, accelerated 
maturation villi from control, and hypermature villi from control respectively. 
 
CD163 and iron storage are increased in GDM placentae 
To examine the impact of GDM on placental macrophages and iron stores, we stained 
full placental cross-sections for CD68, CD163, and iron. The chorion of GDM placentae 
contained a significantly higher number of moderately stained CD163 positive cells compared to 
controls (Figure 3). The total number of positive cells as well as the total number of moderately 
staining CD163 positive cells was greater in the decidua of GDM placentae compared to 
controls. The higher expression of CD163 in the placentae of GDM mothers remained significant 
after adjustment for maternal hematocrit (Table 3).  
We examined the amount of iron storage within the placenta by Prussian blue staining. 
The difference in Prussian blue stained positive area was not significantly different in the chorion 
or decidual areas independently of the villous core (Table 3). However we observed a significant 
increase in iron positive area within the entire tissue, indicating that the increase in iron staining 
was localized to the fetally-derived villous core. The difference remained significant after 
adjustment for the maternal hematocrit levels.  
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Table 3 Differences in CD68, CD163, and iron staining by gestational diabetes status 
Histological characteristics were identified on H & E stained slides by a clinical pathologist 
blinded to gestational diabetes status.  
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Figure 3 Differences in CD68, CD163, and iron staining by gestational diabetes status. 
FFPE blocks of placental specimens from women with GDM and control were stained for A) 
CD68 B) CD163 C) Prussian blue staining for iron.  Slides were then digitally scanned and 
imaged for digital quantification purposes. Representative images were randomly captured at 
20x. 
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Discussion 
A growing body of evidence suggests and supports an association between GDM and 
altered histological and physiological characteristics within the placenta, an increase in maternal 
and placental inflammation, and an increase in maternal iron status (Afkhami-Ardekani & 
Rashidi, 2009; al-Okail & al-Attas, 1994; Amiri et al., 2013; Calderon et al., 2007; Chen et al., 
2006; Kuzmicki et al., 2008; Mrizak et al., 2014; Pendeloski et al., 2015; Radaelli et al., 2003; 
Rawal et al., 2017; Rudge et al., 2011; Schober et al., 2014; Sisino et al., 2013; Yu et al., 2013). 
In this study we used a novel approach to retrieve archived placental tissue linked to de-
identified patient records in order to investigate differences in placental histology, placental 
macrophage number, distribution, CD163 expression, and iron storage within the placenta in 
order to gain a better understanding of how GDM affects these placental characteristics. Indeed, 
we found an increase in abnormal placental histological characteristics, and increase in CD163 
expression, and an increase in iron storage within the placenta of women with GDM. The 
findings presented here shed light on specific pathological and cellular changes that occur within 
the placenta as a result of GDM. These changes may mediate the pre and postnatal complications 
associated with GDM and confirm the need to look further into the role of iron and iron 
supplementation during pregnancy in women at risk for GDM.  
 
GDM and Maternal Hematocrit 
Our study identified an association between GDM and an increase in maternal hematocrit 
level, which is consistent with reports in pregnant and non-pregnant persons with diabetes. 
Associations between hematocrit levels and diseases of insulin resistance and metabolic 
syndrome have been reported, however, associations vary depending on study design and 
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population (Barbieri et al., 2001; Capoglu, Unuvar, Bektas, Yilmaz, & Kaya, 2002; Nebeck et 
al., 2012; G. Wannamethee & Shaper, 1994; S. G. Wannamethee, Perry, & Shaper, 1996). Lao 
reported women with GDM have higher hemoglobin, red blood cell count, and hematocrit levels 
in the third trimester, but not earlier in gestation (Lao & Ho, 2002). Another study reported no 
increase in hematocrit levels during pregnancy in cases of GDM; however, they described an 
increase in maternal hemoglobin levels throughout the duration of pregnancy and have a high 
hemoglobin and hematocrit level at baseline (Tan, Chai, Ling, & Omar, 2011). Elevated 
hematocrit levels have been reported to be an independent risk factor for the development of 
T3D and impaired glucose tolerance (Capoglu et al., 2002). Hyperinsulinemia and insulin 
resistance are features of metabolic syndrome, type 2 diabetes, and GDM. Hematocrit levels 
increase as a result of increased erythropoiesis, which might explain the increase observed in 
GDM patients. Previous studies have provided evidence for a relationship between 
hyperinsulinemia and an increase in erythropoiesis (Barbieri et al., 2001). Insulin resistance is 
associated with increased levels of insulin-like growth factor-1, which may lead to an increase in 
erythropoiesis, hence increasing hematocrit levels within GDM patients. This phenomenon has 
been demonstrated previously in rats (Kurtz et al., 1988). In healthy individuals, an increase in 
hematocrit levels would suggest superior oxygen delivery throughout the body. Alternatively, it 
is possible that GDM causes worse oxygen delivery to the placenta and the combination of 
elevated hematocrit levels and accelerated villous maturation that we report here are 
compensatory responses to an increased need for oxygen within the placenta. Future studies are 
needed to confirm our findings and assess these possible mechanisms. 
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Placental Histopathological Changes in GDM 
The histopathological changes identified in the placentae of women with GDM were 
heterogeneous and varied in their severity. Our analysis discovered a significant increase in the 
presence of meconium-laden macrophages and epithelial changes presumed reactive to 
meconium within the amnion of GDM placentae. Meconium is fetal stool composed of bile acid, 
phospholipases, and other components. While the passage of meconium prior to 32 – 34 weeks is 
rare, 15 – 20 % of placentas are affected by the passage of meconium at delivery. The passage of 
meconium in utero may be indicative of fetal stress, typically hypoxic or ischemic stress, 
although not always present in cases of fetal stress. Although the exact implications of increased 
numbers of meconium-laden macrophages with the amnion are unknown, the uptake of 
meconium by alveolar macrophages has been shown to decrease macrophage phagocytosis and 
increase the release of TNF-α from macrophages (Craig, Lopez, Hoskin, & Markham, 2005; 
Lally, Mehall, Xue, & Thompson, 1999).  
Villi arborize and mature throughout gestation, with more mature villi showing a smaller 
cross section and peripheral capillaries (Khong et al., 2016). These changes can be expected to 
maximize surface area and thus oxygen diffusion. Villous maturation varies in pathologic 
circumstances – immature villi have been repeatedly reported in GDM, while precocious 
maturity has been reported in conditions with impaired maternal-fetal circulation (Daskalakis et 
al., 2008; Khong et al., 2016; Rudge et al., 2011). In clinical practice, as in this study, villous 
maturation is based on a gestalt impression, rather than systematic measurement. Perhaps 
surprisingly, this gestalt impression has been shown to correlate with maturation-based gene 
expression changes (Leavey et al., 2017). It is unclear why our results differ from previously 
reported studies in GDM. There are several minor methodologic differences; however the most 
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likely cause is the use of a retrospective case: control design with matching by maternal and 
gestational age in the present study as compared to the prospective cohort-based designs in other 
studies. As noted in the results, the difference in villous maturation was no longer apparent when 
controlling for hematocrit. This suggests a unifying mechanism wherein GDM impairs oxygen 
delivery to the placenta, thus inducing the compensatory responses of accelerated villous 
maturation and increased red cell mass. 
The presence of villous calcifications was elevated in GDM placentae compared to 
controls prior to adjustment for maternal hematocrit levels, with a fairly large effect size 
(unadjusted odds ratio of 4.67 (95% confidence intervals of 1.30-16.76, Table 2).  Calcifications 
are indicative of an aging placenta (Jeacock, 1963). The clinical significance of such 
calcifications is not well defined although calcification is likely due to an increase in available 
calcium and phosphate within the placenta (Jeacock, 1963). Prominent in late term and post-term 
placentae, they can occur in the absence of other placental pathologies, particularly in peripheral 
areas. However, the mineralization process through which calcifications occur may be 
accelerated in some disorders of pregnancy. The early appearance of calcifications may represent 
accelerated placental maturation and or senescence brought about as a result of fetal stress and 
maternal complications such as maternal hypertensive disorders (Quinlan, Cruz, Buhi, & Martin, 
1982). Quinlin and colleagues first noted that placentae from pregnancies complicated by 
diabetes develop calcifications earlier in gestation than non-complicated pregnancies and may 
represent early placental dysfunction (Quinlan et al., 1982). Although significance was lost after 
adjustment for maternal hematocrit, the effect size was 3.70 (95% confidence intervals of 0.86-
16.89), suggesting that the small samples size might have played a role in the lack of 
significance. A difference in placental calcifications indicates that GDM may influence nutrient 
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availability within the placenta as well as leading to accelerated placental maturation and cellular 
senescence. The hypothesis that GDM may accelerate placental maturation is further 
strengthened by our reported finding that we observed an increase in villous maturation within 
the GDM cohort compared to control. The mechanism driving the accelerated maturation which 
could be linked to an increase in villous calcifications is yet to be defined.  
 
Placental Macrophages and GDM 
CD68 is a pan-macrophage marker found on monocytes and macrophages (Pulford, 
Sipos, Cordell, Stross, & Mason, 1990). We utilized this marker as way to localize and 
enumerate macrophages within the placenta. Our study identified no significant difference in the 
number or distribution of placental CD68+ cells between cases and controls. Another study 
which looked for CD68 expression levels within placental tissue of GDM and control patients 
found no significant difference in the levels of CD68 transcript levels (Abumaree et al., 2013). 
These findings contradict other reports where increases in the mRNA expression of CD68, in 
conjunction with increased expression levels of IL-6 and TNF- α, were observed in pregnancies 
complicated with GDM (Li et al., 2013). Mrizak et al also reported an increase in transcript 
levels of CD68 and CD14, both common human monocyte/macrophage markers, within placenta 
recovered from women with GDM (Schober et al., 2014). That study, however, only collected 
placentae from women diagnosed with GDM whose child was born with macrosomia. The 
presence of macrosomia as an inclusion criterion may have biased the results for more severe 
cases of GDM than we included. Other studies reported conflicting results regarding the level of 
CD68 mRNA in gene expression analysis studies. The discrepancies in results regarding the 
expression of CD68 mRNA or the enumeration of CD68+ stained cells via microscopy between 
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GDM and control placentae are not yet explained. The infiltration or expression of CD68 within 
placental tissue may depend on multiple factors, not just the presence or absence of GDM. The 
severity of insulin resistance, the amount of circulating inflammatory factors, and the degree to 
which glucose levels are controlled during pregnancy may all influence macrophage numbers 
and distribution within the placenta.     
 
 
Figure 4  Macrophage Iron metabolism is coupled to inflammatory status The expression of 
iron regulatory proteins such as CD163, a hemoglobin scavenger receptor, ferritin, an iron 
storage protein, and ferroportin, an iron export protein, are affected by the inflammatory status of 
the macrophage. High levels of intracellular iron stores in the form of ferritin and low levels of 
CD163 and ferroportin expression are characteristic of M1 or pro-inflammatory macrophages. 
This phenotype allows for the sequestration of iron from the extracellular environment. M2 or 
anti-inflammatory macrophages store less intracellular iron and increase expression of CD163 
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and ferroportin permitting for increased uptake and degradation of hemoglobin/haptoglobin 
(Hb/Hp) complexes and the recirculation of iron to the extracellular environment.  
 
A hemoglobin scavenger receptor that mediates the endocytosis of hemoglobin-
haptoglobin complexes, CD163, is exclusively expressed on macrophages and is often utilized as 
a marker for placental macrophages (Kristiansen et al., 2001; Z. Tang et al., 2011). We identified 
an increase in CD163+ cells within the decidua of GDM placentae and an increase in the amount 
of moderately stained CD163+ cells within the chorion. Expression of CD163 has been 
associated with an anti-inflammatory (M2) macrophage phenotype (Abumaree et al., 2013; Z. 
Tang et al., 2013). Anti-inflammatory mediators such as IL-10 promote the expression of CD163 
while pro-inflammatory mediators such as IFN-γ and TNF-α have been shown to decrease its 
expression (Buechler et al., 2000). CD163 also exists in soluble form, sCD163 (Etzerodt et al., 
2010). Similar to TNF-α, the ectodomain of CD163 is cleaved from the surface of macrophages 
in an inflammation-driven fashion (Etzerodt et al., 2014). Levels of circulating sCD163 increase 
in mothers with GDM in conjunction with increases in circulating TNF-α and IL-6 (Bari et al., 
2014). Placental tissue, as well as adipose tissue, from GDM mothers is a source of increased 
sCD163 circulating in maternal serum as described by placental and adipose tissue explant 
studies (Bari et al., 2014). GDM appears to not only increase the expression of CD163, but also 
increase levels of sCD163 in maternal serum. These findings are in agreement with previous 
findings of elevated sCD163 in GDM (Bari et al., 2014). The molecular mechanisms leading to 
the cleavage of CD163 from placental macrophages has yet to be elucidated in the case of GDM 
so future attention should be paid to discovering the mechanisms involved in this phenomenon. 
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Placental Iron Load Increases in GDM 
Placental iron load for the tissue as a whole was significantly increased in GDM. 
However, close examination of both the decidua and chorion independently revealed no 
difference, indicating that the increase in iron load within the placenta is found primarily within 
the fetally-derived villous tissue. The opposite was found to be true for the presence of CD163. 
CD163 showed significance within the chorion and decidua individually, but not the tissue as a 
whole. The villous core, the majority of the placental specimen, is primarily fetally-derived 
tissue, bathed in maternal blood, and acts as the site of exchange between maternal and fetal 
circulation. As this area is saturated in maternal blood, it makes sense that the villous core stores 
iron at a higher level than within the chorion or decidua. Iron enters and exits macrophages in 
many different forms through many different pathways, including CD163 (Donovan et al., 2005; 
Soe-Lin et al., 2009). If macrophage polarization is impacted in cases of GDM, the relative 
expression of CD163 as well as iron storages within the macrophage may be altered in response. 
As reviewed by Cairo, et al., macrophage iron metabolism is influenced by the local 
inflammatory environment (Cairo et al., 2011). If GDM influences the inflammatory 
environment, CD163 expression and iron storage within the placenta may be effected as well. 
Multiple other cell types within the placenta are involved in iron homeostasis. Our findings of 
increased iron stores within GDM placentae correspond with previously reported data indicating 
that women with GDM have a significantly increased iron stores, as measured by hemoglobin, 
ferritin, and transferrin saturation (Afkhami-Ardekani & Rashidi, 2009). The physiological 
mechanism driving the increase in stored iron and more information regarding the cells in which 
the iron is stored needs further investigation and may shed light onto the apparent link between 
GDM, iron, and possible mechanisms driving adverse phenotypes. 
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Study Limitations 
Our study has important limitations, which may reflect the retrospective nature of, and 
small number of subjects included in this study. Our pilot study was relatively small and 
designed to be inclusive of a large range of maternal ages and gestational ages while representing 
diverse ethnicities. This inclusivity may have introduced variability into our results. Future 
studies should be designed to account for variability due to gestational age, maternal age, and 
ethnicity.  The previously archived placental tissues included in this study were sent to pathology 
at the discretion of the obstetrician present at delivery. While there are recommended indications 
for placental examination, they are inconsistently followed. This could introduce difficult to 
measure confounders, since normal-appearing placentas from normal pregnancies are rarely sent 
for pathology. This study was likely underpowered to confirm a previously reported association 
between increased placental weight and GDM (Taricco, Radaelli, Nobile de Santis, & Cetin, 
2003). Although both placental weight and volume were higher in cases than in controls in our 
study, neither difference reached statistical significance. This may also reflect more aggressive 
treatment of GDM than in the time period when prior studies were conducted (Metzger et al., 
2008). Prepregnancy obesity is a risk factor for GDM but we did not have prepregnancy height 
and weight measurements on most of the subjects in this study. Although we matched our GDM 
samples to our controls for variables such as maternal age and gestational age at birth, 
differences in other patient characteristics might have introduced variability. Differences in some 
of our measured parameters may be evident in some subgroups for which this pilot study is 
undersized. The nature of FFPE placental tissue and the age of some of the blocks themselves 
did not allow us to gather quantifiable information on all sections of the placenta due to quality 
and loss of tissue.  
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Conclusion 
In conclusion, this study demonstrates that the presence of GDM influences 
multiple iron related parameters including an increase in maternal hematocrit levels, an increase 
in CD163 within the chorion and decidua, and an increase in iron stores within the fetally 
derived villous core. Our results also highlight GDM’s influence on multiple placental 
physiological parameters such as meconium-laden macrophages, placental villous size and 
maturation, and an increase in the presence of villous calcifications. Taken together, the 
alterations exhibited by the placenta in cases of GDM may provide insight into the role of the 
placenta in the complications associated with this common metabolic disorder of pregnancy. 
However, future studies are needed to further elucidate the role of placental iron and 
inflammation in the development, progression, and postnatal complications associated with 
GDM.  
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CHAPTER 3 
 
GESTATIONAL DIABETES MODIFIES MIA INDUCED GENE EXPRESSION IN THE 
FETAL BRAIN 
 
Theresa Barke, Kelli M. Money, Krassimira A. Garbett, Karoly Mirnics, and David M. Aronoff 
 
Introduction 
Genetics alone cannot explain the development of many psychiatric disorders. Maternal 
exposure to a wide array of pro-inflammatory environmental factors can increase the risk of 
certain developmental and psychiatric disorders. It is not necessary that the inflammatory 
conditions be excessive or chronic in nature in order for the risk of psychiatric disorders to 
increase (Berk et al., 2013; Derry, Padin, Kuo, Hughes, & Kiecolt-Glaser, 2015). Multiple 
studies have revealed that in utero stressors have the potential to induce adverse consequences on 
brain development and influence behavior (Hamlyn, Duhig, McGrath, & Scott, 2013; Patterson, 
2009; Rapoport, Giedd, & Gogtay, 2012). Most studies thus far have investigated the impact of a 
single environmental stressor and its influence on the development of psychiatric disorders. As a 
result of these individual studies, it has been shown that both maternal infection and gestational 
diabetes impact brain development and have been suggested to increase risk of developing 
psychiatric disorders later in life (Abell et al., 2015; Mandal et al., 2013; Urs Meyer, 2014; 
Patterson, 2011; Salbaum & Kappen, 2012; Torres-Espinola et al., 2015). Multiple studies have 
previously suggested that even low levels of chronic inflammation interact with environmental 
and genetic risk factors increasing the risk for psychiatric disorders (Maes et al., 2009; Michel, 
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Schmidt, & Mirnics, 2012; Patterson, 2009). Despite our current knowledge, it is currently 
unknown how maternal infection and gestational diabetes, two well established inflammation-
inducing psychiatric disorder risk factors, interact with one another to influence fetal brain 
development. In order to address this, we characterized models of poly(I:C) induced MIA and 
high fat diet induced gestational diabetes then assessed the changes in fetal brain gene expression 
as a result of MIA, high fat diet induced GDM, and the combination of the two.  
 
Materials and Methods 
 
Animal procedures 
 All animal procedures were approved by the Vanderbilt Animal Care and Use 
Committee. Mice were housed under standard laboratory conditions and allowed ad libitum 
access to food and water. Female and male C57Bl/6J mice were obtained from The Jackson 
Laboratory (Bar Harbor, ME, USA). Control female mice were given standard chow throughout 
the experiment (5LOD, Lab Diet, St. Louis, MO, USA). In order to induce GDM, females 
received 60% calories by fat diet (58Y1, Test Diet, St. Louis, MO, USA) from 4 weeks of age 
until 10 weeks of age and continued throughout pregnancy. At 10 weeks of age, mice were 
mated overnight, and the presence of a vaginal plug the following morning marked gestational 
day 0.5 (GD0.5). Pregnant females were left undisturbed except for cage changes and weight 
measurements.  
 High fat diet and control fed females were randomly assigned to the saline or poly(I:C) 
treatment groups. At GD12.5, pregnant females were injected intraperitoneally with either sterile 
saline or 20 mg/kg poly(I:C) potassium salt (Sigma Aldrich, St. Louis, MO, USA) in sterile 
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saline creating 4 treatment groups: control fed saline (SAL), high fat fed saline (HFS), control 
fed poly(I:C) injected (MIA), and high fat fed poly(I:C) injected (HFM). Pregnant mice were 
then sacrificed at one of two time points; either 3 hours after injection at GD12.5 or 4 days post 
injection at GD16.5. Experimental design is outlined in Figure 5. Maternal serum was collected 
from each pregnant female and fetal brains were collected from all viable pups. Maternal serum 
was utilized for cytokine, adipokine, and non-fasting insulin measurements. Cytokine and 
adipokine levels were measured with the assistance of the Vanderbilt Hormone core via 
antibody-conjugated bead-based multiplex assays. Brains were flash frozen until RNA isolation 
was performed, and tail snips were taken from each embryo for sex genotyping. Each group at 
each time point (4 groups, 2 time points) contained 9 pregnant females with the exception of 
GD12.5 MIA which only contained 8 females, making a total of 71 females. 
 
Glucose tolerance testing and body composition analysis 
 A separate cohort of control fed and high fat fed females were bred and treated as 
described above for comparative glucose tolerance and body composition testing (n= 6 per 
group). At GD12.5, pregnant control fed and high fat fed females were fasted for 6 hours. Body 
composition was then measured via whole body NMR (Minispec Model mq7.5, Bruker 
Instruments) with the assistance of the Vanderbilt Mouse Metabolic Phenotyping Center. Blood 
samples utilized for glucose tolerance testing were obtained from tail snips. Fasting glucose and 
insulin samples were taken followed by intraperitoneal injection of 2g dextrose/kg body weight. 
Utilizing an Aviva Accu-Chek glucometer, blood glucose measurements were taken at 10, 20, 
30, 45, 60, 75, 90, and 120 minutes post-injection. Blood samples were collected for insulin 
measurement at 10, 30, 60, 90, and 120 minutes post-injection and were processed by the 
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Vanderbilt hormone core. Dams were sacrificed after all testing was complete to confirm 
pregnancy and gestational age. In order to evaluate the effects of the high fat diet alone on 
glucose parameters and body composition, one 10-12 week old non-pregnant control group (n=8) 
was utilized as the control for non-pregnant high fat females age 10 weeks (n=7) and age 12 
weeks (n=8).  
 
Sex genotyping 
 Sex genotyping was performed on each embryo. Digested tail snips from each embryo 
were utilized for sex determination. Forward (5’-CGCTGCCAAATTCTTTGG - 3’) and reverse 
(5’- TGAAGCTTTTGGCTTTGAG - 3’) primers for SmcXY locus were utilized (Jacobs, Fogg, 
Emeson, & Stanwood, 2009). Thermocycler conditions started with 93°C for 2 minutes; 
followed by 30 cycles of 93°C for 30 seconds, 58°C for 45 seconds, and 72°C for 45 seconds; 
and ended with 72°C for 10 minutes. Female embryos resulted in an upper band at 330 bp while 
male embryos had both an upper (330 bp) and a lower (290 bp) band.  
  
Antibody-conjugated bead-based analysis 
 Immediately after sacrifice, blood was collected directly from the heart via cardiac 
puncture. Approximately 0.5 to 1 mL of blood was collected from each pregnant dam and 
allowed to clot at room temperature for 30 minutes. The samples were spun at 8,000 rpm for 10 
minutes at 4°C. Supernatant was transferred to a new sterile tube and spun again at 8,000 rpm for 
10 minutes at 4°C in order to remove any residual red blood cells. The resulting supernatant, 
serum, was transferred to a new tube and stored at -80°C until antibody-conjugated bead-based 
analysis was performed. 
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 Luminex analysis utilizes a multiplexed assay, using x-map technology via the MagPix 
system. Luminex analysis was performed by the Vanderbilt hormone core 
(http://hormone.mc.vanderbilt.edu), which is funded in part by NIH grants (DK059637 and 
DK020593). The Luminex multiplex panels (EMD Millipore, Darmstadt, Germany) used for 
analysis of the maternal serum were the mouse metabolic hormone panel (insulin and leptin – 
Cat# MMHMAG-44K), mouse adiponectin (Cat # MADPNMAG-70K-01), and mouse 
cytokine/chemokine panel 14 plex (eotaxin, IFNγ, IL1α, IL1β, IL4, IL6, IL10, IL12p40, IL13, 
IL17, KC, MCP1, RANTES, and TNFα- Cat# MCYTOMAG-70K).  
 
RNA isolation and Nanostring gene expression analysis 
 The right hemisphere from each fetal brain, which included both the telencephalon and 
diencephalon, was utilized for RNA isolation. RNA was isolated according to the manufacturer’s 
protocol in 1 mL Trizol. Resulting samples then underwent a Qiagen RNeasy clean-up, by 
following the protocol provided by the manufacturer. RNA concentration was measured using a 
Thermo Scientific Nanodrop 2000. Equal amounts of RNA (1250 ng) from each fetal brain were 
combined to create 1 pooled sample per litter. The resulting pooled samples underwent another 
Qiagen RNeasy clean-up step to remove any remaining contaminants. To measure final 
concentration and purity (260/280 values above 2 and 260/230 values above 1.5) the Thermo 
Scientific Nanodrop 2000 was utilized. The Agilent 2100 Bioanalyzer was employed to ensure 
RNA integrity, with all RNA integrity numbers falling between 9.5 and 10. 
 150 ng of purified RNA from each pooled sample was used for Nanostring nCounter 
analysis (http://www.nanostring.com/applications/technology). Two panels, the mouse 
inflammation V2 panel- 254 genes- and a custom inflammation and neurodevelopment panel 
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containing 4 genes, were utilized to measure gene expression values. Nanostring multiplexed 
gene expression technology utilizes a digital color-coded reporter tag to identity and count 
expression of genes. RNA samples were hybridized with an identifying reporter probe as well as 
capture probes at 65°C for 24 hours. The hybridized samples were then placed in the Nanostring 
nCounter prep station where the complexes were aligned and immobilized in the nCounter 
cartridge then read on the Nanostring nCounter digital analyzer. The resulting raw counts were 
normalized to positive and negative spike in’s and the 5 included housekeeping genes (Cltc, 
Gapdh, Gusb, Hprt, and Tubb5). In order to reduce background noise, a baseline of 10 counts 
was set, and all counts below 10 were raised to 10 for analysis. Any results made statistically 
significant by this manipulation were excluded from the resulting analysis as being significant. 
Normalized counts were then log2 transformed for analysis. To investigate the effects of high fat 
diet or MIA alone, HFS and MIA were each compared to SAL. To investigate the effect of MIA 
in the context of high fat diet, HFM was compared to HFS. To uncover differences in the MIA 
induced changes in the context of high fat diet induced gestational diabetes compared to in the 
context of control diet, dMIA [each MIA log2(counts) – the average SAL log2(counts)] and 
dHFM [each HFM log2(counts) – the average HFS log2(counts)] was calculated and then 
compared.  
 
Statistical Approaches 
To investigate the effects of diet and treatment exposure on litter statistics, a two-way 
ANOVA with Bonferonni post hoc analysis was performed, with a p-value <0.05 considered 
significant. In all other instances, an unpaired student t-test with Welch’s correction was used to 
compare values between two groups, with a p-value <0.05 considered significant. With regards 
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to the gene expression data, criteria for significance included having a >10% change (>0.138 
ALR) in value and significance by an unpaired student t-test with Welch’s correction which was 
not artificially created if the baseline was raised.  
 
Results 
 
High fat diet and poly(I:C) treatment affect dam weight, but not litter statistics 
A total of 35 pregnant mice were used per GD12.5 and GD16.5 time point in our study; 9 
pregnant dams per SAL, HFS, and HFM group and 8 pregnant dams in the MIA group.  
Poly(I:C) treatment has been shown to cause a transient increase in cytokine production, 
accompanied by anorexia, fever, and sickness behaviors that usually resolves within the first 24-
48 hours. The poly(I:C) treatment in our study caused the dams to either lose weight or fail to 
gain weight compared to saline treated dams (SAL = 0.60 ± 0.33, MIA = -0.83 ± 0.34; GDM = 
1.33 ± 0.25, GDM+MIA = -0.67 ± 0.31), p<0.05. Neither the high-fat diet nor the poly(I:C) 
treatment altered the average number of embryos per litter, the number of resorptions, embryo 
size, or the male: female ratio (Supplemental Table 2).  
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Figure 5. Diet and treatment experimental design. Mice were received at 4 weeks of age and 
randomly stratified into either the high-fat diet group or normal chow diet. Mice remained on 
their assigned diet for 6 weeks until they were mated at 10 weeks of age. 12 days after mating at 
GD12.5, for mice in which pregnancy was confirmed by the presence of a vaginal plug, the dams 
were randomly injected with either poly (I:C) or saline creating four distinct treatment groups.  
 
High fat diet leads to GDM mid-gestation 
Although the high fat diet dams were on a 60% by calorie fat diet for 6 weeks prior to 
mating and throughout pregnancy, these mice were not obese compared the control diet fed mice. 
Weight differences between the high-fat diet group and the control fed group were not 
significantly different at GD0.5, however gained significance, across the entire cohort, at GD9.5 
(control diet = 24.6 g ± 0.3, high fat diet = 25.8 g ± 0.4, p<0.05) and GD12.5 time points (Figure 
6A). To demonstrate that the high-fat diet successfully produced a gestationally diabetic 
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phenotype, glucose tolerance testing was conducted on mice fed normal or high-fat diets. 
Compared to control diet fed dams, the high-fat fed dams had increased body weight and percent 
fat mass at GD12.5 (Figure 6 A/B). In addition, the high fat diet dams had both impaired fasting 
glucose and increased fasting insulin after a 6 hour fast (Figure 6 C/D). When challenged with 2 
g/kg dextrose after the 6 hour fast, high fat diet fed dams displayed significant glucose 
intolerance and exaggerated glucose-induced insulin secretion that remained high even at 2 hours 
post-injection (Figure 6 E/F/G).  
It was important to confirm whether or not the diabetic phenotype is truly gestation-
dependent. In order to test this, two separate cohorts of high-fat fed dams, age matched at GD0.5 
and GD12.5, were used to compare to our pregnant cohorts for selected assessments. Confirming 
that the diabetic phenotype is gestation dependent, high-fat fed dams at GD0.5 showed no 
significant differences in body weight, composition, fasting glucose, or fasting insulin 
(Supplemental Figure 1). High-fat fed dam at GD0.5, when challenged with 2 g/kg dextrose, 
did not show significant differences in blood glucose levels at any time point throughout the test 
(Supplemental Figure 1). This data suggests that the high-fat fed dams did not have a diabetic 
phenotype at conception. To test whether or not the diabetic phenotype is a result of being on the 
high-fat diet for the duration of the study, GD12.5 age-matched non-pregnant high-fat fed dams 
were assessed. The non-pregnant high-fat and control diet fed dams age-matched to the GD12.5 
cohort did not demonstrate a diabetic phenotype although they did show trends towards an 
impaired glucose tolerance and displayed an increase in weight gain (Supplemental Figure 2). It 
is likely that over time the high-fat diet would lead to glucose intolerance, however, the 
pregnancy induced increase in glucose production and insulin insensitivity is the likely the cause 
of the diabetic phenotype at an earlier time point (Abell et al., 2015; Gallou-Kabani et al., 2007).      
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Figure 6. High fat diet produces a diabetic phenotype midgestation. Body composition, 6 
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hour fasting glucose and insulin, and glucose tolerance measurements were performed on a 
cohort of high fat(HF) and control(CTR) fed GD12.5 pregnant dams (n=6 per group). (A) High 
fat fed dams (HF) showed significant increases in body weight at GD9.5 and GD12.5. (B) Whole 
body NMR at GD12.5 showed significant changes in % body mass in high fat dams with 
increased % fat mass and decreased % lean body mass. (C-D) 6 hour fasting blood glucose and 
serum insulin were both significantly increased in high fat dams. (E-G) After a 6 hour fast, dams 
were injected intraperitoneally with 2 g dextrose/kg body weight. High fat fed dams 
demonstrated a higher peak and prolonged increase in blood glucose with significant differences 
from control dams observable at 0 10, 20, 30, 60, and 75 minutes post-injection, which is 
supported by a significantly increased area under the curve. A significant heightened insulin 
response that was maintained up until the 2 hour end point was also observed in high fat dams. 
Error bars represent SEM. Significance of p<0.05 is indicated by * and determined by unpaired 
student t-test with Welch’s correction in all assays, n=6 dams per group. 
 
MIA produces an acute increase in maternal cytokines and chemokines 
In order to assess the immune response within pregnant dams as a result of poly(I:C) as 
well as differences between normal and GDM mice, a panel of common cytokines and 
chemokines were measured in maternal serum at the time of sacrifice either 3 hours post 
poly(I:C) or saline exposure at GD12.5 or 4 days post poly(I:C) or saline exposure at GD16.5. 3 
hours after either poly(I:C) or saline injection, MIA-exposed dams in both the control and GDM 
groups demonstrated increases in Eotaxin, IL-1β, IL-6, IL-10, IL-12p40, IL-17, KC, TNF-α, 
MCP1 (CCL2), and RANTES (CCL5) (Figure 7). A subset of the cytokines and chemokines 
interrogated either exceed the range of the assay, in the case of MCP1 and IL-6, or fell below the 
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level of detection. In these cases, the analyte was analyzed at either the lowest or the highest 
detectable value. Not surprisingly, by GD16.5, almost no serum factor changes with MIA were 
observed, suggesting that the single poly(I:C) injection effects were acute and had largely 
subsided (Supplemental Figure 3). 
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Figure 7. MIA increases maternal serum levels of chemokines and cytokines. Maternal 
serum collected 3 hours post injection on GD12.5 was analyzed for chemokine and cytokine 
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levels via antibody-conjugated bead-based multiplex assay. (A-J) Significant increases were 
observed with MIA in both the context of control diet and high fat diet in all shown but IL1β, 
which demonstrated a significant increase with MIA exposure only in the context of high fat diet 
induced gestational diabetes. Error bars represent SEM. Significance of p<0.05 is indicated by * 
and determined by unpaired student t-test with Welch’s correction in all assays. 
 
Maternal metabolic hormones are altered by both HFS and MIA 
Maternal serum levels of metabolic hormones were found to be altered by both high-fat 
saline, diet-induced gestational diabetes, and MIA at GD12.5. HFS mice were found to have 
decreased levels of circulating adiponectin. These levels were not found to be further altered by 
the addition of MIA in the context of high-fat diet induced gestational diabetes (Figure 8A). 
Non-fasting serum insulin levels trended toward an increase with HFS alone, but the 
combination of HFS and MIA exposure produced a significant increase in serum insulin levels 
not seen with MIA exposure alone (Figure 8B). Interestingly, the immune-activating, satiety-
inducing hormone leptin was significantly increased by HFS and increased even further by the 
combination of high-fat diet induced gestational diabetes and MIA exposure (Figure 8C). At 
GD16.5, reduced adiponectin and increased leptin levels were still observable in the high-fat diet 
induced gestational diabetes. Not previously seen at GD12.5, at GD16.5 we observed a 
significant increase in adiponectin levels induced by MIA in the context of gestational diabetes 
(Supplemental Figure 4). Although the effect of gestational diabetes on metabolic hormones 
remains consistent between GD12.5 to GD16.5, the combined effect of inflammatory and 
metabolic stress appears to evolve as the effect of MIA moves from the acute phase to the post-
acute phase. Taken together, the maternal serum metabolic hormone levels likely promote a pro-
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inflammatory phenotype in diet-induced gestational diabetes, which is intensified in combination 
with MIA. Thus, the combined stressors of GDM and MIA induce a pro-inflammatory profile as 
shown through the levels of cytokines, chemokines, and metabolic hormones. 
  
 
Figure 8. High fat diet induced gestational diabetes alters non-fasting levels of metabolic 
hormones. Maternal serum collected 3 hours post injection on GD12.5 was analyzed for non-
fasting adipokine and insulin levels via antibody-conjugated bead-based multiplex assay. (A) 
The anti-inflammatory metabolic hormone adiponectin is significantly decreased by high fat diet 
induced gestational diabetes, with a trend towards a decrease with MIA. (B) Non-fasting serum 
insulin levels are not quite significantly increased with high fat diet induced gestational diabetes 
alone, but MIA in the context of high fat diet does produce a significant increase. (C) The pro-
inflammatory satiety hormone leptin is significantly increased by high fat diet induced 
gestational diabetes. Leptin levels are also significantly increased by MIA in the context of high 
fat diet induced gestational diabetes. Error bars represent SEM. Significance of p<0.05 is 
indicated by * and determined by unpaired Student t-test with Welch’s correction in all assays. 
Serum was collected from dams whose embryos were utilized for Nanostring gene expression 
analysis (SAL n=9, MIA n=8, HFS n=9, HFM n=9). 
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Inflammation and development related gene expression in the embryonic brain is disrupted by 
HFS and MIA 
Both high fat diet-induced GDM (HFS) and MIA resulted in altered gene expression in 
the fetal brain at GD12.5, with brains being collected 3 hours after poly(I:C) treatment. We 
evaluated numerous genes with a predominant inflammation related function along with a small 
number of genes related to neurodevelopment as well as the major neuronal glucose transporters. 
When comparing gene expression changes significantly different between SAL and MIA, HFS, 
or HFS+MIA in a supervised hierarchical clustering analysis, each diet x treatment group 
aggregated together, demonstrating group-specific gene expression profiles (Figure 9, 
Supplemental table 3).  
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Figure 9. Both HFS and MIA alter gene expression at GD12.5. Genes that demonstrated a 
significant change in expression in either HFM, MIA, or HFS when compared to SAL (57 genes) 
were utilized for supervised hierarchical clustering analysis. Each diet x treatment group 
aggregates together, demonstrating distinct gene expression changes in each group. Significance 
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was determined by unpaired student t-test with Welch’s correction and p<0.05. Values are in 
Supplemental table 3. 
 
High-fat diet alone displayed significant differences in gene expression when compared 
to SAL. Neurodevelopmental genes involved in patterning (En1, En2) and cholinergic signaling 
(Chat) were repressed (Chiang et al., 1996; Sadler, Liu, & Augustine, 1995). A number of 
inflammation-related genes were also induced (e.g. Cls, Ccl8, Ifit3, Mx2) while others were 
repressed (e.g. Ccl21a, Ifi44, Tgfb2, Tgfb3), with these genes functioning in IFN/antiviral 
response, growth, cell cycle regulation, and apoptosis (Liu, Sanchez, & Cheng, 2011; McKinsey, 
Zhang, & Olson, 2002; H. Yanai et al., 2009). Moreover, GDM increased Vegfa expression, 
which is associated with a hypoxic environment (Figure 10, Supplemental Table 3) (Paschen, 
Gissel, Linden, Althausen, & Doutheil, 1998; Pearce, Butler, Abrassart, & Williams, 2011).  
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Figure 10. Gestational diabetes mellitus (GDM) and maternal immune activation (MIA) 
alter expression of neurodevelopmental and inflammatory genes at GD12.5. Venn diagrams 
denote the number of genes increased (A) or decreased (C) in diet induced gestational diabetes 
(GDM), MIA, or GDM + MIA when compared to control mice. The graphics represent gene 
counts increased (B) or decreased (D) in GDM and GDM + MIA, MIA and GDM + MIA or 
GDM, MIA, and GDM + MIA as indicated. (A and C) Significant changes in gene expression 
were determined by multiple t-tests, and genes with p<0.05, false discovery rate (FDR) <0.01 
were selected. (B and D) Tukey’s multiple comparisons two-way analysis of variance (ANOVA) 
was used to determine significance (**p<0.05) among the groups.   
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Diet-induced gestational diabetes potentiates MIA induced gene expression changes 
Three hours following injection, poly(I:C) treatment in the context of high-fat diet 
induced GDM produced marked induction of multiple inflammation and neurodevelopment 
genes (Figure 11). The combined treatment of HFS and MIA both induced (Foxg1, Gad1, Mbp, 
Vamp1) and repressed (En1, En2, Fgf8, Pax5) subsets of neurodevelopment genes involved in 
patterning, migration, and oligodendrocyte development (Danesin & Houart, 2012; Marin, 2013; 
Ohtsuka et al., 2013; Ozgen et al., 2014; Smith et al., 2011; Toma, Kumamoto, & Hanashima, 
2014; Walshe & Mason, 2003). A number of inflammation related genes were induced by the 
combination of the metabolic and inflammatory stress of MIA and diet-induced GDM and were 
largely involved in the antiviral/IFN response (Ifi44, Ifit1, Ifit2, Ifit3, Ifitm3, Irf1, Irf7, Maff, 
Mx2, Oasl1) and the generalized innate immune response (Ager, Ccl21a, Csf1, Il1r1), however, 
other genes known for their role in cell growth (Tgfb2) and apoptosis (Mef2d) were also induced 
(Barton & Medzhitov, 2003; Liu et al., 2011; McKinsey et al., 2002; X. Zhou et al., 2013). 
Contrastingly, the combination of diet-induced GDM and MIA (HFS+MIA) also led to the 
repression of a number of genes associated with the antiviral/IFN response (Irf3, Irf5), 
apoptosis/cell cycle regulation (Ddit3, Hmgb2, Ripk1, Tradd, Traf2), and cell growth (Pdgfa) 
(Demoulin & Essaghir, 2014; Liu et al., 2011; Spellman et al., 1998). Also repressed in the 
combined metabolic and inflammatory stress condition of HFS+MIA were genes critical for 
intracellular signaling pathways associated with both pro- and anti-inflammatory processes such 
as Creb1, Jun, and Nfe2l2 (Bryan, Olayanju, Goldring, & Park, 2013; Janeway & Medzhitov, 
2002). Furthermore, both the constitutively expressed GLUT1 and high affinity neuronal specific 
GLUT3 genes (Slc2a1, Slc2a3) as well as the hypoxia-associated genes Flt1 and Vegfa were 
induced in HFS+MIA compared to HFS alone. Despite the fact that several inflammation-related 
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genes were found to be repressed, many more genes responsible for encoding apoptosis-
regulating proteins and other innate immune response proteins were induced when MIA and diet-
induced GDM were combined. This data suggests that the combination of the two stressors 
further disrupts the complex metabolic and inflammatory environment of the developing fetal 
brain. This disruption is made evident by both unique and differentially altered transcript 
changes induced by MIA and/or diet-induced GDM (Figure 10). This interesting phenomenon is 
enhanced in changes in both dopamine neuronal differentiation pathways as well as multiple 
inflammation related pathways (Figure 12).  
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Figure 11. Maternal immune activation (MIA), gestational diabetes mellitus (GDM) and 
GDM+MIA produce unique transcriptional changes in the developing fetal brain. Genes 
significantly altered in either GDM (a), MIA (b), or GDM+MIA (c) compared with control were 
utilized for functional gene network diagrams. Predicted functional gene networks were 
generated with Genemania’s algorithm available within Cytoscape. For each condition in 
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comparison with control, genes significantly induced are shown in green, whereas genes 
significantly repressed are shown in red. Gray nodes represent additional genes strongly 
associated with the predicted network, with node size proportional to strength of association of 
gene within the network. Lines demonstrate functional association with line thickness indicating 
association strength. Significant genes were determined by one-way analysis of variance 
(ANOVA) with post hoc Bonferonni correction (P<0.05, false discovery rate (FDR) <0.01). 
(P<0.05, false discovery rate (FDR) <0.01). 
 
 
 
Figure 12. Differentially expressed transcripts in diet-induced GDM and maternal immune 
activation (GDM+MIA) condition at GD12.5. Gene ontology (GO) was performed using genes 
significantly altered in GDM+MIA when compared to control mice fed a normal diet and treated 
with saline. Clustering was performed using DAVID bioinformatics database analysis (p<0.05).  
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At GD16.5, smaller and fewer changes in relative gene expression were detected with 
MIA and GDM+MIA. This decreased level of change was as expected since the acute immune 
response induced by poly(I:C) exposure passes after 24 – 48 hours (Supplemental Figure 5, 
Supplemental Table 5). In contrast to the combined stress of MIA and diet-induced GDM, the 
effect produced by GDM alone is still occurring at GD16.5, we observed a similar number of 
gene expression changes produced by GDM alone at GD16.5 as was observed at GD12.5. The 
changes in fetal brain gene expression patterns that remain at GD16.5 include the induction of 
neurodevelopment genes (En2, Pax5) and both the repression (Ccr1, Cd163, Itgb2) and 
induction (Hras1, Ptger3) of inflammation genes. This data supports the hypothesis that GDM 
has continued effects on the fetal brain. All be it subtle, this evolving phenotype reflects ongoing 
changes in both neurodevelopment and the immune response in the brain of the developing fetus. 
 
Discussion 
There is abundant epidemiological evidence supporting an association between either 
GDM or infection-associated MIA and neurocognitive disabilities in offspring, including 
disorders such as autism and schizophrenia (Atladóttir et al., 2010; Brown et al., 2004; 
Krakowiak et al., 2012; Xiang et al., 2015). Despite these associations, the extent to which these 
two stressors interact with one another has not yet been closely assessed. The clinical relevance 
of the potential interactions between GDM and MIA are growing in developed countries such as 
the United States, where the incidence of GDM is increasing (DeSisto et al., 2014), and where 
infections continue to pose a persistent threat to pregnant mothers. In low- or middle-income 
countries this possible interaction may be even more important due to increasingly high rates of 
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infectious diseases and the recent and ever increasing shift from undernutrition to excess 
adiposity (J.A. Goldstein, S.A. Norris, & D.M. Aronoff, 2017).  
The work discussed in this chapter presents new evidence for a significant interaction 
between GDM and MIA in the developing fetal brain as well as their impact on maternal 
inflammation. We modeled two commonly occurring environmental stressors that can and often 
times occur during gestation, are known to induce inflammation, and have been associated with 
increased risk for psychiatric disorders later in life- GDM, as modeled in this study by the high 
fat diet induction of gestational diabetes (HFS) mice, and maternal infection, as modeled by MIA 
(Atladóttir et al., 2010; Brown et al., 2004; Gardener et al., 2009; Xiang et al., 2015; Yamashita 
et al., 2003). The combination of these two models demonstrates that 1) individually, both GDM 
and MIA produce a pro-inflammatory maternal state and alter inflammation-associated and 
neurodevelopmental embryonic gene expression, 2) the combination of GDM and MIA 
intensifies the maternal inflammatory state and produces a novel transcriptional phenotype, and 
3) these novel transcriptional changes are associated with pathways implicated in psychiatric 
disorders such as the dopamine neuron differentiation and innate immune response pathways. 
These findings provide insight into how multiple environmental stressors interact with one 
another and the impact they may have on increasing the risk for developing psychiatric disorders 
later in life. 
Consistent with previous reports (Liang et al., 2010), we found that administration of a 
high fat diet for 6 weeks prior to mating and throughout pregnancy successfully induced a GDM 
phenotype in mice. Although elevated maternal body mass index (BMI) is not necessary for the 
development of GDM, it is a strong predictor of the disorder (Whiteman et al., 2015). After 8 
weeks of consuming a high fat diet, mice showed a significant increase in weight independent of 
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pregnancy. Despite significant weight gain, non-pregnant mice did not show the same level of 
glucose intolerance and insulin insensitivity/resistance present in their pregnant counterparts, 
confirming that these phenomena were gestationally-dependent. 
The two environmental stressors we chose to study, GDM and MIA, are both known to 
induce a state of maternal inflammation. It is known that prolonged inflammation has the 
potential to produce a “primed” state, thus altering and potentially exacerbating the bodies 
response to any additional inflammatory stimuli that may occur (Abell et al., 2015; Leboyer, 
Oliveira, Tamouza, & Groc, 2016). Environmental stressors such as midgestation maternal 
infection, perinatal hypoxia, or early childhood trauma, are considered co-factors and are known 
to trigger this “primed” state (Maes et al., 2009; Millan et al., 2016).  
The maternal serum data discussed in this chapter supports a pro-inflammatory maternal 
state in the setting of MIA, in both the presence and absence of GDM. These results also confirm 
previous models of MIA in mice, where analogous transient increases in cytokine and chemokine 
levels were observed during the acute-phase response to poly(I:C) (Arrode-Bruses & Bruses, 
2012; Khan et al., 2014; Mandal et al., 2013). Most studies have reported very subtle or no 
increases in cytokines or chemokines in maternal serum between 1 – 8 days post injection, which 
is expected given the transitory maternal response to poly(I:C) (Arrode-Bruses & Bruses, 2012; 
Mandal et al., 2013; U. Meyer, Engler, Weber, Schedlowski, & Feldon, 2008). Our results 
further support the body of evidence that poly(I:C) administration at GD12.5 produces an acute, 
but strong increase in multiple cytokines and chemokines, including IL-6, that is no longer 
present 4 days post injection at GD16.5 in maternal serum. We speculate that this increase in 
pro-inflammatory cytokines within the maternal environment may be the driving force behind 
the changes in gene expression within the fetal brain.  
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In addition to markers of inflammation, we investigated the extent to which either GDM, 
MIA, or the combination of the two induced changes in metabolic hormone levels in the 
maternal serum. Increased serum leptin and insulin levels, as well as leptin and insulin 
insensitivity have been previously reported in adult mice fed a high fat diet (Gallou-Kabani et al., 
2007; Van Heek et al., 1997). In our studies however, non-fasting serum insulin levels were only 
significantly affected at GD12.5 and only with the combination of GDM and MIA. As the acute 
inflammatory period of the poly(I:C) induced MIA passed the levels were no longer significantly 
different at GD16.5; suggesting that MIA had a greater impact on circulating, non-fasting insulin 
levels then GDM. The significant increase in pro-inflammatory leptin levels in GDM was further 
increased when MIA was introduced at GD12.5. This increase dissipated by GD16.5, with only 
the combination of GDM+MIA still producing significant increases in leptin at this time point 
(Gallou-Kabani et al., 2007). Although the effects of GDM on metabolic hormones appeared to 
remain consistent between the GD12.5 and GD16.5 time points, the interaction between MIA 
and GDM appeared to evolve to a mostly normalized state. The observed alterations in insulin 
and leptin levels likely contributed to the pro-inflammatory phenotype seen in GDM, which was 
further exacerbated when combined with MIA. In summation, the combined effect of GDM and 
MIA resulted in a pro-inflammatory profile of cytokines, chemokines, and metabolic hormones 
in dams. 
The hypoxic response caused by both GDM and MIA was interesting. Most likely 
resulting as a consequence of the antiviral response mounted in response to poly(I:C), signs of 
hypoxia were detected in the MIA-exposed fetal brain. As for the increase in hypoxic markers in 
the GDM-exposed fetal brain, it is known that oxygen demand can increase with the heightened 
metabolic demand associated with maternal hyperglycemia (Bastian et al., 2015; Cerf et al., 
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2010). VEGF is known to increase under conditions of  hypoxia and has been shown to mediate 
the vascular remodeling that occurs with chronic hypoxia, which is likely the cause of the Vegfa 
and Flt1 induction observed within the fetal brains of our GDM and MIA models (Nilsson, 
Shibuya, & Wennstrom, 2004; Osada-Oka, Ikeda, Imaoka, Akiba, & Sato, 2008; Pearce et al., 
2011). This change aligns with microvascular and cerebral blood volume alterations that are 
theorized to increase risk for psychiatric disorders observed in patients with schizophrenia 
(Meier et al., 2013; Talati, Rane, Skinner, Gore, & Heckers, 2015). 
 We also set out to determine if GDM and MIA interact with one another in order to 
produce a novel phenotype. We found that MIA differentially affected inflammation and 
neurodevelopment associated gene expression when in combination with GDM, suggesting that 
GDM and MIA interacted with one another leading to an exacerbated transcriptional response 
within the fetal brain. The genes differentially regulated in the the comined treatment of GDM 
and MIA are multifunctional neurodevelopmental genes and include crucial patterning genes that 
are part of the neuronal fate differentiation of dopaminergic neurons found within the developing 
midbrain (Stoykova & Gruss, 1994). Partial or complete disruption of these factors has been 
linked to failed development and differentiation of dopaminergic neurons as well as midbrain 
degeneration with models that reach adulthood (Schwarz, Alvarez-Bolado, Urbanek, Busslinger, 
& Gruss, 1997; Simon, Bhatt, Gherbassi, Sgado, & Alberi, 2003; Sonnier et al., 2007). Our work 
suggests that dopaminergic disruption as a consequence of MIA, which is strongly tied to 
psychiatric dysfunction, can be exacerbated in combination with additional environmental 
factors, such as GDM. Although the most prominent response was observed in the MIA group at 
GD12.5, both the induction and repression of neurodevelopment and inflammation associated 
genes was observed in all treatment groups including GDM, MIA, and GDM+MIA. When the 
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effects of MIA were observed in the context of GDM, the fetal brain gene expression response at 
both time points was unique than that observed for the treatments individually, suggesting an 
interaction between these two inflammation-associated risk factors. It is clear that the effects of 
MIA on fetal brain gene expression are modified by GDM, indicating that high fat diet induced 
gestational diabetes, when it is accompanied by maternal infection, induces a novel phenotype 
worth further investigation. 
In summary, we have shown that the combined inflammatory interactions of GDM and 
MIA influence transcriptional responses within the developing mouse brain. It is important to 
note that neither GDM or MIA, either in alone or in combination, are specific to a particular 
outcome later in life, but they have been shown to predispose some to a variety of brain 
disorders, with diagnosis-specificity being genetic context dependent (Horvath & Mirnics, 2014). 
The effects of the co-occurrence of GDM and an infection during pregnancy are most likely 
depend on the genetic makeup of the mother, the developing fetus, or both. Ultimately, our data 
suggests that children born to mothers with GDM that have been exposed to mid-gestation 
infections/immune activation have an increased vulnerability to psychiatric disorders later in life. 
These findings should be further investigated and studied in a large-scale epidemiological study.  
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CHAPTER 4 
 
SEX MODIFIES PLACENTAL GENE EXPRESSION IN RESPONSE TO METABOLIC 
AND INFLAMMATORY STRESS 
 
Theresa L. Barke, Kelli M. Money, Liping Du, Ana Serezani, Maureen Gannon, Karoly Mirnics, 
David M. Aronoff 
 
Introduction 
Disruptions to normal immune homeostasis within the fetal-placental unit can disrupt 
neurodevelopment and predispose to psychiatric disorders (Van Lieshout & Voruganti, 2008). 
Metabolic stress (e.g., gestational diabetes mellitus (GDM) and obesity) and infections are 
common during pregnancy, both of which impact not only fetal development, but the lifelong 
health of offspring as well. Among the most prevalent maternal stressors are obesity (Brenseke, 
Prater, Bahamonde, & Gutierrez, 2013), gestational diabetes mellitus (GDM) (Breyer, 
Bagdassarian, Myers, & Breyer, 2001; Tomar et al., 2015; J. Yan & Yang, 2014)) and infection 
(Howerton & Bale, 2012; Monk, Georgieff, & Osterholm, 2013; Rupérez et al., 2017). How 
these comorbidities impact fetal development and long-term health outcomes for offspring 
remains an open question.  Another interesting unanswered question includes the observation 
that some DOHaD-associated health outcomes exhibit sexual dimorphism, meaning that male 
and female offspring are affected differently (Jeffrey S. Gilbert & Mark J. Nijland, 2008).  
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The placenta, a critical organ important for numerous physiological phenomenon, is also 
an important biological conduit that could mediate the non-genomic transmission of risk for 
NCDs across generations (Konkel, 2016; Peng et al., 2017). To advance our understanding of the 
extent to which metabolic and inflammatory stressors impact placental immune activation, we 
utilized a pregnant mouse model of GDM combined with an acute inflammatory MIA stress 
(Money et al., 2017). GDM was modeled using a high fat diet in female C57/BL6 mice prior to 
and during pregnancy (Money et al., 2017). The process of virus-induced immune activation was 
modeled using a mid-gestational challenge with the viral mimetic poly(I:C), a synthetic, double-
stranded RNA agonist of Toll-like receptor 3 (L. Shi, Fatemi, Sidwell, & Patterson, 2003; L. Shi, 
Tu, & Patterson, 2005). Placental gene expression for 248 genes involved in innate and adaptive 
immunity were evaluated because immune tolerance is important for fetal development 
(Trowsdale & Betz, 2006) and both metabolic and infectious stressors have been shown to alter 
the inflammatory state of the placenta (Altmae et al., 2017; E. L. Johnson & Chakraborty, 2016; 
Pantham, Aye, & Powell, 2015). This study design allowed us to test the tripartite hypothesis 
that (1) either metabolic stress or MIA alone can induce changes in inflammatory gene 
expression within the placenta, (2) these stressors can interact to influence gene expression when 
both are occurring in the same gestation and (3) the effects of these perturbations on gene 
expression is different depending on fetal/placental sex. 
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Materials and Methods 
 
Animal procedures 
Animal procedures were approved by the Vanderbilt Animal Care and Use Committee and 
conducted according to our previously detailed protocol (Money et al., 2017). Briefly, female 
and male C57Bl/6J mice were obtained from The Jackson Laboratory (Bar Harbor, ME, USA). 
Control fed mice received standard chow throughout the experiment (5LOD, Lab Diet, St. Louis, 
MO, USA) and to induce GDM, females received a 60% calories-by-fat diet (58Y1, Test Diet, 
St. Louis, MO, USA) from 4 weeks of age throughout pregnancy. These mice are referred to as 
GDM mice herein and were previously shown by our group to develop a GDM phenotype 
compared to normal diet-fed controls (Money et al., 2017). At 10 weeks of age, mice were 
mated, and the presence of a vaginal plug marked gestational day 0.5 (GD0.5) (Figure 13A). 
Pregnant females were left undisturbed except for cage changes at GD9.5 and weight 
measurements.  
 GDM and controls were assigned to receive a mid-gestational intraperitoneal injection 
with either saline (control) or poly(I:C) (MIA) as reported (Money et al., 2017), creating 4 
experimental groups: control fed saline (SAL or control), high fat fed saline (GDM), control fed 
poly(I:C) (MIA), and high fat fed poly(I:C) (GDM+MIA) (Money et al., 2017). GD12.5 was 
chosen as a mid-gestation timepoint in mice, at which point pregnant females were injected 
intraperitoneally with either sterile saline or 20 mg/kg poly(I:C) potassium salt (Sigma Aldrich, 
St. Louis, MO, USA) in sterile saline, based on the weight of poly(I:C) itself. Pregnant mice 
were sacrificed 3 hours after injection at GD12.5. Sex genotyping was performed for each 
embryo using a previously published protocol (Jacobs et al., 2009). Each of the 4 groups 
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contained 9 pregnant females with the exception of GD12.5 MIA, which contained 8 pregnant 
females, making a total of 35 females. 
 
Tissue collection  
 Immediately after sacrifice, the gravid uterus was removed followed by the removal of 
each individual fetal-placental unit. The amniotic sac was removed from the placenta, at which 
point the decidual tissue was separated and both flash frozen. In total, we collected 64 placentae 
from the saline treated group, 62 from the MIA group, 72 from the GDM group, and 67 from the 
combined MIA and GDM group. Twelve placentae (6 male, 6 female) were chosen for 
Nanostring® gene expression analysis from each experimental condition (except GDM group 
with 5 male, thus total 47 placentae), with 12 pregnant mice contributing 2 placentae each and 23 
pregnant mice contributing one single placenta. Tissues were obtained across 8-9 pregnant dams 
per experimental condition (Money et al., 2017). All pups were measured to have crown/rump 
lengths between 8 mm to 9 mm. It was not possible to choose samples that were evenly 
distributed between the right and left uterine horn, although, all efforts were made to remain as 
evenly distributed while concurrently maintaining an even male to female ratio.             
 
RNA isolation and Nanostring® transcriptional profiling 
           The entire placenta was utilized for RNA isolation. Tissue was dissociated using 
gentleMACS dissociator m-tubes in 1 mL TRIzol. RNA was isolated in TRIzol following 
manufacturer protocols (Invitrogen, Carlsbad, CA, USA). Samples then underwent a Qiagen 
RNeasy clean-up, following manufacturer’s instructions (Qiagen, Hilden, Germany). A Thermo 
Scientific Nanodrop 2000 (Thermo Scientific, Waltham, MA, USA) was untilized to measure 
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RNA concentration and purity (260/280 values above 2 and 260/230 values above 1.5). Agilent 
2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA) was utilized to ensure RNA 
integrity, with all RNA integrity numbers falling between 9.5 and 10. 
          Purified RNA (150ng) from each placental sample was utilized for unblinded Nanostring 
nCounter gene expression analysis (http://www.nanostring.com/applications/technology) using 
the mouse inflammation V2-panel which included 248 inflammation-related mouse genes and 5 
internal reference controls to determine gene expression performed according to manufacturer’s 
instructions (Supplemental Table 6). 
 
Nanostring® gene expression analysis and data visualization 
The count data produced by the n-Counter Digital Analyzer were normalized to positive 
and negative spike-ins as well as 5 housekeeping genes (Cltc, Gapdh, Gusb, Hprt, and Tubb5) 
and used for gene expression analysis.  Principle Component Analysis (PCA) on the scaled gene 
expression data was performed and a 3-D plot using the first 3 components was generated using 
R package “rgl”.   To compare the gene expression level between different treatment and 
placenta gender groups, a linear regression with robust standard errors (Huber-White method to 
account for the pregnant mouse cluster) on the treatment groups, sex, and their interactions was 
ﬁtted for each gene. Estimated effects and p values for different contrasts were reported and 
summarized. We considered each gene as an endpoint and adjustment top values was not 
applied. These statistical analyses were performed using R version 3.5.0 (https://www.R-
project.org).  
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Pathway Analysis 
PANTHER, Protein Analysis Through Evolutionary Relationships, classification system 
was utilized to classify and identify pathways perturbed in our experimental conditions based on 
gene expression data (Mi et al., 2017). All genes upregulated or down regulated within a 
particular treatment segregated based upon sex were uploaded into the PANTHER online 
analysis program and functional pathway classification analysis was performed to determine the 
pathways perturbed in our treatment groups.  
Pie charts represent the pathways involved in each treatment segregated by placental sex 
regardless of directionality of the expression change. Each pathway is color-coded so that each 
pathway is represented by the same color in all figures and are in order of abundance of genes in 
each pathway from the most genes to the fewest genes implicated in the pathway beginning with 
the miscellaneous category and moving clockwise around the circle. Miscellaneous represents 
the compilation of any pathway in which genes are differentially expressed between male and 
female that contains 3 or less implicated genes.  
 
Results 
 
Placental sex is associated with gene expression profiles in pregnant C57BL/6 mice in response 
to metabolic and inflammatory stress 
To model placental transcriptional responses to acute inflammatory stress and determine 
the extent to which such changes were modified, we quantified mRNA of 248 immune response 
genes on GD12.5, three hours following exposure to poly(I:C) or saline. The experimental 
groups were control (normal diet followed by saline injection on GD12.5), MIA (normal diet 
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followed by poly(I:C) injection on GD12.5), GDM (high fat diet followed by saline injection on 
GD12.5), or the combination of GDM+MIA (high fat diet followed by poly(I:C) injection on 
GD12.5). We visualized the data initially by a principal coordinate analysis (PCA) plot, in which 
each data point represents an individual placental tissue. The closer data points are to each other, 
the more closely related are the transcriptional responses. Transcriptional responses varied most 
dramatically between mice exposed to MIA versus saline, regardless of the presence of diet-
induced GDM (Figure 13B). However, the added stress of GDM disturbed gene expression, as 
evidenced by the widening gaps on the PCA plot between data points (transcriptional responses 
of individual placentae). When mice with GDM were subjected to immune activation (MIA), the 
data points did not cluster as tightly as the other experimental group, suggesting a more chaotic 
transcriptional response compared to the other experimental conditions (Figure 13B).  The 
potential impact of placental sex on transcriptional profiles was also observed from the plot, 
particularly among mice not exposed to poly(I:C).  
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Figure 13. Visual comparison of gene expression profiles for male and female placentae 
exposed in utero  to gestational diabetes mellitus (GDM), maternal immune activation 
(MIA) or both GDM and MIA. Control animals received normal chow and saline injections. 
(A). Experimental timeline highlighting the treatment and sample collection conditions. (B). 
Principal component analysis (PCA) of transcription data of 248 endogenous mouse 
inflammation genes in mouse placenta. Each data point represents a single placental sample. 
Experimental groups as indicated, with small symbols for male and large symbols for female 
placental specimens. (C). Heat map displays row z-scores for the expression of genes for which 
 99 
the response to metabolic or inflammatory stress was significantly influenced by placental sex. 
Heat map was generated under R version 3.5.1. 
 
From the regression analysis to test the interaction between sex of placenta and treatment, 
we selected a subset of genes that were statistically significantly perturbed by sex in response to 
GDM, MIA or both GDM+MIA when compared with control (normal diet, saline-injected) 
animals, and generated a heat map with hierarchical clustering on group using the average level 
of gene expression for each group (Figure 13C). Here, it is evident that the placental 
transcriptional profiles of this subset of genes within each of the experimental groups (including 
the normal control mice) differed based upon sex. Metabolic and inflammatory stress induced 
unique changes in gene transcription and the greatest distance was observed between mice 
exposed to GDM and those exposed to GDM+MIA. The heat map reveals that on average, 
mRNA expression within placental tissues exposed to GDM alone was generally lower (more 
blue) than the other experimental groups, while mice exposed to MIA in combination with GDM 
(MIA+GDM) exhibited the highest transcript levels (more red) (Figure 13C). A more detailed 
analysis of the impact of fetal/placental sex on gene transcriptional responses to inflammatory 
and/or metabolic stress is presented in the sections that follow.  
 
Placental sex influences gene expression in normal control mice  
Within the placentae from normal control pregnant dams (normal diet, saline injection), 
gene differential expression analysis revealed that 13 genes (5.2% of the 248 total number of 
genes) were statistically significantly (p value <0.05) differentially expressed comparing male to 
female tissues (C1ra, Ccl4, Ccl24, Cfl1, Cxcl2, Ddit3, Ifna1, Jun, Ptgs2, Rac1, Tlr5, Tlr6, Tlr8) 
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based on linear regression models. Eleven of these genes were more highly expressed in male 
placentae, and two (C1ra and Tlr5) more highly expressed in female placental tissues. The 
estimated mean differences for all 13 genes are displayed in Supplemental Table 8. The sex 
specific differences in gene expression patterns in normal diet saline treated mice indicate that 
even in the absence of any external or environmental stressors, the sex of the fetus influences 
gene expression patterns in the placenta.   
 
Placental sex influences placental gene expression in response to metabolic stress  
A comparison of inflammatory gene expression among placental tissues harvested from 
mice exposed to a high fat diet (GDM mice) and mice exposed to normal diet revealed that levels 
of 93 of 248 (37.5%) genes were statistically significantly different (Figure 14A). Of these 93 
genes, 36 were impacted by GDM with similar direction and scale in male and female placental 
tissues (11 induced and 25 repressed), while the significant changes in the expression of 40 
inflammatory genes (9 up-, 31 down-modulated) were limited to male tissues and 17 genes (8 
up-, 9 down-modulated) were significantly altered in female placentae. The identity and levels of 
changes for these genes are indicated in Supplemental Tables 9-12.   
Pathway analysis revealed male and female placentae exhibited perturbations in multiple 
shared pathways.  Perturbations in the Wnt signaling pathway and pathways governing 
cytoskeletal regulation by Rho GTPases were unique to male placentae exposed to GDM 
(Figure 14B). Female placentae saw unique differences within the Insulin/IGF/MAPK pathway 
(Figure 14C).  
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Figure 14. Sex-associated changes in gene expression in the placenta induced by diet-
induced gestational diabetes mellitus (GDM) compared to the saline treated, normal-diet 
controls. (A.) Number of genes whose expression levels were statistically-significantly impacted 
by GDM compared to control (p<0.05). Large black numbers indicate total number of genes 
altered regardless of directionality. Red numbers indicate number of genes whose expression 
levels increased due to GDM and blue numbers indicate the number of genes who expression 
levels decreased as a result of GDM. (B and C) Pathways perturbed in GDM irrespective of 
change in gene expression directionality. All pathways which contained ≤3 genes were grouped 
together in the miscellaneous category. Pathways listed in red bold print are unique to that sex. 
Data are displayed for male (B) and female (C) placentae separately. Number of genes included 
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in this figure were statistically-significantly impacted by the indicated treatment (p<0.05). See 
methods for detailed description. 
 
Placental sex influences gene expression in response to acute exposure to immune activation 
(MIA) 
Comparison of inflammatory gene expression among placental tissues harvested from 
mice exposed to a normal diet followed by poly(I:C) injection (MIA) with mice exposed only to 
a normal diet demonstrated male and female placentae tended to response differently to MIA 
exposure. Expression levels of 114 genes (of 248; 46%) showed statistically significant changes 
with MIA exposure (Figure 15A). Of these 114 genes, 52 were similarly impacted by MIA in 
male and female placental tissues (39 induced and 13 suppressed), while the significant changes 
in the expression of just 17 inflammatory genes (5 up-, 12 down-modulated) were limited to 
male tissues and 45 genes (33 up-, 12 down-modulated) were significantly altered in female 
placentae. The identity and level of change (induced, repressed) of all of these genes are 
indicated in (Supplemental Tables 13-16).  
Pathway analysis revealed that MIA induced significant changes in four pathways within 
female placentae that were not altered in male tissues: FAS signaling, Huntington disease 
pathway, insulin/IGF/MAPK pathway, and the apoptosis pathway. Although male and female 
placentae exhibited perturbations in multiple shared pathways there were no pathways unique to 
male placentae that were not also changed in female placentae as a result of maternal MIA 
exposure (Figure 15B and C).   
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Figure 15. Sex-associated changes in gene expression in the placenta induced by maternal 
immune activation (MIA) compared to the saline treated, normal-diet controls. (A.) 
Number of genes whose expression levels were statistically-significantly impacted by MIA 
compared to control (p<0.05). Large black numbers indicate total number of genes altered 
regardless of directionality. Red numbers indicate number of genes whose expression levels 
increased due to MIA and blue numbers indicate the number of genes who expression levels 
decreased as a result of MIA. (B and C) Pathways perturbed in MIA irrespective of change in 
gene expression directionality. All pathways which contained ≤3 genes were grouped together in 
the miscellaneous category. Pathways listed in red bold print are unique to that sex. Data are 
displayed for male (B) and female (C) placentae separately. Number of genes included in this 
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figure were statistically-significantly impacted by the indicated treatment (p<0.05). See methods 
for detailed description. 
 
Placental sex influences gene expression in response to exposure of both GDM and MIA  
The impact of sex was next evaluated on inflammatory gene expression among placental 
tissues harvested from mice exposed to a high fat diet (GDM) and poly(I:C) injection (MIA) 
with mice exposed to a normal diet followed by saline injection. These analyses demonstrated 
response differences between male and female tissues as expected from the above results. 
Expression levels of 93 genes (of 248; 37.5%) showed statistically significantly alteration after 
GDM and MIA exposure (Figure 16A; Supplemental Tables 17- 20). Of these 93 genes, 74 
were similarly impacted by GDM+MIA in male and female placental tissues (57 induced and 17 
repressed), while the significant changes in the expression of 21 inflammatory genes (7 up-, 14 
down-modulated) were limited to male tissues and 28 genes (17 up-, 11 down-modulated) were 
significantly altered in female placentae.  
Gene pathway analysis revealed 2 pathways, P53 feedback pathway and Wnt signaling 
pathway, significantly altered and unique to male placentae in GDM+MIA-exposed dams. 
Female placentae exhibited perturbations in multiple shared pathways and 2 unique pathways, 
TGF-beta signaling and Insulin/IGF/MAPK pathways (Figure 16B and C).  
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Figure 16. Sex-associated changes in gene expression in the placenta induced by the 
combination of maternal immune activation and diet-induced gestational diabetes (GDM + 
MIA) compared to the saline treated, normal-diet controls. (A.) Number of genes whose 
expression levels were statistically-significantly impacted by the combination of GDM and MIA 
compared to control (p<0.05). Large black numbers indicate total number of genes altered 
regardless of directionality. Red numbers indicate number of genes whose expression levels 
increased due to GDM + MIA and blue numbers indicate the number of genes who expression 
levels decreased as a result of GDM + MIA. (B and C) Pathways perturbed in GDM + MIA 
irrespective of change in gene expression directionality. Pathways listed in red bold print are 
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unique to that sex. All pathways which contained ≤3 genes were grouped together in the 
miscellaneous category. Data are displayed for male (B) and female (C) placentae separately. 
Number of genes included in this figure were statistically-significantly impacted by the indicated 
treatment (p<0.05). See methods for detailed description. 
 
Discussion 
 Investigating the impact of maternal antenatal stress on the placenta provides an 
important opportunity to understand fetal origins of disease in offspring. Both antenatal 
metabolic stress and infection pose tremendous risks to fetal health and development, risks that 
might be transmitted through actions within the placenta. However, compared to other organs, 
the placenta is a relatively understudied tissue. The present study newly demonstrates two 
fundamental observations relevant to understanding how stressors impact placental 
immunobiology. First, both metabolic stress and immune activation, or the combination of the 
two, perturbs immune gene expression in the placenta. Second, such effects exhibit sexual 
dimorphism.  
 Because much of the placenta is fetally-derived, particularly the metabolically highly-
active trophoblast, its sex is largely fetal (Rosenfeld, 2015). This is reflected in the fact that male, 
rather than female, placentae can be more responsive to changes in the maternal environment, a 
circumstance referred to as sexual dimorphism (Bale, 2016; Clifton, 2005; Mueller & Bale, 
2008; Rosenfeld, 2015). 
 The premise of DOHaD has largely been accepted. A wealth of data supports the 
association between maternal stressors during pregnancy on health outcomes in offspring and has 
been linked to various causal mechanisms including epigenetic changes and damage to fetal 
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tissue (Gabory et al., 2012; D. W. Kim, Young, Grattan, & Jasoni, 2014; Reynolds, Vickers, 
Harrison, Segovia, & Gray, 2015). What has not been frequently studied is the co-occurrence of 
multiple stressors and their ability to converge on fetal development thereby influencing health 
outcomes for the next generation (J. A. Goldstein et al., 2017). Our group has recently 
demonstrated the unique impact of combined maternal stressors (GDM and MIA) on the fetal 
brain, supporting the importance of more realistic in utero investigations (Money et al., 2017). 
Equally important is that studies of these factors incorporate sex as a biological variable. Sex 
differences in the fetal origins of disease are frequently identified (Abuznait, Qosa, Busnena, El 
Sayed, & Kaddoumi, 2013; J. S. Gilbert & M. J. Nijland, 2008). Increasingly, the placenta is 
being viewed as a key mediator of DOHaD-related sexual dimorphism (Andres et al., 2015; 
Gabory, Roseboom, Moore, Moore, & Junien, 2013).  
At baseline we found that the transcription of some immune genes differed significantly 
between male and female placentae (Supplemental table 7). While only 13 genes were 
significantly differentially expressed between male and female tissues, it was interesting that 
several chemokines (Ccl4, Ccl24, Cxcl2), pathogen recognition receptors (Tlr5, Tlr6, Tlr8) and 
the prostaglandin-generating, inducible cyclooxygenase-2 (Ptgs2) were among these. The male-
specific increased expression of Ptgs2 is interesting given that prostaglandins are critically 
important in labor and sexual dimorphism has been observed in the incidence of preterm labor 
(Verburg et al., 2016). Also, cyclooxygenase inhibitors were shown to have sex-specific effects 
in mollifying the inflammatory effects of antenatal stress in the placenta and improving 
behavioral outcomes in male offspring in a mouse model of environmental psychological and 
physical stressors (Bronson & Bale, 2014). Similar to our data, but in humans, Sood and 
colleagues (Sood, Zehnder, Druzin, & Brown, 2006) examined gene expression patterns in 19 
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human placentas from successful full-term pregnancies using microarray analysis and found 
significant differences between male and female tissues within the villus parenchyma. In fact, 
genes expressed at higher levels in female placentae included immunoregulatory genes such as 
JAK1, IL2RB, Clusterin, LTBP, CXCL1, and IL1RL1 (Sood et al., 2006). A more recent study of 
late first trimester placentae from humans demonstrated sex differences in the transcriptome that 
included a set of 18 autosomal genes (Gonzalez et al., 2018).  
The TLR3 dsRNA ligand poly(I:C)  is commonly used to model viral infection 
(Reisinger et al., 2015), most notably to define the impact of MIA on fetal brain development 
and neurocognitive function in offspring (Money et al., 2017) (Reisinger et al., 2015). Notably, 
antenatal poly(I:C) exposure has been shown to differentially alter behaviors in male vs. female 
mouse offspring (Xuan & Hampson, 2014). To our knowledge, this is the first study that has 
examined changes in a large number of inflammatory genes within the placenta provoked by 
poly(I:C) in a sex-specific manner. The impact of this stress on placental inflammation has been 
studied before (E. Y. Hsiao & P. H. Patterson, 2011) but in a more limited way. Hsiao and 
Patterson conducted a study in C57BL/6 mice similar to ours, finding that inflammatory gene 
expression was markedly induced 3 hours following MIA induction (E. Y. Hsiao & P. H. 
Patterson, 2011). However that study examined a small number of prespecified inflammatory 
genes and did not examine sex-specific differences in placental gene expression.  
Pathway analysis in the MIA model demonstrated the most hits in inflammation related 
pathways such as TLR signaling, interleukin signaling, and cytokine and chemokine signaling in 
both male and female placentae. Similar to GDM, the female placentae exhibited a higher degree 
of differential regulation in the insulin/IGF/MAPK pathway, indicating that genes within this 
pathway may be important to the female response to inflammatory stress. Although few studies 
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have focused on this specifically, one study of 987 healthy singleton pregnancies found that 
cord-blood from females had increased concentrations of insulin-like-growth factors (IGF)-1 and 
IGFBP-3 compared to males, while males contained higher levels of growth hormones (Geary, 
Pringle, Rodeck, Kingdom, & Hindmarsh, 2003). The IGF axis has been reported to be 
differentially regulated in a sex-dependent manner in other inflammatory related diseases during 
pregnancy such as asthma (Clifton et al., 2010). The role for the IGF axis within the placenta has 
not been well established although its possible importance in the sex-dependent response to 
inflammatory insults should be investigated further.     
Both obesity during pregnancy and GDM are associated with chronic systemic 
inflammation and have been implicated in provoking placental inflammation (J. E. Hsu & Jones, 
2005; Pantham et al., 2015). Obesity’s impact on placental inflammation appears to affect male 
and female tissues differently (Leon-Garcia et al., 2016) and mice fed a high fat diet have been 
found to have divergent patterns of gene expression in male vs. female placentae (Gabory et al., 
2012). GDM has not, to our knowledge, been associated with sex differences in placental gene 
expression. Our results show sexual dimorphism in GDM induced inflammation-related gene 
expression changes within the placenta. Pathway analysis of the genes found to be differentially 
affected based on sex revealed two pathways more highly changed in males compared to 
females; the cytoskeletal regulation of Rho GTPase and the Wnt signaling pathways. The female 
placentae showed a higher degree of change in the Insulin/IGF/MAPK signaling pathway. 
Studies have interrogated the IGF axis as it relates to fetal development and outcomes in 
maternal asthma, however not in the context of GDM (Clifton, 2010). It is potentially important 
that the prior studies concluded that the IGF axis was regulated in a sex-dependent manner 
(Clifton et al., 2010). 
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A fascinating aspect of our study was the combined GDM and MIA stressors. A total of 
123 genes within the placenta were significantly changed compared to control in the combination 
of GDM and MIA and 74 of these genes were shared between male and female placentae. The 
insulin/IGF/MAPK pathway was more significantly changed in female placentae compared to 
male, similar to results from the GDM and MIA conditions alone. In addition to the 
insulin/IGF/MAPK pathway, the TGF-  signaling pathway was more significantly changed in 
female placentae. TGF-  has been implicated in supporting maternal-fetal immune tolerance 
(Alijotas-Reig, Llurba, & Gris, 2014) so disturbing its expression could have important 
consequences. Similar to what we observed in GDM alone, the Wnt signaling pathway was more 
significantly altered in male placentae. In addition, the p53 feedback loop pathway was more 
significantly altered in males. Alterations in the p53 feedback loop pathway have been 
implicated in increased levels of apoptosis within the placenta in the context of preeclampsia 
(Sharp et al., 2014). It will be important for future studies to establish how sex influences these 
pathways. 
Limitations of our study are important. Gene expression was assessed using a preselected 
set of 248 immune genes, which introduces bias and limits conclusions about many other 
functions of the placenta, such as nutrient transport or metabolism. Our GDM model was 
generated with a high fat diet, which itself could produce inflammation in the absence of diabetes 
(D. Zhou & Pan, 2015). We used this model because mice consistently exhibited enhanced 
glucose intolerance and hyperinsulinemia following a glucose challenge only while pregnant 
(Money et al., 2017). The use of poly(I:C) to provoke a systemic inflammatory response 
mimicking a viral infection during pregnancy has advantages, including the lack of live virus that 
might cross the placenta and a more consistent, controlled inflammatory response; however, a 
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viral mimetic lacks the complexities of host-pathogen interactions, thus limiting generalizability. 
The use of a mouse model is an important caveat, given differences between human and mouse 
placentae (Malassine, Frendo, & Evain-Brion, 2003). Another limitation is a lack of 
understanding of the exact mechanisms whereby these antenatal stressors, singly and in 
combination, impact gene expression. Whether through epigenetic or other modifications, such 
mechanisms await future studies to define. Despite these limitations, our work sheds new light 
on the convergence of stressors at the maternal-fetal interface that deserves ongoing attention. 
In summary, our work suggests that common antenatal stressors impact immune gene 
expression within the placenta and appear to interact. Placental sex can influence the relationship 
between stress and immune homeostasis, supporting a placental role in the sexual dimorphism 
observed in human clinical studies of DOHaD-related health outcomes in offspring. We strongly 
support that future studies continue to model multiple stressors and pay heed to sex-related 
effects.  
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CHAPTER 5 
 
METABOLIC STRESS AND IL-1β PRODUCTION BY THE PLACENTAL 
MACROPHAGE 
 
Theresa L. Barke, Lisa M. Rogers, David M. Aronoff 
 
Introduction 
IL-1β has long been known to exert metabolic effects, most notably being implicated in 
the progression of insulin resistance and obesity. The consequences of IL-1β signaling is context, 
time, and tissue dependent. For example, in the absence of acute inflammatory stimuli, IL-1β 
signaling is essential for maintaining adipose tissue homeostasis and normal body weight (Garcia 
et al., 2006; Matsuki, Horai, Sudo, & Iwakura, 2003; Somm et al., 2005). In the context of 
chronic inflammation, however, as in obesity and diabetes, IL-1β signaling largly corresponds 
with a pro-inflammatory phenotype and an increase in pathogenic inflammation (McGillicuddy 
et al., 2011; Miura et al., 2010; Nov et al., 2013; Stienstra et al., 2010). IL-1β plays such an 
important role in the pathogenesis of metabolic disease that its use as a drug target is actively 
being studied with promising results. Pharmaceutical intervention blocking IL-1 signaling in 
mouse models of T2D and atherosclerosis was effective and improved glycemia, β-cell function, 
and reduced inflammation releaving the T2D phenotype (Bhaskar et al., 2011; Ehses et al., 
2009). 
Differential effects of IL-1β can be seen impacting metabolic signaling in multiple 
different organs and cells types. It has been reported that IL-1β is a potent inhibitor of insulin 
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signaling in adipocytes as well as interfering with adipocyte differentiation (Lagathu et al., 2006; 
Stienstra et al., 2010). In models of non-alcholic fatty liver disease, IL-1 signaling induces 
lipogenesis leading to the detrimental accumulation of tiglycerides in the liver (Negrin et al., 
2014). Important in the context of diabetes and obesity, macrophage inflammasome activation in 
obese individuals within the pancrease leads to increased levels of IL-1β subsequently inducing 
β-cell dysfunction and death (Eguchi et al., 2012; Steer, Scarim, Chambers, & Corbett, 2006; 
Thomas, Darwiche, Corbett, & Kay, 2002). The tissue specific effects of IL-1 in the context of 
obesity and diabetes make it clear that not all tissues and their responses are created equal. While 
limited studies to date have interrogated the role of metabolic stress on the placental macrophage 
IL-1β pathway, unanswered questions still remain. It is important to study tissue and organ 
specific phenotypes in a clinically and contextually relevant manner. The studies put forth in this 
chapter were designed to shed light on the interraction between placental macrophage IL-1β 
expression and metabolic stress in the form of glucose and free-fatty acids (FFA).       
Type-2 diabetes was the first disease shown to involve the NLRP3 inflammasome in its 
pathogenesis and subsequent progression (R. Zhou, Tardivel, Thorens, Choi, & Tschopp, 2010). 
Obesity has been well establihed as a major risk factor for the development of T2D and insulin 
resistance explaining why T2D and GDM are often found in conjunction with maternal obesity 
(K. E. Martin et al., 2015; Whiteman et al., 2015). The loss of metabolic homeostasis in obese 
individuals results in an increase in the levels of glucose and fatty acids (FFA) in circulation and 
within organs (Donath & Shoelson, 2011). Although less research has focused on GDM 
compared with T2D and obesity, GDM has also been characterized by low-grade inflammation 
endotoxemia and elevated circulating FFA (Catalano, 2002; Lappas, 2011; Winzer, 2004; Wolf, 
2004). Multiple studies have demonstrated that these byproducts of diabesity constitue metabolic 
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danger signals with the ability to alter the activation status of the NLRP3 inflammasome 
(L'Homme et al., 2013; Vandanmagsar et al., 2011; Wen et al., 2011; Y. Yan et al., 2013). If 
these findings are correct, then it can be hypothesized that FFAs have the ability to offer both 
signals necessary for inflammasome activation by both priming and activating the inflammasome 
in the setting of diabetes and obesity.   
In humans, oleate (C18:1), palmitate (C16:0), and stearate (C10:0) make up roughly 80% 
of the circulating FFA at a ratio of 1.6:1.0:0.5 (Hagenfeldt, Wahren, Pernow, & Raf, 1972). As a 
consequence of diabetes and obesity, dyslipidemia increases the levels of these FFA in 
circulation making them available to act as ligands for inflammasome activation. Although the 
findings regarding how FFA may induce inflammasome activation are often times conflicting, 
the evidence that FFA play a role in IL-1β production and inflammasome activation is 
overwhelming. In a human monocyte cell line, THP-1 cells, palmitate treatment increased 
caspase activity in parallel with an increase in IL-1β release eventually leading to cell death 
(Pillon et al., 2016). Again in THP-1 cells, another group demonstrated that in the presence of 
high glucose, palmitate and stearate increased TLR2 and TLR4 expression, increased NF-κB 
activity, and increased the release of IL-1β and MCP-1 in a dose and time dependent manner. 
Futhermore, when they reported that the silencing of TLR2 and TLR4 significantly reduced NF-
κB activity and IL-1β and MCP-1 secretion in palmitate treated cells in the presence of high 
glucose (Dasu & Jialal, 2011). It has since been reported that palmitate directly activates TLR2 
inducing inflammasome-mediated IL-1β production in human monocytes (Snodgrass, Huang, 
Choi, Rutledge, & Hwang, 2013). These studies, as well as many others, demonstrate the ability 
for palmitate and potentially other FFA to induce IL-1β production in a TLR-dependent 
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inflammasome mediated fashion. These studies, however compelling, do not recapitulate the 
placental environment.  
How these extracellular danger signals in the form of FFA activate the inflammasome 
culminating in the characteristic increased production of IL-1β seen in metabolic disorders is a 
difficult question to answer. Again, tissue specificity is key. Evidence suggests that FFA and 
glucose may initiate the pro-inflammatory release of IL-1β in an inflammasome-dependent 
pathway through the activation of TLRs. Although relatively widely accepted to occur in many 
tissues, evidence from the placenta is lacking. TLR4 has been reported to play a role in the 
pathogenesis and inflammation associated with obesity and T2D through its interaction with FFA 
(F. Kim et al., 2007; Lu et al., 2015). Placental trophoblast cells produce increased levels of 
multiple pro-inflammatoy mediators in response to saturated fatty acids in a TLR4 dependent 
manner (Yang et al., 2015). TLR expression is altered in the diabetic state as evidenced by a 
study that determined that women with GDM have increased TLR4 expression levels on 
peripheral blood monocytes (Xie et al., 2014). TLR2 and TLR4 are the only TLRs whose 
expression is at high levels within the placenta as well as on placental macrophages throughout 
gestation (Abrahams, 2008) promting us to question the potential role of TLR activation in 
placental inflammation through the production of IL-1β as a consequence of FFA exposure. 
Taken together, the evidence introduced here, as well as evidence presented in the following 
chapter give precedence for our studies investigating the role of FFA- induced IL-1β production 
by placental macrophges. 
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Materials and Methods 
 
Animal procedures 
 Animal procedures were approved by the Vanderbilt Animal Care and Use Committee 
and conducted according to our previously detailed protocol (Money et al., 2017). Briefly, 
female and male C57Bl/6J mice were obtained from The Jackson Laboratory (Bar Harbor, ME, 
USA). Control fed mice received standard chow throughout the experiment (5LOD, Lab Diet, St. 
Louis, MO, USA) and to induce GDM, females received a 60% calories-by-fat diet (58Y1, Test 
Diet, St. Louis, MO, USA) from 4 weeks of age throughout pregnancy. These mice are referred 
to as GDM mice herein and were previously shown by our group to develop a GDM phenotype 
compared to normal diet-fed controls (Money et al., 2017). At 10 weeks of age, mice were 
mated, and the presence of a vaginal plug marked gestational day 0.5 (GD0.5) (Figure 13A). 
Pregnant females were left undisturbed except for cage changes at GD9.5 and weight 
measurements.  
GDM and controls were assigned to receive a mid-gestational intraperitoneal injection 
with either saline (control) or poly(I:C) (MIA) as reported (Money et al., 2017), creating 4 
experimental groups: control fed saline, high fat fed saline, control fed poly(I:C), and high fat fed 
poly(I:C) (Money et al., 2017). GD12.5 was chosen as a mid-gestation timepoint in mice, at 
which point pregnant females were injected intraperitoneally with either sterile saline or 20 
mg/kg poly(I:C) potassium salt (Sigma Aldrich, St. Louis, MO, USA) in sterile saline, based on 
the weight of poly(I:C) itself. Pregnant mice were sacrificed 3 hours after injection at GD12.5. 
Each of the 4 groups contained 9 pregnant females with the exception of GD12.5 MIA, which 
contained 8 pregnant females, making a total of 35 females.  
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Antibody-conjugated bead-based analysis 
 Immediately after sacrifice, amniotic fluid was removed from each intact amniotic sac 
and pooled together resulting in one representative amniotic fluid sample per pregnant dam.  
Approximately 0.5 to 1 mL of amniotic fluid was collected from each pregnant dam and kept at -
80°C until submitted for antibody-conjugated bead-based analysis. 
 Luminex analysis utilizes a multiplexed assay, using x-map technology via the MagPix 
system. The reactants are attached to the surfaces of tiny fluorescent microspheres. Each set of 
microspheres carries a unique biological reagent distinguishable by internal dye ratios. 
Identification of an analyte is based upon specific fluorescent emission spectra of the bead 
associated with the analyte. Two LEDs with high speed digital signal processors and computer 
algorithms distinguish which analyte is being carried on each microsphere while quantifying the 
reaction based on fluorescent reporters signals. This allows for analysis of multiple analytes from 
a single aliquot of sample. Luminex analysis was performed by the Vanderbilt hormone core 
(http://hormone.mc.vanderbilt.edu), which is funded in part by NIH grants (DK059637 and 
DK020593). The Luminex multiplex panels (EMD Millipore, Darmstadt, Germany) used for 
analysis of the maternal serum were mouse cytokine/chemokine panel 14 plex (eotaxin, IFNγ, 
IL-1α, IL-1β, IL-4, IL-6, IL-10, IL-12p40, IL-13, IL-17, KC, MCP-1, RANTES, and TNF-α 
Cat# MCYTOMAG-70K).  
 
Cell isolation and stimulation  
Primary placental macrophages (PMs) were isolated from healthy donors undergoing 
term scheduled C-sections using a previously published protocol (Z. Tang et al., 2011). Briefly, 
placental tissue was enzymatically digested then subjected to various rounds of stepwise 
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filtrations followed by Percoll gradient to separate possible cells of interest. The resulting cells 
underwent CD14+ positive selection via magnetic sorting. In all cell experiments, freshly 
isolated cells were allowed to rest overnight in RPMI-1640 with 1% antibiotic and 10% FBS 
media then pretreated with a glucose free RPMI-1640 (#11879 Invitrogen) media for 1 hour prior 
to experimental exposure. Experimental exposures included a metabolic cocktail (MetaC) 
comprised of 30 mM glucose, 0.4 mM palmitate, and 10 nM human insulin for 4 or 24hr. 
Euglycemic conditions were 5mM glucose and acted as the control. PMs were also stimulated 
with 0.4 mM palmitate, 10 nM insulin, or 30 mM glucose (hyperglycemic condition) alone. For 
inhibition of caspase-1, PMs were exposed for 1hr prior to experimental conditions in glucose-
free RPMI to an irreversible caspase-1 inhibitor zYVAD-FMK (Millipore #218746) at a 
concentration of 10uM. 
 
ELISA 
Freshly isolated PMs were plated at a density of 3.5e6 PMs in 6 well dishes and allowed 
to rest overnight in RPMI with 1% antibiotic and 10% FBS. Prior to experimental treatment, 
cells were pretreated with a glucose free RPMI media for 1 hour. Experimental exposures 
included MetaC, 30 mM glucose, 0.4 mM palmitate, 10 nM human insulin, or 0.4 mM Oleate for 
either 4 or 24hrs. Supernatants were collected for ELISA analysis after 4 hours or 24 hours of 
exposure to the treatment conditions. IL-1β was measured using the Duo-set ELISA from R&D 
and caspase-1 was measured using Human Caspase-1/ICE Quantikine ELISA kit from R&D. 
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Immunofluorescence for NLRP3-ASC localization 
Freshly isolated PMs were plated at a density of 300,000 cells per chamber slide and 
allowed to rest overnight in RPMI with 1% antibiotic and 10% FBS. Prior to experimental 
treatment, cells were pretreated for 1 hour in glucose-free RPMI. Experimental exposures 
included a metabolic cocktail that simulates a state of diabesity which is comprised of 30 mM 
glucose, 10 nM human insulin, and 0.4 mM palmitate (MetaC), 5 mM glucose and 0.4 mM 
palmitate for 4 hrs. Immunofluorescence to interrogate NLRP3-ASC complex formation was 
completed using the Duolink In Situ PLA Kit from Sigma following manufacturer’s instructions, 
using Anti-ASC pAB (AL177) at 1:200 and anti-NLRP3 mAB (Cryo-2) at 1:200 (AdipoGen). 
 
Results and Future Directions 
Numerous studies have indicated that gestational diabetes and metabolic stress impact 
placental macrophage (PM) number, polarization, and expression patterns to adopt a more pro-
inflammatory phenotype (Altmae et al., 2017; Barke et al., 2018; Mrizak et al., 2014; Pantham et 
al., 2015; Yu et al., 2013).  Macrophages regulate inflammation in the context of many systems, 
tissues, and disease states and have the ability to control both local and systemic inflammation. 
While conducting our experiments outlined in chapter 3 and chapter 4 we discovered that within 
the amniotic fluid of mice fed a high-fat diet (exhibiting a phenotype consistant with GDM), 
there was a significant increase in the levels of IL-1β (Figure 17). The increase in IL-1β was 
present only in the context of  GDM and GDM+MIA, but not MIA alone. This increased level of 
IL-1β was also not observed in the maternal serum. Li, et al. described an increase in IL-1β 
levels in placental tissues harvested from mice fed a high-fat diet exhibiting signs consistent with 
GDM compared to healthy control mice (Li et al., 2013). In our studies we did not see an 
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increase in the levels of IL-1β in the maternal serum, but we did see an increase in the amniotic 
fluid in the GDM and GDM+MIA mice. Taken together with the data that placentae from GDM 
mice produce higher levels of IL-1β, we hypothesized that the increased levels of IL-1β originate 
from the placenta and more specifically macrophages as they are the predominant immune cell in 
the placenta throughout gestation and have been shown to have increased numbers within the 
placenta and produce high levels of IL-1β in the context of GDM (Sisino et al., 2013; Yu et al., 
2013).   
 
Figure 17. GDM and MIA alter cytokine, chemokine and metabolic hormone profiles 
within amniotic fluid at GD12.5 Amniotic fluid was collected via membrane puncture for all 
pups and pooled together for each individual dam. Amniotic fluid collected 3 hours post 
injection with either saline or 20mg/kg Poly I:C potassium salt on GD12.5 was analyzed for 
chemokine and cytokine levels via conjugated bead array multiplex assay. Significance indicated 
by letters with similar letters dictating no significance as determined by one-way ANOVA with 
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Tukey’s multiple comparisons post test in all assays. (n=9 except for Poly I:C treated non-HFD 
where n=8).  
 
Given the association between dyslipidemia and diabetes we interrogated the idea that 
FFAs can induce the increased expression and release of IL-1β from placental macrophages. At 
the cellular level, FFAs act as messengers with the ability to modulate a wide array of signaling 
transduction pathways (H. Shi et al., 2006). As thouroughly introduced earlier in this document, 
ample evidence suggests that FFAs, in the form of palmitate and stearate, have the ability to 
induce the production and subsequent release of IL-1β from multiple different cells and tissues. 
The ability of primary placental macrophages to produce increased levels of IL-1β in a FFA-
dependent manner has not been reported to date. Not only did we want to see if FFAs alone were 
enough to stimulate the cells to produce more IL-1β we also sought to induce a more GDM like 
environment with the use of a metabolic cocktail that more closely mimics the high glucose, high 
insulin, high FFA environment of the GDM patient. Media containing high levels of glucose, 
insulin, and palmitate, termed the metabolic cocktail (MetaC), was previously developed and 
utilized to induce a metabolically activated phenotype in adipose tissue macrophages (Kratz et 
al., 2014). When we treated freshly isolated PMs with MetaC we saw a significant increase in the 
amount of IL-1β secreated from the cells into the supernantants (Figure 18A). Similar to 
treatment with MetaC, palmitate alone increased the release of IL-1β from the cells. This 
increase was not seen when PMs were treated with insulin or glucose alone (Figure 18A). 
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Figure 18. Metabolic stress increases IL-1β and cleaved caspase-1 (p20) in placental 
macrophages. PMs were treated for 24 hours with 5 mM glucose, MetaC, palmitate, 30 mM 
glucose, or insulin alone. A) Levels of extracellular IL-1β from cell culture supernatants as 
measured by ELISA B) Levels of extracellular caspase-1 from supernatants as measured by 
ELISA 
 
Cleavage of pro- IL-1β  into its active secreted form requires caspase-1 (Wilson et al., 1994). In a 
similar pattern to IL-1β, we saw an increase in the amount of extracellular cleaved caspase-1 in 
the MetaC and palmitate treated PMs (Figure 18B). This increase was not seen after treatment 
with high glucose levels or insulin alone suggesting that the increase is as a result of palmitate 
activation of the PMs.  
IL-1β processing requires active caspase-1. Caspase-1 activation in turn requires 
assembly of the NLRP3 inflammasome. Activation of the NLRP3 infammasome, in this case 
through FFA activation, induces oligomerization of NLRP3 leading to the recruitment of ASC, 
which in turn, forms large structures leading to the recruitment of pro-caspase-1. Autocatalytic 
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cleavage of pro-caspase-1 into the p10 and p20 subunits allows for the formation of active 
caspase-1 as the two subunits form hetero-tetramers which are then able to convert pro-IL-1β 
into their bioactive secreted forms (C. A. Dinarello, 2009; Wilson et al., 1994). To interrogate if 
MetaC and its components lead to inflammasome assembly in PMs we performed 
immunoflourescence to visualize inflammasome assembly. In this assay, if ASC is in complex 
with NLRP3 it will flouresce red. PM stimulation with MetaC and palmitate show evidence of 
inflammasome formation as represented by the red specs within the cells. Quantification of the 
number of specs per cell indicates that both MetaC and palmitate induced inflammasome 
formation in PMs (Figure 19). 
 
 
 
Figure 19. Metabolic stress activates the NLRP3-ASC inflammasome in placental 
macrophages. PMs were treated for 4h with 5mM glucose, MetaC, or palmitate alone and ASC-
NLRP3 complex formation was quantified as indicated by specs per cell. 
 
Thus far, our studies have concluded that palmitate alone is capable of inducing IL-1β 
production and NLRP3 inflammasome assembly as evidenced by the formation of the NLRP3-
ASC complex in PMs. High levels of glucose and insulin are not, on their own, enough to 
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stimulate a similar response in IL-1β production. Concluding that in instances of metabolic stress 
such as diabetes, the increased levels of FFA could be the driver of IL-1β production in PMs. As 
for the receptor or receptors that mediate this interaction there are a multitude of possibilies. 
Many studies have shown that TLR2 and TLR4 may be possible receptors for FFAs and thus 
play a role in the production of IL-1β in PMs (J. Y. Lee & Hwang, 2006; Schaeffler et al., 2009; 
H. Shi et al., 2006). Given the fact that both TLR2 and TLR4 are rather ubiquitously expressed 
throughout the placenta, and on PMs, during all three trimesters these receptors are likely 
candidates. A recent study, however, has reported that TLR4 is not a receptor for saturated fatty 
acids although it does play a role in lipid-induced sterile inflammation through the action of 
altering macrophage metabolic programming (Lancaster et al., 2018). Even though evidence now 
shows that palmitate does not directly bind to and activate TLR4 in the classical sense, their 
findings confirming that palmitate does indeed induce a TLR4-dependent primig that alters 
cellular metabolism and gene expression gives precedence to the importance of this pathway and 
the need to further study this interaction in the context of PMs and inflammasome-dependent IL-
1β production.   
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Figure 20. Hypothetical model of palmitate-induced IL-1β production in human placental 
macrophages This model outlines what the studies outlined in this chapter have confirmed as 
indicated by solid black arrows. Unanswered questions that require further investigation are 
indicated by the dashed red arrows. 
 
Although preliminary studies investigating the role of palmitate in initiating the release of 
IL-1β from primary PMs have been completed, much work remains ongoing and many more 
questions need to be addressed (Figure 20).  The most important questions to answere next are 
represented in figure 22 by the red dotted arrows. First we need to address the question if indeed 
plamitate is inducing the release of IL-1β in an inflammasome/caspapse-1 dependent manner. In 
order to test this we would  block caspase-1 activity through the use of zYVAD-FMK, an 
irreversible caspase-1 inhibitor, and repeat the above experiments looking at IL-1β release 
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through ELISA and western blots. If IL-1β release is due to the activity of caspase-1, we would 
expect to see a decrease in the amount of extracellular IL-1β in supernatants and an increase in 
intracellular pro-IL-1β through western blot. Secondly, we will test whether the palmitate-
dependent induction of IL-1β release is dependent upon TLR4 in PMs. Similar sets of 
experiments as outlined previously using rs-LPS, a potent antagonist of TLR4, would be 
completed to test the cleavage and subsequent release of IL-1β through ELISA and western 
blots. The NLRP3/ASC complex assembly would also be interrogated after PM stimulation with 
palmitate in the presence of rs-LPS to test if TLR4 is necessary for palmitate-induced 
inflammasome assembly. Although preliminary in nature, these studies are essential to the 
understanding of the machanism by which IL-1β increases under metabolic stress.  
Taken together these studies will lay the ground work for future studies investigating the 
role of metabolic stress induced production of IL-1β in the placenta by PMs. This work is 
important to the understanding of how maternal inflammation and metabolic stress in the form of 
dyslipidemia can impact the fetus through placental mechanisms and could possibly be leveraged 
to decrease fetal responses to adverse maternal stimuli.       
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CHAPTER 6 
 
SUMMARY AND FUTURE DIRECTIONS 
 
Summary 
The prenatal environment is widely recognized to play a vital role in the development of 
non-communicable diseases (NCD) later in life. The idea that many NDCs have their origins in 
prenatal life is the basis of the DOHaD paradigm. Exposure to prenatal insults such as metabolic 
stress, maternal immune activation, and infections have been associated with an increased risk 
for the development of neurocognitive disorders, such as autism and schizophrenia, as well as the 
increased risk of developing metabolic diseases such as coronary heart disease and T2D (Buka et 
al., 2001; Eriksson, Sandboge, Salonen, Kajantie, & Osmond, 2014; Gardener et al., 2009).  The 
mechanisms through which this prenatal programming occurs likely involves complex 
interactions between the maternal immune environment, the placenta, and the fetus and can be 
influenced by factors such as fetal sex and developmental stage during gestation (Bale, 2011; 
Dunn, Morgan, & Bale, 2011; Mao et al., 2010). Better understanding the mechanisms that drive 
the increased risk of NCDs in response to maternal stress is vital to developing new and effective 
intervention techniques.  
A major barrier to reducing the risks and complications associated with GDM is a lack of 
clarity regarding how this disease changes placental physiology, morphology, and the overall 
pathophysiological mechanisms within the placenta contributed to this disease. The placenta acts 
not only as a barrier between the mother and the developing fetus, but as a regulatory conduit 
through which all communication between mother and fetus occurs.  
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Given the relationship among GDM, placental macrophage activation and iron 
homeostasis, chapter 2 summarized a retrospective, case-control, study of archived human 
placental tissue from women with or without GDM to better define placental pathology, 
placental iron stores, and both macrophage density and CD163 expression in situ. We tested the 
hypothesis that women with gestational diabetes exhibited altered placental physiology and 
placental macrophage phenotypes.  
It had been reported previously that macrophage numbers were increased in placentae 
from women with GDM and that this increase in macrophage number was accompanied by an 
increase in pro-inflammatory cytokines (Yu et al., 2013). Their assessment did not factor in 
macrophage localization throughout the different placental regions. Our comparison of placentae 
from women with GDM and healthy controls did not find a significant difference in the number 
or localization of CD68+ cells in the placenta. We did however; find a significant difference in 
the expression of CD163 on macrophages within the chorion and decidual regions of the placenta 
indicating either a change in macrophage polarization phenotype, iron metabolic potential, or 
both. In conjunction with the increase in CD163+ cells, we reported a significant increase in the 
amount of iron in the placenta. This iron appeared to be localized to macrophages, but was also 
detectable within other cells in smaller amounts. High maternal iron has been linked to glucose 
metabolism disorders such as GMD and T2D (Afkhami-Ardekani & Rashidi, 2009; Barbieri et 
al., 2001; Choi et al., 2003; Rawal et al., 2017). As iron can be highly toxic to cells in high 
amounts, this increase in stored iron within the placenta may be one mechanism by which 
placental macrophages sequester and recycle iron in an attempt to reduce the transfer of iron to 
the fetus. Overall, our results add to the growing amount of evidence that GDM has direct effects 
on placental structure and macrophage phenotypes. 
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In chapter 3 and 4, we proposed that GDM modifies MIA-induced gene expression 
changes within the fetal brain and placenta. To interrogate this hypothesis, we studied the 
combined effect of two commonly occurring insults during pregnancy, GDM and maternal 
infection. We based these hypotheses on the following findings. First, both MIA and GDM 
increase inflammation (Abell et al., 2015; Deverman & Patterson, 2009). Secondly, both GDM 
and MIA have their peak influence on programming midgestation (Buka et al., 2001; Xiang et 
al., 2015). Third, both have been shown to alter cytokine levels that can cross the placenta 
(Elaine Y. Hsiao & Paul H. Patterson, 2011; Hsiao & Patterson, 2012; Li et al., 2013). And 
lastly, both GDM and MIA have been linked to increased occurrence of autism and 
schizophrenia (Atladóttir et al., 2010; Mary Cannon et al., 2002; B. K. Lee et al., 2015; Van 
Lieshout & Voruganti, 2008; Xiang et al., 2015). We chose to induce GDM through the 
administration of a high fat diet (Pasek & Gannon, 2013). In our model, the presence of impaired 
glucose tolerance, fasting glucose, and fasting insulin are consistent with a gestationally diabetic 
phenotype. To model maternal infection and induce MIA, we utilized the viral mimetic 
poly(I:C).   
To gain insight into the maternal inflammatory status of these models, we measured 
maternal serum cytokine, chemokine, adipokine, and insulin levels 3 hours after MIA exposure 
at GD12.5 and four days after exposure at GD16.5.  At GD12.5 the MIA-induced 
cytokine/chemokine profile was similar to what was observed in GDM, suggesting that GDM 
does not modify the cytokine/chemokine response to MIA. Although no changes reached 
significance with GDM alone, we did observe significantly increased leptin and decreased 
adiponectin levels. This metabolic profile is expected with a diabetic phenotype (Fasshauer, 
Blüher, & Stumvoll, 2014; Gallou-Kabani et al., 2007; Kautzky-Willer et al., 2001; Van Heek et 
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al., 1997; Vitoratos et al., 2001). Taken together, the maternal serum data supports that 1) MIA 
produces a transiently heightened inflammatory state 2) that GDM induces adipokine changes 
consistent with a diabetic phenotype 3) that MIA and GDM interact to produce an even higher 
increase in pro-inflammatory leptin levels. This demonstrates that our models of MIA and GDM 
are pro-inflammatory as well as provides novel insight into the interaction at the maternal level 
of MIA and GDM.  
We utilized these models to gain insight into gene expression changes within the fetal 
brain in order to better understand how MIA and GDM could impact neurodevelopmental 
pathways. Overall our results demonstrate that 1) GDM alters expression of IFN response, 
growth and cell cycle regulation, apoptosis, and fetal brain neuronal patterning genes in the brain 
2) MIA alters expression of genes both alone (antiviral/IFN response, lipid peroxidation, cell 
cycle regulation/apoptosis, cell growth, inflammation-associated intracellular signaling, hypoxia, 
and neuronal migration) and in the context of GDM (antiviral/IFN response, innate immune 
response, cell cycle regulation/apoptosis/growth, inflammation-associated intracellular signaling, 
neuronal patterning/migration/myelination, hypoxia, and glucose transport), 3) GDM modifies 
MIA gene expression in the fetal brain with a stronger induction of inflammation associated 
genes, and 4) the majority of gene expression changes are only present during the acute immune 
response at GD12.5.  
As mentioned earlier, fetal sex can also be a driver of NCD risk during development (Al-
Qaraghouli & Fang, 2017). To our knowledge, this study is the first of its kind to investigate the 
combined stressors of GDM and MIA from the standpoint of sexual dimorphism and placental 
gene expression. The data gathered will lay the groundwork for future studies to elucidate the 
mechanistic basis for sex-dependent risk for NCDs.  At baseline we found some genes to be 
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differentially expressed between male and female placentae. Interestingly several chemokines, 
pathogen recognition receptors, and the prostaglandin-generating, inducible cyclooxygenase-2 
(Ptgs2) were among these. The male-specific increased expression of Ptgs2 is interesting given 
that prostaglandins are critically important in labor and sexual dimorphism has been observed in 
the incidence of preterm labor (Verburg et al., 2016). Also, cyclooxygenase inhibitors were 
shown to have sex-specific effects in mollifying the inflammatory effects of antenatal stress in 
the placenta and improving behavioral outcomes in male offspring in a mouse model of 
environmental psychological and physical stressors (Bronson & Bale, 2014). Taken together, the 
role of cyclooxygenase should be reviewed more in depth for its sex-specific role in fetal 
outcomes independent of maternal inflammation. 
GDM induced a significant change in the expression of 37.5% of the genes interrogated. 
Of the genes that decreased in expression, 62% displayed sexual dimorphism and of those with 
increased expression 61% displayed differential expression in a sex-dependent manner. Our data 
is consistent with others who have reported that obesity impacts placental inflammation in a sex-
dependent manner (Leon-Garcia et al., 2016) and that mice fed a high fat diet have been found to 
have divergent patterns of gene expression in male vs. female placentae (Gabory et al., 2012). 
Males had upregulated expression of the cytoskeletal regulation of Rho GTPase and the Wnt 
signaling pathways while female placentae showed a higher degree of change in the 
Insulin/IGF/MAPK signaling pathway. Prior studies have concluded that the IGF axis was 
regulated in a sex-dependent manner (Clifton et al., 2010). Making this pathway one that 
deserves further interpretation in the context of maternal inflammation and placental function. 
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Mice exposed to MIA revealed significant changes in gene expression in 46% of the total 
genes interrogated. Of the genes with decreased expression levels, 65% displayed sexual 
dimorphism while only 49% of those with increased expression differed based upon sex. The 
pathways with the most perturbations were related to TLR signaling, interleukin signaling, and 
cytokine and chemokine signaling in both male and female placentae. Similar to GDM, the 
female placentae exhibited a higher degree of differential regulation in the insulin/IGF/MAPK 
pathway, indicating that genes within this pathway may be important to the female response to 
inflammatory stress. Although not interrogated in the context of GDM, the IGF axis has been 
reported to be differentially regulated in a sex-dependent manner in other inflammatory related 
diseases during pregnancy such as asthma (Clifton et al., 2010). The role for the IGF axis within 
the placenta has not been well established although its possible importance in the sex-dependent 
response to inflammatory insults should be investigated further.     
The most fascinating aspect of our study was the combination of GDM and MIA. The 
combined inflammatory stress of GDM and MIA reveals changes in 38% of the genes in our 
panel. Of the genes decreased in expression, 60% were regulated in a sex-dependent manner 
while only 30% of those genes increasing in expression displayed sexual dimorphism. Again, the 
insulin/IGF/MAPK pathway was more significantly changed in female placentae compared to 
male, stressing its possible importance in the placental response to maternal inflammatory stress. 
Although a more comprehensive study on the placental transcriptome is necessary to make any 
conclusions regarding the role of sexual dimorphism in the context of maternal inflammatory 
stress, these studies have laid the groundwork for studies to come. In summary, this work 
suggests that the common antenatal stressors of GDM and MIA impact immune gene expression 
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within the placenta and that when combined they appear to interact changing placental gene 
expression patterns in a sex-dependent manner. 
The underlying mechanism driving the increased risk of NDCs in the context of maternal 
inflammation is unknown, although multiple studies have described how metabolic stress in the 
form of dyslipidemia can influence inflammatory mediators (Robbins, Wen, & Ting, 2014). In 
chapter 5 we began to mechanistically test some of the observations described in earlier chapters. 
The increases in IL-1β seen in the amniotic fluid of GDM mice, but not in the maternal serum, 
lead us to hypothesize that the placenta may be the source of this pro-inflammatory cytokine. 
The role of the IL-1 family of cytokines has been well established in T2D (Banerjee & Saxena, 
2012) and studies have identified its dysregulation in cases of GDM (Lappas, 2014; S. Yanai et 
al., 2016). We established that primary PMs secrete increased levels of IL-1β in response to 
stimulation with palmitate, but not in response to levels of glucose and insulin physiologically 
relevant in diabetic states. This increase in IL-1β was accompanied by an increase in caspase-1 
release. Pro-caspase-1 is autocatalytically cleaved into its active form upon activation and 
assembly of the NLRP3 inflammasome (Wilson et al., 1994).  We were also able to show that 
inflammasome assembly was occurring in PMs as a consequence of palmitate exposure by 
NLRP3-ASC complex formation. Although much works needs to be done in order to fully 
understand the mechanisms through which palmitate is stimulating increased levels of IL-1β 
production by PMs we were able to establish that PMs are indeed able to produce IL-1β in 
response to palmitate and that this increase is accompanied by inflammasome assembly and 
increased levels of caspase-1.  
Altogether, this body of work concludes that maternal stress, either in the form of 
metabolic stress induced by GDM or immune stress as induced by maternal infection, affects 
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multiple aspects of development and maternal and fetal health in some cases in a sexual 
dimorphic manner. Defining the phenomenon that occur as a result of maternal inflammatory 
stress within the placenta and fetal brain will allow for more focused and insightful future 
questions regarding the underlying mechanisms to be interrogated. Ultimately these studies will 
help lead to a better understanding how maternal stressors influence the developmental origins of 
health and disease. 
 
Future directions 
 
Behavioral studies of GDM and MIA mice 
First and foremost, I believe that one of the most important studies that should be 
completed to round out the work presented in chapters 3 and 4 are behavioral studies of the 
offspring born to mothers who were exposed to our models of GDM, MIA, and the combination 
of the two. The research conducted by our collaborators and others defined the neurocognitive 
phenotypes in the offspring of MIA mice and pioneered our understanding of the topic leading us 
to form the hypotheses presented here. I feel like it is essential to move beyond just gene 
expression studies and look at real world phenotypes that are characteristic of autism and 
schizophrenia in mice. These behavioral studies would truly allow for us to see if the interactions 
between the two maternal stressors of GDM and MIA culminate in differential or synergistic 
behavioral phenotypes in the offspring. Once the baseline phenotypes were evaluated, we could 
expand our knowledge by repeating the entire set of experiments using inhibitors of or antibodies 
against particular mediators of interest such as IL-6 and IL-1β in order to gain mechanistic 
insight into the phenotypes of interest. 
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Use of live flu virus in conjunction with GDM 
Although widely used as a viral mimic, poly(I:C) is not a live virus. As mentioned in 
previous sections there are many advantages to using poly(I:C) over live viruses, however, live 
viruses may initiate phenotypes and interact in ways that you would not see given the use of a 
viral mimic. I would propose to repeat the experimental design outlined and utilized in chapters 3 
and 4 using live Influenza virus in the context of GDM. The use of live virus may initiate 
perturbations not otherwise seen and interact with cells in ways independent of its contact with 
the immune system. In conjunction with the use of live Influenza virus, I would also propose to 
use other viruses known to cause complications either during pregnancy or to the offspring as a 
result of maternal infection such as Cytomegalovirus. These experiments would allow us to 
identify virus specific outcomes in gene expression, maternal and fetal inflammation, and 
offspring behavioral studies.  
In conjunction with the use of live virus, I would propose to expand the gene expression 
panel to a more global and non-biased RNAseq platform. This way we could better monitor 
global changes in fetal brain and placental development as a consequence of infection and GDM. 
 
Explore sexual-dimorphism in neurobehavioral comorbidities in MIA and GDM 
Our study design outlined in chapter 3 did not make it possible for us to explore the role 
of sexual-dimorphism in fetal brain gene expression patterns. As evidence mounts suggesting 
that fetal and placental sex play a large part in conferring the risk of NCDs to the offspring as a 
result of maternal inflammatory insults I think it will be of the utmost importance to include fetal 
and placental sex as a variable in data analysis.  
The effect of paternal inflammatory status on fetal outcomes 
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The developing fetus, and thus the placenta, is genetically influenced by both the mother 
and the father equally. The vast majority of studies that interrogate the DOHaD paradigm do so 
from the stand point of the mother and how the maternal environment influences fetal outcomes. 
Although limited in number, studies have shown that paternally derived factors also have the 
ability to influence pregnancy related outcomes and offspring health (Ding, Lambert, Aronoff, 
Osteen, & Bruner-Tran, 2018; Ding, Mokshagundam, Rinaudo, Osteen, & Bruner-Tran, 2018). It 
would be interesting to expose the paternal germ line to inflammatory insults such as MIA, live 
viral infections, and or GDM prior to mating in order to assess how the heightened inflammatory 
status of the father affects his progeny. Assessment of fetal brain gene expression patterns and 
placental gene expression patterns when compared to our data from maternal stimulation would 
allow for a direct comparison looking at the contribution of both parents to changes in fetal 
outcomes.  
 
The impact of GDM and MIA on the maternal, fetal gut, and placental microbiome  
Until recently the placenta was considered a sterile pathogen-free zone. Recent evidence 
has suggested otherwise. In fact, the placenta contains a distinct microbial signature (Aagaard et 
al., 2014). Furthermore, it has been reported that these distinct placental microbes begin to 
colonize the fetal gut shortly before birth (Collado, Rautava, Aakko, Isolauri, & Salminen, 
2016).  These fascinating findings lead me to my most exciting future direction which explores 
the impact of maternal inflammatory stress in the form of viral infection and GDM on the fetal 
gut and placental microbiome in a sex-dependent manner. This future direction even ties in our 
mechanistic studies presented in chapter 5 as it is known that inflammasomes are important 
regulators of the gut microbiome and gut homeostasis (Henao-Mejia et al., 2012). These sets of 
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experiments, although ambitious, would lead to a great deal of insight into the DOHaD paradigm 
while incorporating multiple different realms of biomedical research.         
 
 
 
  
 138 
SUPPLEMENTAL INFORMATION 
 
Supplemental Table 1. Gestational diabetic case demographics 
25 placental samples from women diagnosed with GDM were chosen for this study. Displayed 
below is the case patient information gathered from the synthetic derivative electronic medical 
record. These cases were matched to controls based upon the information provided in this table.  
 
maternal age weeks gestation Race/Ethnicity delivery method 
39 37 2/7 Caucasian cesarean 
25 38 2/7 Caucasian cesarean 
19 38 5/7 African American cesarean 
28 36  Caucasian cesarean 
21 35 5/7 African American cesarean 
19 38 1/7 African American vaginal 
26 33 6/7 Caucasian vaginal 
34 39  Caucasian cesarean 
28 39 Caucasian cesarean 
28 35 3/7 Caucasian vaginal 
37 36 3/7 Caucasian vaginal 
38 39 Asian-pacific Vaginal 
33 36  Caucasian  Vaginal 
31 38  Caucasian Vaginal 
36 33  African American Vaginal 
31 39  Asian-pacific cesarean 
32 37  Unknown cesarean 
23 36.2  Caucasian cesarean 
28 36  Caucasian vaginal 
27 34  Caucasian cesarean 
29 39  African American cesarean 
31 34 1/7 other non-Hispanic vaginal 
32 39  Caucasian cesarean 
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41 39 Hispanic cesarean 
25 39 African American cesarean 
 
 
Supplemental Table 2. Litter statistics 
35 GD12.5 pregnant dams and 36 GD16.5 pregnant dams were sacrificed, and the embryos 
collected. Average litter size, average number of resorptions and mal-developed pups (runts, 
severe hemorrhage or hypoxia) per litter, average ratio of male:female embryos, and average 
embryo crown-rump length are listed with SEM in the table below. 
 
Diet Exposure 
GD 
age 
Number 
of litters 
litter 
size resorptions 
mal-
developed 
embryos 
male : 
female 
ratio 
Crown 
– rump 
length 
CTR SAL 12.5 9 7.0 ± 
0.4 
1.3 ± 0.7 0.2 ± 0.2 0.6 ± 0.1 8.6 ± 0.1 
CTR MIA 12.5 8 7.8 ± 
1.0 
1.6 ± 0.6 0.3 ± 0.3 0.6 ± 0.1 8.3 ± 0.1 
HF SAL 12.5 9 8.0 ± 
0.5  
1.1 ± 0.6 0.2 ± 0.2 0.5 ± 0.1 8.4 ± 0.1 
HF MIA 12.5 9 7.4 ± 
0.4 
2.0 ± 0.8 0.1 ± 0.1 0.5 ± 0.0 8.4 ± 0.1 
                  
CTR SAL 16.5 9 6.8 ± 
0.8 
1.8 ± 0.8 0.3 ± 0.2 0.5 ± 0.1 15.5 ± 
0.2 
CTR MIA 16.5 9 7.3 ± 
0.4 
1.4 ± 0.4 0.1 ± 0.1 0.6 ± 0.1 14.8 ± 
0.1 
HF SAL 16.5 9 7.8 ± 
0.6 
0.9 ± 0.3 0.1 ± 0.1 0.7 ± 0.1 15.1 ± 
0.2 
HF MIA 16.5 9 6.7 ± 
0.7 
2.4 ± 0.6 0.2 ± 0.2 0.6 ± 0.1 14.9 ± 
0.2 
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Supplemental Figure 1. High fat diet does not produce a diabetic phenotype at GD0.5. Body 
composition, 6 hour fasting glucose and insulin, and glucose tolerance measurements were 
performed on a cohort of high fat and control fed GD0.5 pregnant dams (n=8 per group). (A) 
High fat fed dams did not show significant increases in body weight. (B) Whole body NMR also 
did not show significant changes in % body mass. (C-D) Neither 6 hour fasting blood glucose or 
serum insulin were significantly altered in high fat dams. (E-F) After a 6 hour fast, dams were 
injected intraperitoneally with 2 g dextrose/kg body weight. No significant difference in blood 
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glucose between control and high fat dams was observable at 0 10, 20, 30, 60, and 75 minutes 
post-injection. Error bars represent SEM. Significance of p<0.05 is indicated by * and 
determined by unpaired student t-test with Welch’s correction in all assays, n=6 dams per group. 
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Supplemental Figure 2. 8 weeks of high fat diet produces increased body weight and a 
trend towards altered glucose tolerance. Body composition, 6 hour fasting glucose and insulin, 
and glucose tolerance measurements were performed on a cohort of high fat and control fed non-
pregnant dams (n=8 per group). The purpose of this experiment was to determine if the GD12.5 
high fat dams were glucose intolerant due to pregnancy + 8 weeks of high fat diet or if 8 weeks 
of high fat diet alone was sufficient to induce glucose intolerance. (A-B) High fat dams had a 
significantly increased body weight but not altered body composition. (C-D) Fasting glucose and 
insulin after a 6 hour fast were NOT impaired in HF dams, unlike that seen in the pregnant 
cohort. (E-F) When challenged with 2 g/kg dextrose after a 6 hour fast, HF dams show 
significant differences at two time points (45 and 60 minutes post-injection), and there is a strong 
trend although not significant of a significantly increased area under the curve (best measure of 
glucose intolerance). Error bars represent SEM. Significance of p<0.05 indicated by * and 
determined by unpaired student t-test, n=8 for HF and CTR. 
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Supplemental Figure 3. HFD and MIA do not alter cytokine or chemokine profiles within 
maternal serum at GD16.5 Maternal serum collected via cardiac puncture 4 days  post injection 
with either saline or 20mg/kg Poly I:C potassium salt on GD12.5 was analyzed for chemokine 
and cytokine levels via conjugated bead array multiplex assay. Error bars represent SEM. 
Significance indicated by letters with similar letters dictating no significance as determined by 
one-way ANOVA with Tukey’s multiple comparisons post-test in all assays. (n=9 except for 
Poly I:C treated non-HFD where n=8).  
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Supplemental Figure 4. High fat diet induced gestational diabetes and MIA continue to 
alter serum factor levels at GD16.5. Maternal serum collected at GD16.5- 4 days after 
poly(I:C) exposure- was analyzed for chemokine, cytokine, and metabolic hormone levels via 
Luminex multiplex assay. Only those serum factors that demonstrated a significant difference in 
at least one comparison (SAL vs. MIA, SAL vs. HFS, or HFS vs. HFM) are shown. (A) The only 
cytokine/chemokine significantly increased by MIA at GD16.5 was IL13, which actually was not 
significantly different at GD12.5. This was only observed in the control context and not in the 
context of high fat diet induced gestational diabetes. (B) The anti-inflammatory metabolic 
hormone adiponectin remained significantly decreased by high fat diet induced gestational 
diabetes at GD16.5, but was also increased by MIA in the context of high fat diet induced 
gestational diabetes, bringing the HFM group to a similar level as MIA and SAL. (C) The pro-
inflammatory satiety hormone leptin also remained significantly increased by high fat diet 
induced gestational diabetes, but the further increase by MIA only in the context of high fat diet 
induced gestational diabetes was no longer observable. Error bars represent SEM. Significance 
of p<0.05 is indicated by * and determined by unpaired student t-test with Welch’s correction in 
all assays. Serum was collected at GD16.5, four days after poly(I:C) exposure, from dams whose 
embryos were utilized for Nanostring gene expression analysis (SAL n=9, MIA n=9, HFS n=9, 
HFM n=9). 
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Supplemental Table 3. Both high fat diet and MIA alter gene expression at GD12.5. 
Genes listed demonstrated a significant change in expression in either HFM, MIA, or HFS when 
compared to SAL (57 genes). The log2(counts) values, which are listed with SEM, for each 
group was utilized for a supervised hierarchical clustering analysis shown in Figure 7. 
Significance was determined by unpaired student t-test with Welch’s correction and p<0.05 
(significant values are shaded).  
 
 SAL HFS MIA HFM 
Gene 
log2 
(counts) 
log2 
(counts) 
ALR 
(HFS-
SAL) p-value 
log2 
(counts) 
ALR 
(MIA-
SAL) p-value 
log2 
(counts) 
ALR 
(HFM-
SAL) p-value 
Ager 
7.21 ± 
0.11 
7.38 ± 
0.07 0.17  0.182 
7.41 ± 
0.04 0.21 0.088 
7.64 ± 
0.07 0.44 0.003 
Alox12 
4.37 ± 
0.08 
4.43 ± 
0.21 0.06 0.778 
4.89 ± 
0.12 0.52 0.003 
3.96 ± 
0.18 -0.42 
0.045, 
ns 
Bcl6 
4.89 ± 
0.13 
4.73 ± 
0.09 -0.16 0.302 
4.22 ± 
0.12 -0.67 0.001 
4.81 ± 
0.11 -0.08 0.637 
C1qb 
9.05 ± 
0.04 
8.99 ± 
0.05 -0.06 0.303 
8.97 ± 
0.05 -0.08 0.242 
8.91 ± 
0.05 -0.14 0.030 
Cd55 
6.90 ± 
0.12 
6.78 ± 
0.06 -0.13 0.342 
6.63 ± 
0.05 -0.27 0.049 
6.62 ± 
0.07 -0.29 0.051 
Creb1 
7.64 ± 
0.06 
7.66 ± 
0.06 0.02 0.793 
7.34 ± 
0.09 -0.30 0.014 
7.45 ± 
0.05 -0.19 0.025 
Cysltr1 
3.45 ± 
0.09 
3.50 ± 
0.13 0.06 0.718 
3.73 ± 
0.18 0.28 0.188 
3.90 ± 
0.17 0.45 0.030 
Dckl1 
12.19 ± 
0.09 
12.11 ± 
0.05 -0.08 0.45 
11.87 ± 
0.10 -0.32 0.024 
12.19 ± 
0.07 0.00 0.994 
Ddit3 
9.69 ± 
0.03 
9.84 ± 
0.05 0.14 0.017 
9.71 ± 
0.04 0.02 0.631 
9.69 ± 
0.05 0.00 0.988 
En1 3.97 ± 3.46 ± -0.51 0.049 3.92 ± -0.05 0.855 3.71 ± -0.27 0.360 
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0.23 0.06 0.21 0.19 
Flt1 
8.84 ± 
0.02 
8.92 ± 
0.03 0.08 0.051 
9.04 ± 
0.07 0.20 0.025 
9.24 ± 
0.05 0.41 0.000 
Foxg1 
10.75 ± 
0.03 
10.85 ± 
0.04 0.11 0.052 
10.83 ± 
0.08 0.09 0.311 
11.07 ± 
0.05 0.33 0.000 
Fxyd2 
7.09 ± 
0.06 
7.15 ± 
0.06 0.06 0.509 
6.83 ± 
0.10 -0.26 0.048 
7.07 ± 
0.06 -0.03 0.730 
Gabra2 
9.42 ± 
0.09 
9.30 ± 
0.04 -0.11 0.243 
9.01 ± 
0.13 -0.41 0.018 
9.26 ± 
0.07 -0.16 0.162 
Gad1 
9.74 ± 
0.09 
9.77 ± 
0.06 0.02 0.837 
9.64 ± 
0.10 -0.11 0.396 
10.07 ± 
0.06 0.33 0.006 
Gnaq 
12.67 ± 
0.04 
12.62 ± 
0.02 -0.05 0.295 
12.52 ± 
0.04 -0.15 0.028 
12.65 ± 
0.03 -0.02 0.722 
Hmgb2 
9.92 ± 
0.05 
10.11 ± 
0.04 0.19 0.009 
9.88 ± 
0.05 -0.03 0.636 
9.97 ± 
0.04 0.05 0.464 
Ifi44 
3.82 ± 
0.19 
3.54 ± 
0.12 -0.28 0.197 
4.94 ± 
0.35 1.12 0.017 
5.70 ± 
0.40 1.88 0.001 
Ifit1 
3.54 ± 
0.12 
3.47 ± 
0.09 -0.07 0.627 
4.61 ± 
0.34 1.07 0.017 
5.63 ± 
0.41 2.09 0.001 
Ifit2 
8.86 ± 
0.04 
8.81 ± 
0.05 -0.04 0.483 
8.95 ± 
0.04 0.09 0.074 
9.18 ± 
0.09 0.32 0.004 
Ifit3 
4.66 ± 
0.14 
4.93 ± 
0.16 0.27 0.197 
5.77 ± 
0.32 1.11 0.010 
6.79 ± 
0.38 2.13 0.000 
Ifitm3 
8.41 ± 
0.10 
8.15 ± 
0.05 -0.26 0.027 
8.54 ± 
0.13 0.13 0.410 
8.79 ± 
0.12 0.38 0.017 
Ifna1 
3.36 ± 
0.04 
3.86 ± 
0.20 0.51 0.026 
3.44 ± 
0.08 0.09 0.350 
3.54 ± 
0.13 0.18 0.191 
Il11 
3.32 ± 
0.00 
3.56 ± 
0.10 0.23 0.043 
3.35 ± 
0.03 0.03 0.374 
3.39 ± 
0.07 0.06 0.358 
Il18rap 3.79 ± 4.15 ± 0.36 0.102 4.02 ± 0.23 0.161 4.30 ± 0.51 0.002 
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0.10 0.19 0.12 0.11 
Irf1 
7.01 ± 
0.08 
7.01 ± 
0.07 0.00 0.973 
7.14 ± 
0.09 0.13 0.270 
7.28 ± 
0.10 0.27 0.040 
Irf5 
4.86 ± 
0.08 
4.82 ± 
0.07 -0.05 0.637 
4.92 ± 
0.11 0.06 0.685 
4.64 ± 
0.04 -0.22 0.019 
Irf7 
3.78 ± 
0.16 
3.64 ± 
0.13 -0.14 0.478 
4.62 ± 
0.36 0.84 0.060 
5.22 ± 
0.35 1.45 0.002 
Maff 
6.21 ± 
0.07 
6.21 ± 
0.11 0.00 0.985 
6.35 ± 
0.10 0.14 0.258 
6.69 ± 
0.07 0.48 0.000 
Map3k
5 
6.93 ± 
0.13 
6.76 ± 
0.07 -0.17 0.238 
6.58 ± 
0.08 -0.34 0.033 
6.61 ± 
0.08 -0.32 0.040 
Mapk1 
11.22 ± 
0.04 
11.26 ± 
0.04 0.04 0.416 
11.26 ± 
0.05 0.04 0.514 
11.37 ± 
0.04 0.15 0.009 
Mef2a 
9.38 ± 
0.07 
9.19 ± 
0.03 -0.19 0.027 
9.16 ± 
0.07 -0.23 0.031 
9.12 ± 
0.05 -0.26 0.007 
Mef2c_
Mm 
8.94 ± 
0.09 
8.76 ± 
0.04 -0.18 0.074 
8.71 ± 
0.03 -0.23 0.026 
8.87 ± 
0.05 -0.06 0.500 
Mx2 
4.29 ± 
0.17 
4.93 ± 
0.09 0.64 0.004 
5.54 ± 
0.21 1.25 0.000 
6.18 ± 
0.21 1.88 0.000 
Myc 
9.85 ± 
0.07 
9.72 ± 
0.03 -0.13 0.081 
9.53 ± 
0.09 -0.32 0.010 
9.72 ± 
0.05 -0.13 0.140 
Myd88 
7.52 ± 
0.06 
7.40 ± 
0.03 -0.12 0.097 
7.32 ± 
0.04 -0.20 0.016 
7.34 ± 
0.06 -0.19 0.043 
Ncam1 
13.75 ± 
0.08 
13.71 ± 
0.04 -0.05 0.603 
13.49 ± 
0.07 -0.26 0.020 
13.82 ± 
0.05 0.07 0.483 
Ncam2 
9.41 ± 
0.08 
9.37 ± 
0.02 -0.04 0.646 
9.17 ± 
0.09 -0.24 0.048 
9.46 ± 
0.06 0.06 0.560 
Nfe2l2 
10.52 ± 
0.04 
10.44 ± 
0.06 -0.08 0.238 
10.34 ± 
0.04 -0.18 0.006 
10.26 ± 
0.04 -0.26 0.000 
Nr3c1 8.80 ± 8.70 ± -0.10 0.261 8.63 ± -0.17 0.047 8.65 ± -0.15 0.073 
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0.07 0.06 0.03 0.04 
Oasl1 
3.32 ± 
0.00 
3.32 ± 
0.00 0.00 1.000 
4.39 ± 
0.34 1.07 0.016 
5.30 ± 
0.36 1.97 0.000 
Pdgfa 
9.60 ± 
0.09 
9.50 ± 
0.03 -0.09 0.299 
9.27 ± 
0.07 -0.33 0.010 
9.37 ± 
0.05 -0.23 0.026 
Ppp1r1
2b 
9.07 ± 
0.05 
9.08 ± 
0.04 0.01 0.877 
8.88 ± 
0.05 -0.19 0.016 
9.01 ± 
0.03 -0.06 0.255 
Ptgs1 
6.28 ± 
0.06 
6.07 ± 
0.07 -0.21 0.031 
6.16 ± 
0.07 -0.11 0.199 
6.15 ± 
0.09 -0.13 0.236 
Ripk1 
8.28 ± 
0.04 
8.25 ± 
0.05 -0.03 0.648 
8.07 ± 
0.06 -0.21 0.014 
8.06 ± 
0.04 -0.22 0.001 
Rock2 
9.88 ± 
0.04 
9.81 ± 
0.03 -0.07 0.180 
9.73 ± 
0.05 -0.15 0.026 
9.78 ± 
0.04 -0.10 0.077 
Shh 
10.71 ± 
0.07 
10.90 ± 
0.03 0.19 0.024 
10.88 ± 
0.09 0.17 0.143 
10.83 ± 
0.05 0.12 0.180 
Slc2a1 
11.23 ± 
0.02 
11.28 ± 
0.01 0.05 
0.040, 
ns 
11.37 ± 
0.06 0.14 0.046 
11.46 ± 
0.05 0.23 0.001 
Slc2a3 
9.61 ± 
0.04 
9.73 ± 
0.02 0.12 
0.021, 
ns 
9.70 ± 
0.06 0.10 0.201 
9.90 ± 
0.07 0.29 0.003 
Stat1 
9.31 ± 
0.03 
9.34 ± 
0.03 0.03 0.457 
9.43 ± 
0.05 0.12 
0.046, 
ns 
9.50 ± 
0.07 0.19 0.025 
Syt1 
9.55 ± 
0.09 
9.53 ± 
0.06 -0.02 0.864 
9.26 ± 
0.09 -0.29 0.025 
9.61 ± 
0.06 0.07 0.517 
Tcf4 
13.84 ± 
0.04 
13.75 ± 
0.03 -0.09 0.095 
13.65 ± 
0.07 -0.19 0.040 
13.80 ± 
0.04 -0.04 0.519 
Tgfb3 
8.24 ± 
0.17 
7.95 ± 
0.06 -0.29 0.119 
7.80 ± 
0.08 -0.45 0.028 
8.07 ± 
0.09 -0.18 0.349 
Tnfaip3 
7.33 ± 
0.06 
7.46 ± 
0.05 0.13 0.107 
7.29 ± 
0.09 -0.04 0.733 
7.58 ± 
0.09 0.25 0.036 
Traf2 9.62 ± 9.67 ± 0.05 0.326 9.46 ± -0.15 0.040 9.44 ± -0.18 0.008 
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0.03 0.04 0.06 0.05 
Vamp1 
7.78 ± 
0.08 
7.89 ± 
0.03 0.11 0.233 
7.81 ± 
0.08 0.03 0.765 
8.09 ± 
0.03 0.31 0.004 
Vegfa 
11.20 ± 
0.03 
11.42 ± 
0.04 0.22 0.000 
11.44 ± 
0.10 0.24 0.033 
11.69 ± 
0.07 0.49 0.000 
 
 
 
Supplemental Table 4. GDM and MIA alter gene expression at GD12.5. 
Genes listed demonstrated a significant change in expression in HFS, MIA, or HFS+MIA when 
compared to S. The difference of log2 (counts) between control and each treatment/diet group 
was utilized for Venn diagram in Figure 10. Significance was determined by multiple t-tests 
with FDR<0.01 and p<0.05.  
 
Genes induced in GD12.5 high-fat diet induced GDM 
 Difference Fold Change FDR p-value 
C1s 2.51 1.18 * 7.33E-09 
Ccl8 3.91 1.20 * 6.43E-12 
Hspb1 14.79 1.20 * 9.51E-21 
Ifit3 5.20 1.21 * 1.62E-14 
Il18rap 3.94 1.29 * 1.72E-12 
Masp2 4.26 1.26 * 2.13E-09 
Mx2 10.89 1.56 * 2.46E-20 
Tslp 2.89 1.19 * 2.27E-09 
Pax5 5.45 1.23 * 1.22E-15 
Vegfa 394.12 1.17 * 0.00E+00 
 
Genes repressed in GD12.5 high-fat diet induced GDM 
 Difference Fold Change FDR p-value 
Arg1 -12.04 0.70 * 2.42E-15 
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Ccl21a -42.76 0.84 * 9.51E-28 
Ccl7 -2.73 0.82 * 5.66E-10 
Ifi44 -2.52 0.82 * 1.90E-09 
Itgb2 -5.38 0.80 * 1.16E-12 
Nlrp3 -2.60 0.81 * 2.45E-13 
Oas1a -3.56 0.84 * 7.15E-10 
Pla2g4a -16.20 0.85 * 8.64E-24 
Ptger4 -3.37 0.78 * 4.14E-11 
Ptgfr -9.61 0.77 * 1.37E-16 
Tgfb2 -121.72 0.84 * 1.81E-38 
Tgfb3 -55.39 0.82 * 5.81E-32 
Twist2 -23.33 0.75 * 6.96E-18 
Chat -2.11 0.85 * 4.39E-10 
Cryab -6.48 0.75 * 1.35E-11 
En1 -4.70 0.70 * 5.39E-13 
En2 -2.63 0.81 * 2.06E-09 
Ifitm3 -55.76 0.84 * 1.52E-35 
 
Genes induced in GD12.5 MIA 
 Difference Fold Change FDR p-value 
Ager 22.62 1.15 * 4.95E-27 
Alox12 9.06 1.44 * 6.42E-20 
Ccl2 5.58 1.30 * 3.38E-13 
Ccl3 3.89 1.15 * 8.25E-13 
Ifi44 16.63 2.18 * 3.06E-17 
Ifit1 12.84 2.11 * 3.47E-16 
Ifit3 29.20 2.15 * 8.91E-22 
Il18rap 2.38 1.17 * 1.22E-10 
Irf7 10.85 1.79 * 1.44E-14 
Masp2 2.68 1.16 * 1.08E-05 
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Mx2 27.07 2.38 * 8.62E-23 
Oas1a 6.65 1.29 * 4.41E-13 
Vegfa 423.91 1.18 * 0.00E+00 
 
Genes repressed in GD12.5 MIA 
 Difference Fold Change FDR p-value 
Arg1 -10.47 0.74 * 2.66E-14 
Bcl6 -11.03 0.63 * 9.79E-20 
Ccl21a -60.27 0.77 * 7.00E-28 
Cd55 -20.79 0.83 * 1.21E-25 
Creb1 -37.13 0.81 * 5.81E-31 
Fxyd2 -22.69 0.83 * 4.33E-27 
Ifi27l2a -6.04 0.77 * 2.94E-12 
Il6ra -3.39 0.76 * 5.24E-12 
Map3k5 -25.65 0.79 * 3.62E-26 
Mef2b -2.85 0.80 * 6.19E-09 
Mmp9 -31.25 0.76 * 1.95E-24 
Myc -183.11 0.80 * 0.00E+00 
Nlrp3 -2.07 0.85 * 5.55E-10 
Pdgfa -156.80 0.80 * 0.00E+00 
Prkca -73.22 0.84 * 5.61E-34 
Ptger3 -13.07 0.79 * 1.91E-17 
Ptger4 -2.49 0.83 * 1.59E-07 
Ptgfr -11.97 0.71 * 3.76E-17 
Tgfb3 -80.95 0.73 * 3.37E-32 
Twist2 -15.91 0.83 * 3.74E-13 
Bdnf -8.10 0.82 * 2.49E-16 
Dckl1 -925.97 0.80 * 0.00E+00 
Drd1a -13.08 0.66 * 1.09E-16 
Drd2 -13.28 0.80 * 6.89E-22 
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En2 -2.09 0.85 * 2.20E-07 
Gabra2 -168.67 0.75 * 1.89E-38 
Ncam1 -2295.92 0.83 * 0.00E+00 
Ncam2 -102.90 0.85 * 3.46E-37 
Npy -112.55 0.80 * 4.26E-35 
Pax5 -3.85 0.84 * 1.83E-11 
Syt1 -135.50 0.82 * 1.33E-38 
 
Genes induced in GD12.5 GDM + MIA 
 Difference Fold Change FDR p-value 
Ager 52.37 1.35 * 4.54E-34 
C1s 4.71 1.33 * 1.16E-13 
Ccl2 7.23 1.39 * 5.01E-16 
Ccl8 3.32 1.17 * 5.39E-13 
Cysltr2 5.62 1.19 * 2.59E-15 
Flt1 148.59 1.32 * 0.00E+00 
Fos 5.07 1.16 * 2.71E-14 
Ifi44 37.87 3.68 * 3.95E-23 
Ifit1 37.87 4.26 * 2.26E-23 
Ifit2 115.49 1.25 * 0.00E+00 
Ifit3 85.49 4.38 * 1.97E-29 
Iigp1 3.43 1.30 * 3.06E-09 
Il18rap 5.84 1.42 * 1.01E-17 
Irf1 26.56 1.21 * 2.62E-29 
Irf7 23.66 2.72 * 7.09E-21 
Maff 28.93 1.39 * 2.46E-31 
Map3k9 19.09 1.21 * 2.09E-25 
Masp2 3.12 1.19 * 2.35E-07 
Mx2 52.75 3.69 * 6.72E-29 
Myl2 3.70 1.32 * 2.73E-07 
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Tlr2 4.92 1.23 * 3.51E-12 
Tlr5 3.60 1.30 * 2.44E-11 
Tnfaip3 30.35 1.19 * 5.03E-31 
Tslp 3.61 1.24 * 1.41E-11 
Foxg1 437.41 1.25 * 0.00E+00 
Gad1 220.45 1.26 * 0.00E+00 
Ifitm3 102.30 1.30 * 1.62E-37 
Slc2a1 415.71 1.17 * 0.00E+00 
Slc2a3 175.35 1.22 * 0.00E+00 
Vamp1 52.83 1.24 * 1.66E-36 
Vegfa 953.36 1.41 * 0.00E+00 
 
Genes repressed in GD12.5 GDM + MIA 
 Difference Fold Change FDR p-value 
Alox12 -5.17 0.75 * 4.61E-15 
Arg1 -17.33 0.57 * 2.06E-18 
Cd55 -21.52 0.82 * 3.81E-27 
Itgb2 -4.06 0.85 * 6.48E-13 
Map3k5 -24.12 0.80 * 1.45E-27 
Mef2a -111.62 0.83 * 0.00E+00 
Mef2b -2.32 0.84 * 1.29E-07 
Nfe2l2 -244.85 0.83 * 0.00E+00 
Tradd -8.93 0.84 * 5.59E-20 
En1 -2.64 0.83 * 6.64E-08 
En2 -2.60 0.81 * 4.53E-09 
Fgf8 -23.17 0.84 * 8.28E-27 
Pax5 -3.92 0.83 * 5.72E-12 
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Supplemental Figure 5. GDM and MIA exposure still show altered gene expression 
patterns at GD16.5. Venn diagrams representing the number of genes induced or repressed in 
GDM, MIA or GDM+MIA when compared to control mice fed a normal diet and treated with 
saline. Significant changes in gene expression were determined by multiple t tests, and genes 
with p<0.05, FDR<0.01 were selected. 
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Supplemental Table 5. GDM andMIA exposure continues to show altered gene expression 
patterns at GD16.5. Genes found to be significantly different between SAL and GDM, MIA, 
and GDM+MIA are shown. Significance was determined by multiple t-tests with FDR<0.01 and 
p<0.05. Although less prominent than at GD12.5, each condition continues to show significant 
differences in both inflammation and neurodevelopment gene expression. This demonstrates that 
MIA continues to alter gene expression patterns days after the immune stimulus has passed, and 
GDM continues to have an effect late gestation.  
 
Genes induced at GD16.5 in diet-induced GDM 
 Difference Fold Change FDR p-value 
C8b 12.10 1.50 * 9.83E-14 
Ccl22 4.99 1.20 * 4.23E-13 
Ccl8 2.39 1.20 * 2.82E-06 
Cd55 77.91 1.16 * 1.21E-34 
Hras1 23.34 1.18 * 1.12E-33 
Il1a 2.89 1.16 * 1.10E-06 
Maff 26.20 1.18 * 4.80E-28 
Max 400.42 1.16 * 0.00E+00 
Mef2b 3.84 1.22 * 1.33E-06 
Ptger3 25.02 1.15 * 4.38E-31 
En2 6.27 1.53 * 4.07E-09 
Pax5 13.62 1.96 * 5.60E-15 
 
Genes repressed at GD16.5 in diet-induced GDM 
 Difference Fold Change FDR p-value 
Ccl17 -8.92 0.58 * 4.15E-13 
Ccl7 -4.66 0.82 * 5.97E-07 
Ccr1 -5.29 0.75 * 4.58E-15 
Cd163 -10.69 0.79 * 5.05E-24 
Cfb -4.20 0.75 * 2.34E-10 
Csf1 -32.71 0.79 * 1.54E-24 
Ifi27l2a -8.81 0.83 * 1.37E-17 
Ifit1 -10.15 0.67 * 7.58E-14 
Irf7 -5.23 0.75 * 4.36E-12 
Itgb2 -12.64 0.68 * 4.91E-21 
Lta -2.09 0.84 * 2.11E-08 
Oasl1 -2.95 0.77 * 1.89E-10 
Tlr7 -3.07 0.82 * 5.02E-10 
Tlr9 -4.30 0.81 * 1.39E-14 
Fgf8 -4.81 0.75 * 4.69E-13 
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Genes induced at GD16.5 in MIA 
 Difference Fold Change FDR p-value 
C1ra 2.75 1.21 * 3.40E-08 
C2 6.13 1.16 * 9.01E-15 
C8b 6.20 1.26 * 8.60E-10 
Ccl17 5.84 1.28 * 2.17E-08 
Ccl22 6.71 1.27 * 2.59E-14 
Ccl7 21.32 1.82 * 6.42E-17 
Ccl8 4.24 1.36 * 7.80E-09 
Ccr2 8.82 1.47 * 2.38E-13 
Fasl 4.69 1.26 * 7.74E-11 
Ifi44 13.62 1.46 * 9.50E-19 
Il1a 5.84 1.32 * 1.33E-12 
Irf7 8.14 1.38 * 4.99E-15 
Ltb 3.36 1.16 * 2.59E-09 
Mef2b 16.73 1.94 * 4.37E-15 
Myl2 12.86 1.24 * 6.67E-18 
Nlrp3 3.57 1.16 * 1.53E-07 
Tlr2 6.50 1.26 * 1.13E-13 
Pax5 5.40 1.38 * 5.25E-11 
 
Genes repressed at GD16.5 in MIA 
 Difference Fold Change FDR p-value 
Cd163 -8.69 0.83 * 1.44E-19 
Cfb -3.53 0.79 * 2.06E-09 
Csf1 -29.35 0.82 * 6.66E-24 
Gngt1 -2.29 0.82 * 1.39E-07 
Itgb2 -6.00 0.85 * 1.81E-19 
Oasl1 -2.31 0.82 * 1.10E-08 
Chat -8.93 0.77 * 2.56E-19 
 
Genes induced at GD16.5 in diet-induced GDM+MIA 
 Difference Fold Change FDR p-value 
Alox5 3.08 1.23 * 2.66E-11 
C2 7.25 1.18 * 2.53E-16 
Ccl22 4.44 1.18 * 3.90E-12 
Masp1 504.87 1.17 * 0.00E+00 
Nlrp3 3.86 1.18 * 9.03E-08 
Tlr2 12.50 1.50 * 4.11E-19 
En2 3.00 1.25 * 1.78E-08 
Pax5 11.68 1.82 * 1.44E-15 
 
 
 157 
Genes repressed at GD16.5 in diet-induced GDM+MIA 
 Difference Fold Change FDR p-value 
Arg1 -5.75 0.74 * 6.34E-13 
Ccl17 -10.47 0.51 * 1.07E-14 
Ccl24 -6.69 0.85 * 6.18E-19 
Ccr1 -4.97 0.77 * 4.46E-15 
Cd163 -12.32 0.76 * 1.39E-21 
Cfb -5.07 0.70 * 1.73E-11 
Csf1 -24.08 0.85 * 1.69E-22 
Fos -11.48 0.84 * 5.13E-23 
Hspb2 -2.68 0.83 * 6.09E-11 
Ifit1 -8.10 0.74 * 4.38E-11 
Iigp1 -5.23 0.83 * 1.26E-11 
Irf7 -4.19 0.80 * 1.81E-09 
Itgb2 -11.18 0.71 * 3.50E-20 
Oasl1 -2.73 0.79 * 6.52E-10 
Ptgs2 -2.07 0.84 * 1.20E-06 
Tlr5 -2.65 0.82 * 1.39E-08 
Tlr9 -4.48 0.80 * 2.78E-13 
Chat -9.62 0.76 * 7.39E-19 
 
 
Supplemental Table 6. Genes that are included in the Nanostring V2 Mouse Inflammation panel 
utilized in the placental gene expression analysis 
 
Gene Names Included in the Nanostring V2 Mouse Inflammation Panel 
C1s Ccl20 Cxcr4 Il10rb Ltb4r1 Nfatc3 Rock2 
C4a Ccl22 Cysltr1 Il11 Ltb4r2 Nfe2l2 Rps6ka5 
C7 Ccl24 Cysltr2 Il12a Ly96 Nfkb1 Shc1 
Ccl19 Ccl3 Daxx Il12b Maff Nlrp3 Smad7 
Ccl21a Ccl4 Ddit3 Il13 Mafg Nod1 Stat1 
Ccl8 Ccl5 Elk1 Il15 Mafk Nod2 Stat2 
Chi3l3 Ccl7 Fasl Il17a Map2k1 Nos2 Stat3 
Defa-rs1 Ccr1 Flt1 Il18 Map2k4 Nox1 Tbxa2r 
Ifit3 Ccr2 Fos Il18rap Map2k6 Nr3c1 Tcf4 
Ifna1 Ccr3 Fxyd2 Il1b Map3k1 Oas1a Tgfb1 
Il1a Ccr4 Gnaq Il1r1 Map3k5 Oas2 Tgfb2 
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Il22 Ccr7 Gnas Il1rap Map3k7 Oasl1 Tgfb3 
Rhoa Cd163 Gnb1 Il1rn Map3k9 Pdgfa Tgfbr1 
Ager Cd4 Gngt1 Il2 Mapk1 Pik3c2g Tlr1 
Alox12 Cd40 Gpr44 Il21 Mapk14 Pla2g4a Tlr2 
Alox15 Cd40lg Grb2 Il22ra2 Mapk3 Plcb1 Tlr3 
Alox5 Cd55 H2-Ea-ps Il23a Mapk8 Ppp1r12b Tlr4 
Areg Cd86 H2-Eb1 Il23r Mapkapk2 Prkca Tlr5 
Arg1 Cdc42 Hc Il3 Mapkapk5 Prkcb Tlr6 
Atf2 Cebpb Hdac4 Il4 Masp1 Ptger1 Tlr7 
Bcl2l1 Cfb Hif1a Il5 Masp2 Ptger2 Tlr8 
Bcl6 Cfd Hmgb1 Il6 Max Ptger3 Tlr9 
Birc2 Cfl1 Hmgb2 Il6ra Mbl2 Ptger4 Tnf 
C1qa Creb1 Hmgn1 Il7 Mef2a Ptgfr Tnfaip3 
C1qb Crp Hras1 Il9 Mef2b Ptgir Tnfsf14 
C1ra Csf1 Hsh2d Irf1 Mef2c_Mm Ptgs1 Tollip 
C2 Csf2 Hspb1 Irf3 Mef2d Ptgs2 Tradd 
C3 Csf3 Hspb2 Irf5 Mknk1 Ptk2 Traf2 
C3ar1 Cxcl1 Ifi27l2a Irf7 Mmp3 Rac1 Trem2 
C6 Cxcl10 Ifi44 Itgb2 Mmp9 Raf1 Tslp 
C8a Cxcl2 Ifit1 Jun Mrc1 Rapgef2 Twist2 
C8b Cxcl3 Ifit2 Keap1 Mx1 Rela Tyrobp 
C9 Cxcl5 Ifnb1 Kng1 Mx2 Relb   
Ccl11 Cxcl9 Ifng Limk1 Myc Retnla   
Ccl17 Cxcr1 Iigp1 Lta Myd88 Ripk1   
Ccl2 Cxcr2 Il10 Ltb Myl2 Ripk2   
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Supplemental Table 7. Pathways represented in PANTER analysis based upon the genes in 
the Nanostring V2 inflammation panel. All genes that were assessed for gene expression 
changes in the Nanostring V2 inflammation panel were put into the PANTER pathway analysis 
software. The pathways represented by the V2 panel and the number of genes in each of the 
pathways is noted in the below table. 
 
Annotated Pathways in V2 Mouse Inflammation Panel Number of 
Genes in 
Pathway 
Inflammation mediated by chemokine and cytokine signaling pathway (P00031) 52 
Gonadotropin-releasing hormone receptor pathway (P06664) 42 
CCKR signaling map (P06959) 33 
Angiogenesis (P00005) 27 
Toll receptor signaling pathway (P00054) 27 
Apoptosis signaling pathway (P00006) 25 
Interleukin signaling pathway (P00036) 24 
Ras Pathway (P04393) 22 
EGF receptor signaling pathway (P00018) 21 
PDGF signaling pathway (P00047) 20 
p38 MAPK pathway (P05918) 18 
VEGF signaling pathway (P00056) 17 
Integrin signalling pathway (P00034) 17 
FGF signaling pathway (P00021) 17 
T cell activation (P00053) 16 
Oxidative stress response (P00046) 15 
TGF-beta signaling pathway (P00052) 14 
B cell activation (P00010) 14 
Endothelin signaling pathway (P00019) 12 
Wnt signaling pathway (P00057) 10 
Angiotensin II-stimulated signaling through G proteins and beta-arrestin (P05911) 10 
Insulin/IGF pathway-mitogen activated protein kinase kinase/MAP kinase cascade 
(P00032) 
9 
PI3 kinase pathway (P00048) 8 
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway 7 
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(P00027) 
Alzheimer disease-amyloid secretase pathway (P00003) 6 
Interferon-gamma signaling pathway (P00035) 6 
FAS signaling pathway (P00020) 6 
5HT2 type receptor mediated signaling pathway (P04374) 6 
Parkinson disease (P00049) 5 
Muscarinic acetylcholine receptor 1 and 3 signaling pathway (P00042) 5 
p53 pathway feedback loops 2 (P04398) 5 
Thyrotropin-releasing hormone receptor signaling pathway (P04394) 5 
Oxytocin receptor mediated signaling pathway (P04391) 5 
Huntington disease (P00029) 5 
Histamine H1 receptor mediated signaling pathway (P04385) 5 
Cytoskeletal regulation by Rho GTPase (P00016) 5 
Axon guidance mediated by netrin (P00009) 4 
JAK/STAT signaling pathway (P00038) 4 
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway 
(P00026) 
4 
Axon guidance mediated by Slit/Robo (P00008) 3 
p53 pathway (P00059) 3 
Enkephalin release (P05913) 3 
Cortocotropin releasing factor receptor signaling pathway (P04380) 3 
Axon guidance mediated by semaphorins (P00007) 2 
Alpha adrenergic receptor signaling pathway (P00002) 2 
Plasminogen activating cascade (P00050) 2 
Muscarinic acetylcholine receptor 2 and 4 signaling pathway (P00043) 2 
Metabotropic glutamate receptor group I pathway (P00041) 2 
Metabotropic glutamate receptor group II pathway (P00040) 2 
Endogenous cannabinoid signaling (P05730) 2 
Hypoxia response via HIF activation (P00030) 2 
Heterotrimeric G-protein signaling pathway-rod outer segment phototransduction 
(P00028) 
2 
Nicotine pharmacodynamics pathway (P06587) 2 
Dopamine receptor mediated signaling pathway (P05912) 2 
Histamine H2 receptor mediated signaling pathway (P04386) 2 
Beta3 adrenergic receptor signaling pathway (P04379) 2 
Beta2 adrenergic receptor signaling pathway (P04378) 2 
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Beta1 adrenergic receptor signaling pathway (P04377) 2 
5HT4 type receptor mediated signaling pathway (P04376) 2 
Toll pathway-drosophila (P06217) 1 
DPP signaling pathway (P06213) 1 
BMP/activin signaling pathway-drosophila (P06211) 1 
Activin beta signaling pathway (P06210) 1 
Alzheimer disease-presenilin pathway (P00004) 1 
Transcription regulation by bZIP transcription factor (P00055) 1 
GABA-B receptor II signaling (P05731) 1 
Metabotropic glutamate receptor group III pathway (P00039) 1 
Insulin/IGF pathway-protein kinase B signaling cascade (P00033) 1 
2-arachidonoylglycerol biosynthesis (P05726) 1 
Opioid proopiomelanocortin pathway (P05917) 1 
Opioid prodynorphin pathway (P05916) 1 
Opioid proenkephalin pathway (P05915) 1 
Blood coagulation (P00011) 1 
5HT1 type receptor mediated signaling pathway (P04373) 1 
 
 
Supplemental Table 8. Placental immune genes differentially regulated by sex in the normal 
diet, saline control group 
 
Gene Name p value Effect Estimate 
C1ra 0.00742 -4.81 
Ccl24 0.02055 1.96 
Ccl4 0.01453 7.14 
Cfl1 0.00539 2095.12 
Cxcl2 0.02904 8.43 
Ddit3 0.01489 368.37 
Ifna1 0.0308 11.13 
Jun 0.00645 257.26 
Ptgs2 0.0433 151.79 
Rac1 0.03921 703.26 
Tlr5 0.04321 -44.74 
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Tlr6 0.0489 8.53 
Tlr8 0.00525 6.99 
 
 
Supplemental Table 9. Inflammatory genes significantly down-regulated in GDM male 
placentae compared to control (normal diet, saline-injected mice) 
 
Gene 
Name 
p value Effect 
Estimate 
Alox5 0.001926946 -42.54733333 
Arg1 0.004757934 -29.95466667 
Bcl2l1 0.00911303 -294.4806667 
Birc2 0.022424927 -86.65766667 
C1qa 5.42307E-06 -67.33933333 
C1qb 7.78421E-06 -87.36233333 
C2 0.034250549 -287.2493333 
Ccl17 0.045018675 -13.04566667 
Ccl5 0.024391854 -14.35166667 
Ccl8 0.001327809 -67.039 
Ccr2 0.001593047 -55.074 
Ccr7 0.000917256 -5.360666667 
Cd55 0.000180472 -2299.446667 
Cdc42 8.19668E-07 -3787.151333 
Chi3l3 0.002931513 -38.79766667 
Fasl 0.000834616 -36.11966667 
Fos 0.032260602 -737.5546667 
Gngt1 0.022292491 -16.52533333 
H2_Eb1 0.000448036 -60.784 
Hc 0.000424382 -43.80033333 
Ifi27l2a 0.000334374 -271.203 
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Ifit1 0.038105124 -186.4636667 
Ifit2 0.003321288 -422.8946667 
Ifit3 0.042938592 -237.8013333 
Iigp1 0.003083693 -127.727 
Il18 0.001186363 -12.35166667 
Il1rap 0.032796542 -98.54566667 
Il1rn 0.003423275 -8.426 
Il6ra 0.000600867 -940.8706667 
Irf1 0.00522281 -151.1853333 
Irf5 0.014295347 -16.592 
Ltb4r1 3.75591E-06 -15.95766667 
Ly96 0.000508472 -206.2116667 
Map3k7 0.014557956 -337.1053333 
Mapk1 0.013142938 -378.2956667 
Masp1 0.00409261 -1236.857 
Mef2a 0.000318597 -179.538 
Mx1 0.001411058 -242.3123333 
Oas2 0.000716271 -61.958 
Pla2g4a 0.04766698 -94.13366667 
Prkcb 0.01605893 -14.98533333 
Ptger2 0.00012342 -15.66466667 
Rac1 0.001496487 -1468.581 
Retnla 2.43648E-07 -18.823 
Ripk1 0.037597673 -51.07433333 
Rock2 0.001292389 -222.8103333 
Stat3 0.017098294 -624.4743333 
Tgfb1 0.000300543 -696.5766667 
Tgfb2 0.026228814 -480.876 
Tlr4 0.002427201 -452.5416667 
Tlr8 1.75227E-05 -10.84533333 
Tnfaip3 0.002507121 -76.42766667 
Tollip 0.013209681 -542.8513333 
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Trem2 0.000159557 -868.547 
Twist2 0.001434843 -49.602 
Tyrobp 0.000131002 -826.4123333 
 
Supplemental Table 10. Inflammatory genes significantly up-regulated in GDM male placentae 
compared to control (normal diet, saline-injected mice) 
Gene Name p value Effect Estimate 
Cxcl2 0.047137709 11.61766667 
Grb2 0.035753225 436.8726667 
Hdac4 0.000646108 485.1873333 
Hspb1 1.66271E-06 8406.071 
Il1r1 0.000860141 510.4433333 
Irf3 0.025725625 17.51666667 
Limk1 0.01536897 588.6323333 
Mafg 0.000571474 323.146 
Mafk 0.026932154 257.3866667 
Map2k6 0.009178745 209.9556667 
Map3k1 0.002014505 103.2533333 
Mapk14 0.000391098 433.9283333 
Mef2b 0.008633252 9.527666667 
Mef2d 0.041015838 262.925 
Myc 0.003347919 432.0903333 
Myd88 0.030464185 236.6826667 
Nfatc3 0.000848957 220.507 
Nos2 1.07767E-06 432.735 
Nr3c1 0.000140557 178.3166667 
Tgfb3 0.004105075 768.624 
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Supplemental Table 11. Inflammatory genes significantly down-regulated in GDM female 
placentae compared to control (normal diet, saline-injected mice) 
 
Gene Name p value Effect Estimate 
Alox5 0.002657516 -42.90666667 
Birc2 0.001678911 -103.39 
Ccl8 0.020947974 -40.58 
Ccr2 0.005000052 -49.24666667 
Cd40 0.002869934 -33.01166667 
Cd55 0.0086493 -1381.636667 
Cdc42 1.69164E-07 -3718.875 
Chi3l3 0.001457773 -37.78 
Fasl 0.011263235 -27.7 
Gngt1 0.000238865 -21.525 
Hc 0.000408656 -38.05333333 
Il10rb 0.006717435 -277.9683333 
Il12b 0.019578984 -3.125 
Il13 0.035996966 -1.623333333 
Il18 0.003353307 -17.66333333 
Il1rap 0.005261877 -59.72833333 
Il6ra 0.000753243 -658.4133333 
Irf1 0.01914598 -102.8866667 
Itgb2 0.02514249 -108.9133333 
Ly96 7.30122E-06 -211.9716667 
Map2k4 0.009317877 -459.2166667 
Map3k7 2.02865E-05 -486.6683333 
Mapk1 6.31208E-05 -357.5 
Mef2a 8.72661E-05 -145.555 
Ppp1r12b 0.04974014 -15.77166667 
Rac1 2.00025E-05 -1502.036667 
Rela 0.014490209 -113.105 
Rps6ka5 0.047803932 -25.605 
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Stat3 0.024819031 -455.045 
Tgfb1 0.001524355 -627.045 
Tnfaip3 0.016694721 -51.63 
Tollip 0.000831075 -542.7566667 
Trem2 6.08834E-05 -816.0333333 
Tyrobp 8.93488E-05 -670.7366667 
 
 
Supplemental Table 12. Inflammatory genes significantly up-regulated in GDM female 
placentae compared to control (normal diet, saline-injected mice) 
Gene Name p value Effect Estimate 
Ccl24 0.032027172 2.115 
Ccl3 0.024972918 17.865 
Csf3 0.003082224 6.7 
Cxcl2 0.004442088 17.14166667 
Daxx 0.019088553 61.27666667 
Gnas 0.017920168 1096.776667 
Grb2 0.012391565 422.545 
Hspb1 4.82945E-14 7136.168333 
Limk1 0.002211185 954.4483333 
Maff 0.001052794 606.1133333 
Mafg 0.048580393 123.6216667 
Mafk 0.036375918 164.645 
Mapk14 0.018899014 106.0633333 
Myc 0.026384777 398.9766667 
Myd88 0.013242547 156.0516667 
Nfatc3 0.032867819 88.93833333 
Nos2 1.32928E-05 299.8416667 
Tlr7 0.026354793 10.08666667 
Traf2 0.041488015 50.87333333 
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Supplemental Table 13. Inflammatory genes significantly down-regulated in MIA male 
placentae compared to control (normal diet, saline-injected mice) 
Gene Name p value Effect Estimate 
Alox5 0.028290457 -38.305 
C8a 0.037954604 -2.596666667 
Ccr2 8.32652E-10 -85.41666667 
Cd55 0.030422733 -1474.191667 
Cdc42 0.000218025 -2717.34 
Cfl1 0.002627437 -2944.211667 
Csf2 0.046893204 -0.476666667 
Cxcr1 0.040973271 -18.895 
Cxcr4 0.001597391 -59.555 
H2_Eb1 0.003301646 -48.40666667 
Hc 0.010176615 -32.42166667 
Hmgb1 0.00271586 -296.3283333 
Keap1 0.004597594 -74.84833333 
Ly96 0.004404948 -132.26 
Mapk14 0.018386112 -195.635 
Masp1 0.027012034 -910.0916667 
Mef2a 0.007008629 -145.815 
Pla2g4a 0.005003258 -113.5766667 
Ppp1r12b 0.025255939 -13.00833333 
Ptgs2 0.003698711 -310.4966667 
Rac1 0.019066249 -1034.328333 
Retnla 0.043272012 -10.215 
Tgfb1 0.009808497 -459.92 
Tlr8 0.007260952 -9.355 
Tollip 0.022370573 -416.54 
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Supplemental Table 14. Inflammatory genes significantly up-regulated in MIA male placentae 
compared to control (normal diet, saline-injected mice)  
 
Gene Name p value Effect Estimate 
Bcl6 4.92493E-05 48.58166667 
C1ra 0.026043722 6.55 
Ccl4 0.000222395 47.79 
Ccl5 3.23584E-05 137.82 
Cebpb 0.000136427 1197.366667 
Cxcl10 2.78515E-13 1869.075 
Cxcl9 6.06393E-05 87.38 
Daxx 9.92234E-10 1291.538333 
Grb2 0.015151275 617.8966667 
Hdac4 0.001243608 498.1866667 
Hsh2d 1.294E-10 79.58333333 
Ifi44 0.000867071 258.1933333 
Ifit1 4.68501E-12 1104.11 
Ifit2 3.06416E-05 739.365 
Ifit3 4.32565E-15 2338.716667 
Iigp1 1.93422E-20 1277.725 
Il15 7.86613E-05 26.085 
Il18rap 0.002163094 5.238333333 
Il1r1 0.015684705 591.06 
Il6 0.000384512 26.64166667 
Irf1 1.39681E-13 590.73 
Irf7 1.48353E-07 889.6433333 
Jun 0.001181313 765.3483333 
Limk1 0.00079421 1077.361667 
Maff 0.000899847 523.2583333 
Mafk 0.000723943 366.1666667 
Map2k1 0.001468616 1773.581667 
Map3k1 6.80898E-09 283.4466667 
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Mx1 0.007468486 230.75 
Mx2 9.37471E-20 1072.621667 
Myc 3.21305E-05 574.11 
Myd88 1.828E-08 1282.4 
Nod1 0.032530351 37.17833333 
Nod2 8.57939E-10 124.4866667 
Nos2 4.78772E-05 524.1266667 
Nr3c1 0.0032139 241.0616667 
Oas1a 2.36618E-05 2625.05 
Oasl1 3.03153E-09 441.2716667 
Ptk2 0.025180371 469.545 
Stat1 9.2138E-09 2480.65 
Stat2 8.56089E-09 2823.29 
Stat3 8.97837E-06 1434.323333 
Tlr3 5.9249E-06 97.89333333 
Tlr5 0.037040533 60.605 
 
 
Supplemental Table 15. Inflammatory genes significantly down-regulated in MIA female 
placentae compared to control (normal diet, saline-injected mice)  
Gene Name p value Effect Estimate 
Ccr2 4.51236E-05 -50.69833333 
Cdc42 4.16829E-05 -2518.83 
Cfl1 0.001907284 -2405.546667 
Cxcr1 0.026250746 -19.37333333 
Cxcr4 1.28666E-09 -105.0666667 
Gpr44 5.37534E-05 -195.49 
Hmgb1 0.000113252 -316.885 
Hmgb2 0.040267232 -6.491666667 
Hmgn1 0.006506691 -1159.956667 
Il10rb 0.001170154 -358.7816667 
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Keap1 0.03801625 -71.37666667 
Ly96 0.000453134 -123.9683333 
Map2k4 0.015424441 -289.9033333 
Map3k7 1.34679E-06 -396.7666667 
Mapk14 3.25408E-05 -285.7333333 
Mapk8 0.001910214 -157.0166667 
Mef2a 0.001033832 -128.03 
Mknk1 0.029765683 -38.68666667 
Ppp1r12b 0.000588804 -17.47 
Ptgfr 4.09749E-06 -42.45333333 
Rac1 9.16008E-06 -1154.17 
Rps6ka5 0.010006455 -25.52666667 
Tgfbr1 0.000179131 -402.1816667 
Tollip 7.45155E-06 -468.9783333 
Tradd 0.026831407 -31.47 
 
 
Supplemental Table 16. Inflammatory genes significantly up-regulated in MIA female 
placentae compared to control (normal diet, saline-injected mice)  
Gene Name p value Effect Estimate 
Alox12 0.003629169 21.16666667 
Bcl6 0.000687227 64.91166667 
C1ra 0.031070011 4.181666667 
Ccl11 0.045540276 3.43 
Ccl19 0.01878264 9.558333333 
Ccl2 0.004767201 211.14 
Ccl21a 0.014500722 10.62166667 
Ccl3 0.006851076 88.76 
Ccl4 4.56563E-06 79.74666667 
Ccl5 0.000280704 199.8266667 
Ccl7 0.015602657 38.92833333 
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Cd86 0.028374925 11.57666667 
Cebpb 4.50835E-08 1828.663333 
Csf1 2.69127E-06 578.1533333 
Csf3 0.007866434 60.34166667 
Cxcl1 0.03566611 143.4666667 
Cxcl10 8.16294E-08 2797.3 
Cxcl2 0.000320823 85.195 
Cxcl9 0.000284436 91.69166667 
Daxx 1.71012E-13 1066.87 
Defa_rs1 0.009160059 6.001666667 
Fos 5.09553E-05 1651.5 
Grb2 0.01408914 407.4666667 
Hif1a 0.026364669 984.345 
Hsh2d 3.49472E-08 58.605 
Ifi44 7.27311E-11 554.315 
Ifit1 1.08477E-06 1725.543333 
Ifit2 3.77589E-06 1447.66 
Ifit3 1.77799E-11 3384.315 
Ifnb1 0.035851348 5.513333333 
Iigp1 2.90761E-11 1857.776667 
Il10 0.038565405 0.38 
Il15 0.002444093 26.215 
Il18rap 0.015146386 7.27 
Il1a 9.63652E-07 30.25333333 
Il1rn 0.002115208 8.963333333 
Il23a 0.001772555 71.49666667 
Il23r 0.000578064 2.325 
Il6 0.001860776 58.6 
Irf1 1.12114E-05 952.8633333 
Irf5 0.001296574 25.09666667 
Irf7 2.06557E-07 882.9216667 
Jun 1.59424E-08 1433.095 
 172 
Limk1 0.000462344 1533.311667 
Lta 0.004037424 2.671666667 
Ltb4r1 0.006243247 9.195 
Maff 0.000171343 900.065 
Mafk 0.01019094 202.5233333 
Map2k1 0.000355357 872.8083333 
Map3k1 4.27795E-07 455.6716667 
Mmp9 0.002644901 14.48 
Mx1 5.79395E-06 481.7316667 
Mx2 1.22494E-12 1181.58 
Myc 0.000656724 428.0033333 
Myd88 4.29751E-08 1026.875 
Nfkb1 0.009908969 254.0583333 
Nlrp3 0.032609536 6.735 
Nod1 1.77147E-05 116.9733333 
Nod2 3.87012E-13 128.31 
Nos2 0.007556955 292.5333333 
Oas1a 6.83764E-08 2171.593333 
Oas2 0.002815711 94.85833333 
Oasl1 7.27486E-09 771.2 
Relb 0.019019242 198.8083333 
Ripk2 0.005675255 46.44 
Stat1 5.06974E-09 2517.636667 
Stat2 8.65277E-09 2206.95 
Stat3 2.75973E-05 1638.223333 
Tlr2 0.000398621 32.04 
Tlr3 7.8327E-06 84.40833333 
Tlr7 0.000143085 13.16166667 
Tnfaip3 0.008358732 110.4916667 
Twist2 0.029954362 34.705 
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Supplemental Table 17. Inflammatory genes significantly down-regulated in GDM + MIA 
male placentae compared to control (normal diet, saline-injected mice) 
Gene Name p value Effect Estimate 
Alox5 0.009382917 -40.7 
C1qa 0.02583044 -44.125 
C8a 0.043156103 -2.525 
Ccr2 4.96434E-06 -69.925 
Ccr3 0.019303864 -4.325 
Cd4 0.006978826 -2.748333333 
Chi3l3 0.000233442 -45.94833333 
Cxcr1 7.47959E-06 -34.23666667 
Cxcr4 0.001819166 -55.275 
Ddit3 0.008834223 -472.5216667 
Elk1 0.018923354 -11.32 
Gngt1 0.015863006 -18.86666667 
Gpr44 0.035287198 -123.4816667 
Il12b 0.011832861 -3.893333333 
Il6ra 0.009179431 -781.9233333 
Keap1 0.034227363 -77.96833333 
Ltb4r1 0.000474657 -15.15833333 
Ltb4r2 0.031927157 -4.535 
Ly96 0.000442878 -186.6933333 
Mapk14 0.009402756 -180.24 
Nox1 0.001977326 -3.24 
Pik3c2g 0.000755689 -1.78 
Ppp1r12b 0.005513036 -16.04333333 
Prkcb 0.003412472 -19.85666667 
Ptgir 0.048415925 -5.196666667 
Retnla 0.000373759 -15.80333333 
Tbxa2r 6.05595E-06 -10.74833333 
Tollip 0.000477353 -668.345 
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Tradd 0.004108641 -45.54333333 
Trem2 0.038806055 -616.9483333 
Tyrobp 0.018122399 -619.5733333 
 
 
Supplemental Table 18. Inflammatory genes significantly up-regulated in GDM + MIA 
male placentae compared to control (normal diet, saline-injected mice)  
Gene Name p value Effect Estimate 
Bcl6 3.63744E-05 54.5 
C1ra 0.000238432 10.855 
Ccl2 3.09502E-06 548.4266667 
Ccl3 5.05631E-06 72.43333333 
Ccl4 1.22171E-05 66.69333333 
Ccl5 1.87953E-05 338.96 
Ccl7 0.004807987 89.98166667 
Cd86 0.049983817 11.22833333 
Cebpb 2.08105E-06 1347.821667 
Csf1 0.004412482 869.8666667 
Csf3 4.20971E-08 74.21833333 
Cxcl1 1.21847E-09 589.1683333 
Cxcl10 1.42746E-09 3830.006667 
Cxcl2 2.92157E-09 109 
Cxcl3 0.017252275 21.08 
Cxcl9 1.17372E-08 156.9933333 
Cysltr1 0.013820893 18.50333333 
Daxx 9.94678E-11 1556.9 
Grb2 0.00363946 946.8583333 
Hif1a 0.001636509 4285.185 
Hsh2d 4.95459E-09 68.22166667 
Hspb1 2.8863E-06 6599.301667 
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Ifi44 0.001850172 800.0316667 
Ifit1 5.6215E-05 2462.636667 
Ifit2 0.001212532 1793.168333 
Ifit3 9.47698E-06 4089.02 
Ifnb1 0.006433125 5.723333333 
Iigp1 4.75649E-06 2180.101667 
Il15 0.008892757 35.51833333 
Il1r1 0.00260618 873.5316667 
Il23a 0.006320893 73.015 
Il6 0.0004182 71.05166667 
Irf1 2.63843E-06 1176.798333 
Irf7 8.93603E-07 986.505 
Jun 8.39928E-09 1402.135 
Limk1 0.048149749 651.13 
Map2k1 2.88349E-06 2529.4 
Map3k1 0.000289534 219.0866667 
Mapkapk2 0.005794269 424.4483333 
Mx1 0.024350915 352.35 
Mx2 4.26271E-10 1248.198333 
Myc 1.03332E-05 925.3633333 
Myd88 3.01594E-07 1823.355 
Nfkb1 0.001913947 424.7266667 
Nod2 2.83017E-08 141.8533333 
Nos2 0.00022415 421.7916667 
Nr3c1 2.19463E-07 366.1683333 
Oas1a 4.268E-06 2743.151667 
Oasl1 0.000146218 948.275 
Plcb1 0.016734861 12.81 
Ptk2 0.025906364 488.845 
Rela 0.00412249 179.6783333 
Relb 1.34072E-05 529.145 
Ripk1 0.029750362 80.19166667 
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Ripk2 1.38362E-08 65.975 
Stat1 4.6516E-07 3307.063333 
Stat2 1.69532E-08 2403.615 
Stat3 8.23455E-08 1521.023333 
Tcf4 0.021048757 689.32 
Tgfb3 0.021186903 890.565 
Tlr2 0.000177751 29.75 
Tlr3 9.53174E-05 71.23833333 
Tnf 5.53161E-08 58.045 
Tnfaip3 0.014218011 109.585 
 
 
Supplemental Table 19. Inflammatory genes significantly down-regulated in GDM + MIA 
female placentae compared to control (normal diet, saline-injected mice)  
Gene Name p value Effect Estimate 
Alox5 0.003532975 -53.17666667 
Ccl17 0.017581283 -11.52333333 
Ccr2 8.06551E-06 -69.265 
Cd163 0.027758806 -3.298333333 
Cd55 0.005511445 -1650.815 
Chi3l3 0.000173896 -45.40666667 
Cxcr1 0.001137625 -26 
Cxcr4 2.67261E-07 -83.26 
Gngt1 0.001902236 -22.365 
Hc 0.003995914 -40.765 
Hmgb1 0.045130659 -146.8016667 
Il6ra 0.001627881 -766.1016667 
Itgb2 0.000939113 -180.1716667 
Ly96 6.95627E-07 -209.065 
Mapk14 0.002091425 -197.2833333 
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Mapk3 1.76091E-06 -274.6433333 
Ppp1r12b 0.008442819 -18.77 
Prkcb 0.003312925 -12.29666667 
Ptgfr 0.005900359 -36.83166667 
Ptgir 0.020011913 -4.73 
Retnla 0.003555347 -19.145 
Tgfb1 0.025148466 -482.03 
Tlr4 0.042272554 -308.44 
Tollip 1.77951E-06 -619.595 
Tradd 0.00267707 -60.4 
Trem2 0.000234666 -868.6833333 
Twist2 0.020610161 -25.87833333 
Tyrobp 0.00159687 -750.8666667 
 
 
Supplemental Table 20. Inflammatory genes significantly up-regulated in GDM +MIA 
female placentae compared to control (normal diet, saline-injected mice)  
Gene Name p value Effect Estimate 
Bcl6 0.000296618 79.42833333 
Ccl11 0.003942223 0.768333333 
Ccl19 2.49961E-05 11.61666667 
Ccl2 1.47849E-05 422.4566667 
Ccl20 6.60833E-05 10.46333333 
Ccl21a 0.033885906 7.008333333 
Ccl3 1.71476E-14 72.79666667 
Ccl4 1.57615E-08 67.32333333 
Ccl5 4.11082E-06 249.965 
Ccl7 0.029596889 56.15333333 
Ccr1 0.03131221 13.65166667 
Cd86 3.18647E-05 19.62833333 
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Cebpb 3.09099E-08 2308.996667 
Cfl1 0.00761819 4554.248333 
Csf1 3.78088E-07 1026.656667 
Csf3 0.001952187 63.56333333 
Cxcl1 3.24085E-08 402.095 
Cxcl10 3.14418E-09 3609.576667 
Cxcl2 5.42194E-07 75.845 
Cxcl3 0.00564542 29.68 
Cxcl5 0.005009756 3.613333333 
Cxcl9 4.30051E-07 166.4733333 
Cxcr2 0.040361123 356.345 
Daxx 3.419E-10 1616.273333 
Fos 5.8073E-05 817.76 
Gnas 0.026555136 1781.951667 
Grb2 0.004143636 818.1983333 
Hif1a 0.001850287 4110.808333 
Hsh2d 1.29079E-08 77.145 
Hspb1 1.22542E-06 6696.811667 
Ifi44 6.61454E-05 688.625 
Ifit1 8.13286E-07 2070.381667 
Ifit2 5.47057E-05 1478.818333 
Ifit3 9.51437E-08 3666.286667 
Ifnb1 0.01834975 5.208333333 
Iigp1 1.12885E-07 1918.485 
Il15 0.002451438 28.93333333 
Il1a 1.3243E-06 35.76333333 
Il1r1 6.27158E-05 1030.191667 
Il23a 0.012122437 44.78333333 
Il6 1.69472E-05 56.21166667 
Irf1 2.2915E-06 1047.678333 
Irf7 8.73794E-10 1192.223333 
Jun 9.67415E-07 1619.001667 
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Limk1 0.007448809 1141.67 
Maff 0.000192269 580.3583333 
Mafk 0.005232445 304.35 
Map2k1 5.39551E-09 2474.553333 
Map2k6 0.012109299 363.8366667 
Map3k1 1.87912E-06 276.655 
Mknk1 0.013391738 47.48 
Mx1 0.000230181 406.7433333 
Mx2 4.83749E-13 1173.906667 
Myc 7.11576E-06 803.48 
Myd88 5.40278E-08 1897.143333 
Nfkb1 0.000691407 403.2116667 
Nod2 1.23466E-09 127.3633333 
Nos2 0.000102455 511.6316667 
Nr3c1 0.004874238 288.035 
Oas1a 5.86408E-07 2834.136667 
Oasl1 4.08791E-06 769.0283333 
Ptk2 0.010638704 453.0783333 
Relb 8.05649E-06 424.87 
Ripk2 0.001923797 52.2 
Stat1 4.88281E-08 3156.975 
Stat2 2.11636E-09 2645.03 
Stat3 9.24011E-09 1509.233333 
Tcf4 0.019953409 521.7816667 
Tgfb3 0.011948836 1221.581667 
Tlr2 1.65059E-07 38.30333333 
Tlr3 0.000361793 95.76833333 
Tnf 3.20358E-06 46.49666667 
Traf2 0.004237746 84.115 
Tslp 0.0122762 21.62833333 
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